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ABSTRACT OF DISSERTATION

THE ROLE OF ABCG2 IN DRUG ACTIVE TRANSPORT INTO MILK
Drug active transport into milk is a major concern for breastfeeding mothers and
healthcare providers. Studies from the literature indicated that breast cancer resistance
protein (ABCG2) plays an important role in drug transfer into milk. There has been
limited study on stereoselective interactions with ABCG2. A mechanistic analysis of flux
across cell monolayer model is a critical first step toward extrapolating in vitro results for
predicting in vivo disposition (including distribution into milk), drug disposition or drugdrug interactions.
The objectives of this thesis were (1) to establish a “Chemical knockout model” in rat
for studying drug accumulation into milk, (2) to investigate the impact of stereoselective
interaction between ABCG2/Abcg2 and pantoprazole on drug transport in milk, (3) to
understand in vitro monolayer flux model using experimental data and a mechanistic
mathematical model.
Quantitive PCR, Western blotting and immunohistochemistry results indicated that
Abcg2 was up-regulated during lactation and localized on apical side of epithelial cells in
mammary gland. In vitro and in vivo experiments confirmed that Abcg2 is responsible for
nitrofurantoin active transport in rat milk and GF120918 was established as a chemical
knockout model.
Abcg2 interacts stereoselectively with pantoprazole isomers. A significant different
apical flux between two pantoprazole isomers was observed in Abcg2-MDCKII cell line.
The milk to serum (M/S) ratio of (-)-pantoprazole was almost 3 times as that of (+)pantoprazole in lactating rats. Administration GF120918 decreased M/S of (-)pantoprazole (p<0.001) but not (+)-pantoprazole (p>0.05).
A stably transfected ABCG2/Abcg2 overexpressing MDCKII cell line was
successfully created and used to explore the theoretical relationships in a monolayer flux
model. Based on the profiles of pantoprazole isomer transport, a simple three
compartment model for drug transfer into breast milk incorporating the permeabilitysurface area products for passive diffusion (PSD), paracellular flux (PSPC) and apically
efflux ABCG2 (PSA,E) transfection was developed. The mathematical model was

developed to more fully understand the interplay of paracellular, passive diffusion, active
transport, and flux kinetic parameters (Km, Vmax, IC50 and Ki). This model provided useful
insights into the meaning and limitation of parameters obtained from monolayer flux.
KEYWORDS: ABCG2, transporter, chirality, transwell model, lactation,
mathematical modeling.
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CHAPTER 1: Introduction
A. The benefit of breastfeeding and breastfeeding trends in the United States

Breast milk has been recommended by many advocacy groups as the
optimal nutrition for infants, such as the American Academy of Pediatrics (AAP),
the American Medical Association (AMA), the American Dietetic Association
(ADA) and the World Health Organization (WHO). An ideal feeding pattern for
infants would include exclusive breastfeeding for the first 6 months of life and
breastfeeding with complementary foods from 6 months until at least 12 months
of age; such consideration would provide optimal nutrition and health protection
for both infants and mothers (James and Lessen, 2009).
Breast milk is considered to be most advantageous for providing protective
nutrients for infants. Some components, including transforming growth factor
(TGF)-β, interleukin (IL)-10 (Penttila, 2010), erythropoietin, and lactoferrin
(Rodriguez-Palmero et al., 1999) can reduce the inflammatory response in the
newborn intestine. These special components from breast milk work individually
or in concert to modulate the neonatal immature anti-inflammatory response. Milk
appears to decrease the incidence of ear infections, diarrhea, lung infections and
urinary tract infections in babies; such that breast-feeding babies are admitted to
the hospital less often than the infants fed formula. Moreover, the composition of
breast milk appears to change according to the newborn infant's needs for
passive protection at the different ages. Some clinical evidence suggests its
protective effect against age-related infectious gastroenteritis (Walker, 2010).
Some elements in breast milk can actively stimulate development of the
newborn's host defense systems to establish a continuous mucosal protection
after breastfeeding is terminated (Walker, 2010). There is some evidence that
breastfeeding improves cognitive development and has an important impact on
children’s IQ, brain size and white matter development (Kramer et al., 2008;
Isaacs et al., 2009). Furthermore, those who were breastfed are less likely to
acquire adult illnesses such as type 1 and 2 diabetes (Kostraba et al., 1993;
Pettitt et al., 1997; Gunderson, 2008), some cancers (Davis, 1998; Bener et al.,
1

2001), asthma (Gdalevich et al., 2001; Chulada et al., 2003), hypertension,
metabolic syndrome (Nobili et al., 2009) and obesity (Gillman et al., 2001;
Armstrong and Reilly, 2002; Plagemann and Harder, 2005). For the mother,
breastfeeding also improves health outcomes, including a reduced risk of breast
and ovarian cancer (Titus-Ernstoff et al., 2009), type 2 diabetes (Villegas et al.,
2008), rheumatoid arthritis (Mason et al., 1995) and maternal postpartum
depression (Ip et al., 2009).

Figure 1-1 National trends in rate of breastfeeding. Data source: pre-1999, Ross
Mothers Survey; 1999–present, CDC NIS (The figure was cited from (Grummer-Strawn

and Shealy, 2009))
Notes: Ross Laboratory Mothers Survey (RLMS), a survey whose primary goal was to
track usage of infant formula by manufacturing brand. CDC: the Centers for Disease
Control and Prevention; NIS: the National Immunization Survey.

Breastfeeding benefits not only the health of mother and infant but also
provides societal and economic advantages as well as convenience of life issues
of parenting (Rohde, 1981). These health benefits decrease acute and chronic
illness in short-term and long-term for both mother and child help to reduce
health care-related expenses. It has become an important public health strategy
for decreasing infant and child morbidity and maternal morbidity, and helping to
2

control health care costs. During the last 39 years (1970-2009) the rate of
breastfeeding had improved in the United States (Figure 1-1)(Grummer-Strawn
and Shealy, 2009). Rates of initiation of breastfeeding more than doubled from a
lowest rate of 26.5% in 1970 to 61.9% in 1982. This trend was slightly decreased
from 1982 until the mid 1990s. In 1990 the rate of initiation of breastfeeding fell to
51.5%; after that time point, the breast feeding rate again rose and reached
74.2% in 2005. Trends in breastfeeding at 6 months have paralleled initiation
trends. In order to drive the maximal benefit for mother, infant and society, new
Healthy People 2010 set objectives to call for breastfeeding with targets of 75%
initiation and 50% continuation at 6 months (Grummer-Strawn and Shealy,
2009).
B.Drug use during breastfeeding

A societal concern of drug transfer into human milk has drawn more attention
following the trend of increasing breastfeeding rate. It was reported the more
than 90% of women take at least one medication during the first week after
delivery (Bennet, 1988). Drug surveys have indicated that about 17% of the
mothers who were still breast-feeding at 4 months had taken at least the
equivalent of one daily dose of one drug. Moreover, 5% of the mothers who
continued to breast-feed were receiving medication for asthma, allergy,
hypertension, arthritis, diabetes, and epilepsy or migraine (Bennet, 1988). Drug
use for infection, pain relief and other acute and chronic disease symptoms
during breast feeding is very common (Hernadez et al., 2009).
Most drugs and their metabolites in maternal blood pass the barrier of the
mammary gland and distribute into the milk. They can modify the production,
volume and composition of the milk to produce possible short- or long-term
harmful effects on the infant. Significant drug-related symptoms in breast-fed
infants [such as irritability, vomiting, sedation, respiratory depression and shock]
have been reported in clinical cases. One extreme example of clinical case
reports is the fatal opioid poisoning in a breastfed neonate whose codeineprescribed mother was a CYP2D6 (Cytochrome P450 2D6) ultrarapid
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metabolizer (UM) (Madadi et al., 2009). CYP2D6 is a member of the cytochrome
P450 system and it is one of the most important enzymes involved in the
metabolism of xenobiotics in the body. The pathway of codeine and morphine
metabolism is shown in Figure 1-2. Although codeine has been recommended
by the American Academy of Pediatrics as being compatible with breastfeeding,
a polymorphism of breastfeeding mother in CYP2D6 added complexity to this
case. Codeine is a prodrug and its analgesic properties are primarily dependent
on its biotransformation into morphine by the cytochrome enzyme P450 2D6
(CYP2D6). Its active product, M6G is almost exclusively catalyzed by the
enzyme uridyl glucuronosyltransferase 2B7 (UGT2B7). Therefore, the breastfed
infant of a mother who is CYP 2D6 UMs combined with the UGT2B7*2/*2
genotype may result in increased in dose exposure level and as a result an
increased risk of life-threatening CNS depression for the newborn (Madadi et al.,
2009). These observations prompted the Food and Drug Administration to issue
a Public Health Advisory on the topic (Use of Codeine By Some Breastfeeding
Mothers May Lead To Life-Threatening Side Effects In Nursing Babies)
There also may be long term, more subtle developmental effects of drug
exposure at early stages of life which are very difficult to monitor or ascribe
cause and effect (Arendt, 1997; Khaksari et al., 2009). Likewise there may be
consequences for mother and child if maternal pharmacotherapy is forgone. For
example, untreated depression may have a deleterious effect on the emotional
development of their children and significant depression, especially if
complicated by delusions, may lead to the mother attempting suicide and
infanticide (Gentile, 2005). Consequently maternal medication during lactation
must consider not only benefit of breastfeeding but also health of mother and
infant. Doctors need to help mothers weigh the risks of prenatal exposure to
drugs for their babies against the potential risks of untreated illness or to forego
the benefits of breastfeeding. These therapeutic considerations include
susceptibility to drug toxicity of the very young or premature infant, significant
individual variations in drug response, the dose-response relationship with
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respect to drug toxicity and the role of pharmacogenetics in both the mother and
the infant (Berlin et al., 2009).

Figure 1-2 The pathway of codeine and morphine metabolism. Figure is cited from
(Thorn et al., 2009)

While the above consideration is warranted, there are very few studies
conducted in breastfeeding women and their infants to make an appropriate risk
assessment for drug use in lactation. A 2003 FDA analysis of the prescribing
information of the 1022 drugs in the Physician’s Desk Reference illustrates the
problem (Uhl et al., 2003). Only 25% of drug labels had information of drug
transport in human milk and/ or effects in nursing infants. In addition, 16% of
drug labels had information on drug excretion into milk in animals and more than
half of them had no information at all. The problem is not limited to older drugs. It
was estimated that less than 10% of the new molecular entities approved
between 1995 and 2002 gave any information on human milk transfer in their
5

regulatory filings (Uhl et al., 2003). Therefore, considerable confusion in the
scientific community regarding this issue exists (Friguls et al., 2010): should a
woman breastfeed her baby while continuing to use prescription drugs and/or
drugs of abuse? What is the mechanism of drug transfer into milk? What is the
extent of drug exposure and does this present a significant risk to the newborn?
The discussion of the mechanism of drug transfer into milk is one of the critical
steps to address these questions.
C.Physiological mechanisms of drug transfer into milk

1.Physiology of mammary gland

Figure 1-3 The development of structure of mouse mammary gland under the control of
hormones in ontogeny. The proportion of epithelial cells in lactating are obviously
increased than in non-lactating and involution. The solid green circle represents the
nipple (N) from which the ducts originate. The ends of growing ducts form terminal end
buds (TEB) during puberty. Mammary ducts (D) are shown as solid lines and the
lobuloalveolar structures are presented as yellow circles (A). Epidermal growth factor
(EGF) signals through the stroma and controls early ductal outgrowth. Together with
estrogen, it also controls ductal elongation and branching during puberty. Progesterone,
placental lactogens, prolactin, and the osteoclast differentiation factor signal alveolar
proliferation and differentiation during pregnancy and possibly lactation. The figure was
modified from Lothar Hennighausen’s paper (Hennighausen and Robinson, 2001).
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Briefly, the mammary gland is comprised of epithelium and stroma. The
functional unit of milk production is alveoli which are formed by two types of
epithelial cells. The majority are luminal secretory cells which produce breast milk
and secrete it into a central lumen. These cells can form the barrier between the
breast milk and the maternal circulation.

The development of the mammary

gland is different from most of other organs. It estabolishes in embryo and further
development, predominant differentiation and proliferation of mammary gland,
occurs after birth and under the control of hormones (Figure 1-3). The embryonic,
prepubertal, pubertal, pregnancy, lactation and involution stages are connected
with sexual development and reproduction. Following initial embryonic and
prepubertal stages, the growth and development of mammary gland is
dependent on the stimulation of hormones. The steroid hormones control ductal
and alveolar development. It has been proposed that progesterone through
activating Wnt signaling pathway is essential for the cell proliferation of mammary
gland (Brisken et al., 2000). Both estrogen and progesterone induce ductal side
branching in mice (Xu et al., 2000). The proliferation and differentiation of
secretory mammary gland epithelium are dependent on the interaction between
prolactin and prolactin receptor (PrIR) (Ormandy et al., 1997) and the
downstream Jak-Stat5 pathway. Jak-Stat5 signaling pathway controls cell
proliferation, differentiation and specification in development of mammary gland.
During a successful pregnancy, hormonal changes associated with pregnancy
induce series changes in the maternal hypothalamus, stimulating maternal body
development to prepare for lactation. The size and number of alveoli grows and
develops under hormonal stimulation and intercellular gaps close for the
preparation of lactation (Neville and Watters, 1983). The inner structure and ratio
of cell types in mammary gland undergoes significant change. The proportion of
epithelial cells in lactation is obviously increased than in non-lactation (Figure 13).
2. Milk components and secretion pathways
Drug is likely to be transported into milk via the same pathways which milk
components secreted from serum or secretary cells into lactating mammary
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gland. Therefore, to fully understand drug accumulation into milk it is helpful to
examine the mechanism of milk formation itself.
Breast milk has evolved in mammals to enrich all necessary nutrients for the
growth and development of the newborn. The various milk components include
lipids, protein, carbohydrates, water, calcium and phosphorus, iron, zinc, copper,
manganese, selenium, iodine, vitamins D, K, A, E, C, thiamine, riboflavin, niacin,
pantothenic acid, pyridoxine, biotin, folate, and cyanocobalamine (Nichols and
Nichols, 1981).
From the cell biology of lactating alveolar cells in mammary gland, there are
a number of potential barriers to the transfer of exogenous substances from
blood to milk side: (1) vascular or stromal membranes; (2) basement membrane;
(3) basal epithelial membranes, (4) paracellular junctional complexes, (5) Golgi
membranes and (6) apical epithelial membranes (McManaman and Neville,
2003). Some proteins in milk are synthesized and secreted by the epithelial cells
themselves. The major amounts of lactation-specific proteins present in milk are
synthesized in rough endoplasmic reticulum (Larson, 1979) and then secreting
into the Golgi apparatus to finish post-translational modifications and ejected into
the lumen with other milk components (Larson, 1979). Substances derived from
maternal circulation get into milk by overcoming the various barriers between
blood and milk. The five pathways for solute to enter milk by transcellular and
paracellular routes are summarized in Figure 1-4 (McManaman and Neville,
2003).
Pathway I: Aqueous solutes include the major milk proteins,
oligosaccharides, and nutrients such as lactose, citrate, phosphate and calcium.
They are secreted through an exocytotic pathway.
Pathway II: Primarily triglycerides and lipid-associated proteins are secreted
by a process unique to mammary epithelial cells (Mather and Keenan, 1998).
Pathway III: It is a transcytosis pathway and transports a wide range of
macromolecular substances derived from plasma or stromal cells, including
endocrine hormones such as prolactin, insulin and estrogen (Koldovsky, 1995;
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Ollivier-Bousquet, 1998); serum proteins such as albumin, transferrin and
immunoglobulins (Hunziker and Kraehenbuhl, 1998); and stromal derived agents
such as secretory immunoglobulin A, cytokines and lipoprotein lipase (Goldman
et al., 1996; McManaman and Neville, 2003).

Figure 1-4 Diagram of mammary alveolus and alveolar epithelial cell showing pathways
for milk secretion. Abbreviations: SV, secretory vesicle; RER, rough endoplasmic
reticulum; BM, basement membrane; N, nucleus; PC, plasma cell; FDA, fat depleted
adipocyte; JC, junctional complex containing the tight and adherens junctions; GJ, gap
junction; ME, myoepithelial cell. MFG, membrane bound milk fat globule. Figure is cited
from (McManaman and Neville, 2003).

Pathway IV: For the transfer of ions and small molecules, such as glucose,
amino acids, and water across basolateral and apical plasma membranes.
Pathway I and II are for secretion of endogenously generated substances.
Pathway III and IV exist for transport of exogenous substances to milk.
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Pathway V: Paracellular transport provides an entry of plasma components,
leukocytes, serum and interstitial substances into milk (Nguyen and Neville,
1998). Pathway V is typically open but becomes very restricted during lactation.
This pathway is open during pregnancy, involution and in inflammatory states
such as mastitis.
D.The pathway of drug transfer into milk
1. Paracellular transport

Paracellular transport (Pathway V) plays minimal role in drug accumulation in
milk. One would anticipate that some small, polar molecules are candidates for
diffusion through the paracellular pathway since molecular size is the most
relevant parameter relating to rate of diffusion through the restricted paracellular
route. Pathway V is closed by the tight junctions between epithelial cells during
lactation in humans and most other species except rabbit (McManaman and
Neville, 2003) (Figure 1-4). Therefore drugs are transferred at a slow rate and in
very low amounts by paracellular transport; hence, this pathway is generally
considered negligible for most drugs.
2. Transcellular passive diffusion
Theoretically, passive diffusion is expected to be a common pathway for
most endogenous or exogenous substances (including drugs, environment toxins
and their metabolites) in blood circulation to pass through the barriers of alveolar
epithelial cell and distribute into milk. Smaller, more lipophilic molecules partition
into lipid bilayers and pass more readily through the epithelial membranes. The
equilibrium between serum and milk tends to be rapid and there is no need for
the assistance of transporters.
The drug concentration in milk is proportional to the corresponding
concentration in maternal serum based on the passive diffusion pathway. The
parameter, milk to serum (M/S) ratio, which compares milk with maternal plasma
drug concentrations, serves as an index of the extent of drug excretion in milk.
Drug distribution resulting in passive diffusion between serum and milk can be
10

predicted or estimated by a diffusion model (Fleishaker, 2003) and calculated by
Eq.1-1.

Eq. 1-1

where fu is the unionized fraction of drug in serum or milk, f is the free fraction of
drug in serum or milk, W/S is the ratio of the drug concentration in whole milk to
the drug concentration in skim milk, and the subscripts s and m represent serum
and milk, respectively.
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Figure 1-5 M/S predicted vs observed in rabbit, rat and human for a number of drugs.
Exceptions include: nitrofurantoin (NF), cimetidine (CM), acyclovir (ACV), ranitidine (RN)
and ciprofloxicin (CP).

Figure 1-5 shows that the results of passive diffusion model (M/SDif) to
predict drug M/S ratios from a series of experiments which were conducted in
lactating rabbits, rats and humans (Fleishaker and McNamara, 1988a; Fleishaker
and McNamara, 1988b; McNamara et al., 1991; McNamara et al., 1992a;
McNamara et al., 1992b). It illustrates the relationship observed M/S versus
M/SDif for ten drugs: propranolol, phenobarbital, phenytoin, diazepam,
acetaminophen, antipyrine, salicylic acid, caffeine, paraxanthine and cimetidine.
The diffusion model predicted well the transport into milk for all drugs in rabbit
and many of the drugs in rat and human. For some drugs, such as cimetidine
and nitrofurantoin, the observed M/S in rat and human milk clearly exceeded the
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diffusion prediction. The prototypical example is nitrofurantoin in rat and clinical
studies. Oo et al. showed that an infusion of 0.5 mg/h nitrofurantoin resulted in an
M/S in vivo that was almost 100 times greater than the value from the diffusion
prediction (31.1± 4.0 v. 0.3 ± 0.1) in rat. In a clinical study, M/S determined by a
ratio of the nitrofurantoin AUC in milk and serum was 22 times as the predicted
M/S diff. (6.21 ± 2.71 vs. 0.28 ± 0.05) (Gerk et al., 2001a). CM and RN transfer
into rat milk could be saturated and inhibited (McNamara et al., 1996). Taken
together, these results suggest the presence of the active transport processes
across the mammary epithelium that are involved in drug accumulation into milk
(Oo et al., 2001).
3. Transcellular active transport
In some instances, physical and chemical properties such as size, charge,
and hydrophilicity are impediments for drug passage across biological
membranes (Klaassen and Aleksunes, 2010). Pathway IV includes some solutespecific mechanisms for the transport of ions and small molecules such as
glucose and amino acids. These processes require the presence of specific
transporters on the basolateral or apical side of epithelial cells. A number of
transporters have been shown to be expressed in lactating mammary epithelial
cells and are responsible for various components transport into milk. Some of
them are likely to be involved in drug accumulation in milk as well.
E.Transporter expression in lactation

During lactating, the change of alveoli in mammary gland is not only in size
and number but also in protein expression on epithelial cells for the preparation
of lactation, including glucose, amino acid transporters. In order to exclude the
effect of the changes of mammary gland in structure on the investigation of
transporter expression during lactation, Alcorn et al first isolated a pure
population of epithelial cells from human breast milk and reduction
mammoplastic clinical samples to investigate 30 transporter expressions in
lactating mammary gland by quantitative reverse transcription-polymerase chain
reaction (Alcorn et al., 2002). In order to cover a broader array of transporter
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expression in lactating mammary gland, Phil Empey (Thesis) used a similar
approach to isolate a pure population of epithelial cells for subsequent gene
expression profiling by microarray. From his dissertation work, the results of
microarray analysis discovered that ABCG2, SLC15A2, SLC22A12, SLC6A14,
and SLCO4C1 were significantly up-regulated during lactation (164-, 70-, 41-, 8-,
and 2-fold, respectively). ABCC10, SLC10A1, SLC16A1, SLC22A4, SLC22A5,
SLC22A9, SLC28A3, SLC29A1, SLC29A2, and SLCO4A1 had an expression
level similar to, or greater than, levels in the kidney or liver (Table 1-1, from Phil
Empey’s dissertation).
PEPT2 is an oligopeptide transporter generally characterized as an apical
uptake transporter (Shen et al., 1999) and if a similar location/function were also
true for lactating mammary epithelium, an associated flux would more likely to
diminish drug concentration in milk. SLC22A12 (an organic anion/urate
transporter) and SLC6A14 (amino acid transporter) are also present at increased
RNA expression level, but these transporters appear to play a less likely role in
drug transport (Anderson et al., 2008; Ohtsu et al., 2010). However, one
investigation showed 1-Methyltryptophan, which is an inducer of immune
surveillance against tumor cells by inhibiting indoleamine dioxygenase, is a
substrate for SLC6A14 [ATB(0,+)](Karunakaran et al., 2008). Therefore,
additional studies should be performed to investigate whether ATB (0, +) has a
role in drug transport into milk. The significant up-regulation of SLCO4C1 is a
novel finding. SLCO4C1 has not been widely studied, but is considered to be an
uptake basolateral transporter (Chu et al., 2007; Cheng and Klaassen, 2009).
SLCO4C1 belongs to the organic anion transporting polypeptides (OATP) family
of influx transporters expressed in numerous tissues (liver, brain, intestine,
kidney) and facilitate the tissue uptake of substrate drugs (Kalliokoski and Niemi,
2009). A number of recent reports have shown that OATP uptake transporters
(e.g, OATP1B1) on the basolateral membrane can function in concert with apical
efflux transporters (e.g., P-gp, MRP2 and ABCG2) to facilitate the transcellular
transport of drugs (Matsushima et al., 2005). The most important and established
efflux transporter on apical side of epithelial cells in lactating mammary gland is
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ABCG2. Therefore, a reasonable hypothesis is that SLCO4C1 coordinates with
ABCG2 to regulate substrate movement into breast milk. However, unpublished
data from our group studies (Kuei-ling Kuo) suggests that SLCO4C1 is on the
apical instead of the basolateral membrane.
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Table 1-1 Comparison of Affymetrix U133 plus 2.0 array transporter probeset expression levels in human LMEC (lactating luminal
mammary epithelial cell) vs. MEC (mammary epithelial cell). Genes are grouped based on whether they are increased or decreased
during lactation. Probesets for the same gene were grouped into sections of the table sorted by fold change in expression (From Phil
Empey’s dissertation).

Gene
Symbol

LMEC
Probeset ID

p-Value

Mean

MEC
SD

Mean

Fold
SD

Change

ABCG2

209735_at

3.69E-02

17536

5964

107

75

164.04

SLCO4C1

222071_s_at

2.39E-03

3362

294

48

31

69.70

SLC15A2

205316_at

3.62E-03

3936

421

96

47

40.80

205317_s_at

2.16E-03

868

182

89

62

9.72

240159_at

8.99E-04

243

31

76

10

3.18

SLC22A12

237799_at

2.79E-02

184

80

24

19

7.84

SLC6A14

219795_at

4.13E-02

3988

1193

1773

500

2.25
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Higher during lactation (p < 0.05, fold change >1)

F. ABCG2

1.General introduction of ABCG2
The ATP binding cassette (ABC) transporter family is a large protein
superfamily. ABC transporters are widely distributed in membranes of all
organisms from bacteria to mammals, such as in the brush border membrane of
intestinal cells, the canalicular and sinusoidal membrane of hepatocytes, the
luminal and basolateral membrane in the proximal tubules of the kidney and in
the endothelial cell of the brain capillaries (Kos and Ford, 2009; Wang et al.,
2009a; Klaassen and Aleksunes, 2010). They are responsible for transport of a
wide variety of compounds through cell membranes against concentration
gradient using the energy of ATP hydrolysis for the process of substrate
translocation (Rocchi et al., 2000). The existence of ABC transporters can have a
significant effect on the absorption distribution metabolism elimination (ADME),
toxicity and the adverse drug-drug interactions of substrate drugs.
ABCG2 is a member of ABC family subfamily G and it has been confirmed as
an important transporter in mammalian defense system. ABCG2 is also named
as mitoxantrone resistance-associated protein (MXR) or breast cancer resistance
protein (BCRP) because it was first cloned from a multidrug-resistant breast
cancer cell line (Doyle et al., 1998); however, subsequent studies indicate that
BCRP is not a unique or special characteristic for breast cancer cells and many
of these cells were found lacking BCRP expression (van Herwaarden and
Schinkel, 2006). A growing body of evidence strongly suggests that ABCG2 is
one of the more important efflux transporters having a strong impact on the
pharmacokinetic profile, pharmacodynamics, and toxicity of drugs.
The typical structure of the majority of mammalian ABC transporters contains
2 types of structural domains: the hydrophobic membrane spanning domain
(MSD) comprising several transmembrane α-helices and the hydrophilic,
intracellular nucleotide binding domain (NBD) (Mao and Unadkat, 2005). The
mRNA of ABCG2 encodes a 655 amino acid protein (72-kDa) that contains a
single N-terminal ATP binding cassette followed by six trans-membrane
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segments. Comparison of protein sequences with that of P-gp and MRP1,
ABCG2 proteins are half transporters that are composed of a single NBD
followed by one MSD. Hence, the structure of ABCG2 appears to be a half
transporter and functions as a homodimer (Doyle and Ross, 2003) or
heterodimers (Xu et al., 2004). Kage et al demonstrated that the breast cancer
resistance protein (BCRP, ABCG2) forms an S-S homodimer (Kage et al., 2002)
and Cys-603 is an important residue in the formation of the covalent bridge
between BCRP monomers (Kage et al., 2005). Recently the results from
mutation of Cys at different position of ABCG2 indicated that Cys-mediated
covalent dimerization is not required for ABCG2 to function as a transporter and
that Cys-603, Cys-608 may also be involved in BCRP dimmer formation (Figure
1-6) (Shigeta et al., 2010).
ABCG2 polymorphisms that alter expression or function of protein have been
observed and it has been reported that variants of ABCG2 greatly impact the oral
bioavailability and clearance of ABCG2 substrates (Ishikawa et al., 2005). Some
studies have characterized the possible physiological relevance of the ABCG2
polymorphism and functional variants (Mao and Unadkat, 2005). To date,
sequencing of the ABCG2 gene from human samples has discovered over 80
different, naturally occurring sequence variations (Ishikawa et al., 2005). In
general, the studies of polymorphisms of ABCG2 have been focused on
resistance of anticancer drugs. For example, a variant at position 482 which is
responsible for the resistance to mitoxantrone, doxorubicin, and daunorubicin,
reduces daunorubicin accumulation and retention, and causes an ATPdependent enhancement of the efflux of rhodamine 123 in the cloned transfected
cells. At least three variant forms of ABCG2 have been documented on the basis
of their amino acid moieties (i.e.,arginine, glycine and threonine) at position 482
(Mitomo et al., 2003). They have been reported causing change of drug
resistance profile and substrate specificity.
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Figure 1-6 Schematic depiction of the breast cancer resistance protein (BCRP) with 12
cysteine residues indicated. Three of these residues, Cys-592, Cys-603, and Cys-608,
are localized in the third extracellular domain (Shigeta et al., 2010).

ABCG2 is abundant in the luminal membrane of endothelial cells of blood
capillaries in the brain, epithelial cells of placenta, kidney, liver and intestine to
limit endogenous or exogenous xenotoxins into body (van Herwaarden and
Schinkel, 2006), and importantly in most of cancer cells where ABCG2 plays
important roles to resist chemotherapy or acquire resistance during treatment.
2. ABCG2 and drug transfer into milk
As mentioned in previous section, nitrofurantoin and cimetidine are actively
transported into human and rat milk, and result in drug accumulation much
greater than predicted by the diffusion model.

However, the mechanism

remained unknown until studies at the Netherlands Cancer Institute (Jonker et
al., 2005; Merino et al., 2005b) which indicated that ABCG2 was strongly upregulated in the mammary gland of mice, cows and humans during lactation and
was responsible for the active secretion of clinically and toxicologically important
substrates into mouse milk, such as the dietary carcinogen PhIP, the anticancer
drug topotecan and the antiulcerative cimetidine (Jonker et al., 2005).
ABCG2 and P-glycoprotein are generally considered to be protective
transporters. In general, they play a role in barrier systems (e.g., blood brain
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barrier, placenta, gut wall) that protect more vulnerable entities (e.g., brain, fetus,
and whole body) from harmful xenobiotics. Hence, the physiologic function of
ABCG2 in lactating mammary epithelium is not fully understood, since high
concentration of drugs and environment toxins in milk may be harmful to infants.
Evolution would tend to favor physiology that is efficient and protects the
developing newborn. ABCG2 transporting drug and toxin to milk would run
counter to this tenet. The study of riboflavin suggests a possible physiological
role for ABCG2 in lactating mammary epithelial cells. As an important vitamin,
riboflavin can be converted to the essential coenzymes which participate as
electron carriers in many important redox reaction chains in body (Powers,
2003); however, riboflavin cannot be synthesized by mammals. Riboflavin is an
ABCG2 substrate and is transferred into milk by ABCG2 (van Herwaarden et al.,
2007) which could imply that ABCG2 may be serve as a milk vitamin and nutrient
transporter.
G. In vivo model to study drug transport

Knockout mouse models are the most popular in vivo approaches for the
function study of transporter or other proteins (Kooij et al., 2009; Lagas et al.,
2009a; O'Byrne et al., 2009). The alteration of drug disposition following the
knockout of a specific transporter provides compelling evidence for the
significance of the transporter (Agarwal et al., 2010; de Waart et al., 2010;
Kodaira et al., 2010). However, mammalian physiology is a complex,
interconnected system and no one protein or pathway is truely independent. In
some transporter knockout mice models, the mice cannot survive from disease or
nutritive deficiency, such as deletion of the taurine transporter gene (taut) which
results in all taut-/- mice succumbing to infections (Delic et al., 2010), whereas in
other examples, the homeostasis is maintained in a relative normal state even if
one important pathway has been impaired. This would imply that the pathway
associated with the transporter may not be the only one responsible for function
or there are adjustments on compensatory mechanism. The body is under an
integrated regulation control to maintain the normal physiologic function.
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It has been observed that the expression of other proteins changes after
knocking out a specific protein in several transporter knockout studies (Chu et al.,
2006; Kooij et al., 2009). For example, Mdr1a deficient mice express 3 times as
much Abcg2 compared to wild-type mice (Cisternino et al., 2004); the level of
Mrp4 mRNA and protein expression in liver and kidney of Mrp2 (-/-) mice
increase approximately 6- and 2-fold, respectively (Chu et al., 2006). Whether or
not these increased expressions of other transporters provide a compensatory
mechanism in these knockout mice models will depend upon the particular
substrates (or biochemical pathway). Nonetheless, there may be unintended
and unknown consequences following the knockout of a specific gene.
Inhibition of transport of a compound by a specific inhibitor is often used for
transporter studies in in vitro experiment, and a chemical knockout could be an
alternative way to overcome shortcomings of a knockout mouse model if the
function of a transporter in vivo can be completely inhibited. A critical criterion in
selecting an inhibitor is specificity. Many inhibitors are nonspecific and they
interact with several transporters and even drug metabolism enzyme (Matsson et
al., 2009). The inhibitor specificities of P-gp, BCRP and MRP2 were shown to be
overlapping. Moreover, P-gp and CYP3A4 have significant overlap in substrate
specificity (Kim et al., 1999). So the specificity of an inhibitor as a “chemical
knockout” should be considered carefully when correlating the organ with
multiple different transporter expressions, such as kidney and liver. GF120918
(N-(4-[2-(1, 2, 3, 4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10dihydro-5-methoxy-9-oxo-4-acridine carboxamide) is an inhibitor for both P-gp
and ABCG2; however, P-gp is not expressed in mammary gland. The rat is the
most common animal model for drug development. A functional blockade of
rAbcg2 by a specific inhibitor (a “chemical knock out”) resulting in a decrease in
active drug transport into milk would be a useful in vivo model for verification of in
vitro experiments.
H. In vitro models to study drug transport
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Optimal pharmaceutical therapy delivers drug to the target site(s) in the body
at concentrations adequate to obtain a positive pharmacological effect. One
factor affecting drug reaching the target site, as well as systemic exposure is
drug transport into and out of cells (David T. Rossi, 2002). The presence of
transporter(s) has been shown to affect the therapeutic consequence of many
important drugs. Therefore, in order to decrease the cost in drug development
and optimize the pharmacokinetic properties of drug candidates during the early
stages, characterizing drug transporter interaction is a widely accepted strategy
(White, 2000; Roberts, 2001). Broadly, in vitro methods are the most common
choice to evaluate key pharmacokinetic properties of drugs in pharmaceutical
industry. These in vitro systems tend to focus on drug metabolism enzymes and
transporter (Yamashita et al., 2002; Schwab et al., 2003; Zhou et al., 2010). In
general, the range of these available in vitro tools scale from relatively simple
biochemical approaches to complex cell culture model.
1. ATPase assay for ABC transporters
ATPase assay is one of a limited number of traditional biochemical available
methods for the assessment of drug transporter function (Stanley et al., 2009).
The method is based on the realization that transporters utilize the energy from
ATP hydrolysis for substrates translocation (Figure 1-7). It measures the
utilization of ATP and indirectly provides an estimate of transporter mediated
drug transport (Gannon et al., 2009; Robey et al., 2009). For example, ATPase
activity measured in the presence of orthovanadate represents non-P-gp ATPase
activity and can be subtracted from the activity generated without orthovanadate
to yield vanadate-sensitive ATPase activity (Schwab et al., 2003). In this method,
isolation of intact membranes is important to estimate vectorial transport but it is
controllable and easier than other biological systems (transwell monolayer or Sf9
vesicles). It can be used for high throughput screening since we do not have to
develop a specific assay for each drug. However, this method is, at best, a proxy
for actual directional transport (Stanley et al., 2009). Also some substrates that
are transported do not stimulate ATPase activity and, hence, this approach would
result in false negatives.
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Figure 1-7 The mechanism of ATPase assay for ABC transporters. This figure is cited
from the homepage of SOLVO Biotechnology Company
(http://www.solvobiotech.com/Solvo%20Solutions/atpase_assays.html )

2. Monolayer flux model for transcellular transport assay
Flux across a monolayer of cells grown on a porous plexiglass filter (i.e.,
sometimes referred to as Transwell after the name of the filter system) is the
most popular method to study transporter. Monolayer flux model provides an
efficient, low throughput pathway to screen new molecule entries in drug
discovery (Balimane et al., 2004; Xiao et al., 2006), or study drug-drug interaction
(Marchetti et al., 2007; Wang et al., 2009b) and drug transport mechanism
(Wang et al., 2009b). It mimics in vivo environment by culturing specific cell lines
on the permeable supports. These cells can polarize and form an integrated
monolayer with tight junction on the support membrane. This model produces a
separate apical or basolateral domain for the different purpose studies, uptake,
efflux or secretion. Selection of an appropriate cell line is a key step to establish
an appropriate model system. The cell lines which are often used for monolayer
flux studies include the following:
22

Primary cell lines
Primary cell culture involves the use of cells that are directly isolated from
tissues or organs and may most closely mimic in vivo environment. Cultures are
established either as explants, using mixed cell populations from small fragments
of tissues, or using purified populations of defined cell types. For the explant
culture, one type cell could adapt in vitro environment quickly than other cell
types by proliferating rapidly and outgrowing (Burdall et al., 2003). It should be
noted that explants culture may be significantly different from the original
structure of tissue or organ. This is a particular problem with explants, and so
primary cultures may be more desirable and controllable. Primary culture
typically involves the preparation of the cells every time and not as a continuous
culture; hence, it tends to be labor intensive and may lack the necessary
reproducibility to compare results across a series of experiments (Stanley et al.,
2009).
Continuous culture cell lines
In order to overcome the disadvantages of primary cell culture and meet the
preference for cell culture that is reproducible and easy to work with, several
continuous cell lines have been established for drug transporter study. They also
can be used as host (parent cell lines) to overexpress a single or double specific
transporter(s) for further function study.
CaCo-2 is a human colon tumor-derived cell line that has been widely used
for the high-throughput screening of drug permeability and identification of
substrates, inhibitors, and inducers of intestinal transporters (Sun et al., 2008).
The CaCo-2 screening system has remained a popular in vitro model to test
compounds for intestinal permeability and efflux liability for more than a decade
(Press and Di Grandi, 2008). CaCo-2 was considered by the pharmaceutical
industry for the development of cell culture systems that could mimic intestinal
mucosa and thereby mimic drug absorption. The CaCo-2 cell line has a welldifferentiated brush border on the apical surface and tight junctions, and
expresses typical small-intestinal microvillus hydrolases and nutrient
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transporters. In addition, since differentiated CaCo-2 cells express various
cytochrome P450 isoforms and phase II enzymes such as UDPglucuronosyltransferases, sulfotransferases and glutathione-S-transferases, this
model could also allow the study of presystemic drug metabolism (Meunier et al.,
1995). The CaCo-2 is popular because it is of human origin, easy to maintain
(Ohashi et al., 2009) and derived from a colon cancer. In addition, as a single cell
line, it expresses the appropriate polarized phenotype as in vivo but it is free of
mucus and underlying submucosal and muscular tissue, which could interfere
with drug transport.
LLC-PK1, the porcine kidney cell line, LLC-PK1, has been used as a model
for drug-transport studies for around 15 years (Aszalos, 2004). LLC-PK1 cells
have a polarized phenotype in culture and express some endogenous P-gp
activity (porcine P-gp). The presence of porcine P-gp in LLC-PK1 cells may
compromise the results of in vitro studies using this cell line (Yamazaki et al.,
2001). The main disadvantage of the LLC-PK1 cell line is it is non-human and
non-rodent origin. However, this cell line is easy to work with and responds well
to transduction with adenoviral vectors (Brimer et al., 2000).
MDCKII (Madin-Darby canine kidney strain II cells), has been used as a
model for drug-transport studies for around 20 years (Aszalos, 2004). This cell
line has been widely used to establish transporter transfection model, such as Pgp (Shirasaka et al., 2009; Tachibana et al., 2010), MRP2 (Lechner et al., 2010)
and ABCG2 (Tournier et al., 2009). MDCKII cells grow fast, form relatively tight
junction, produce interpretable data of relevance for clinicians (Keogh and Kunta,
2006a) and with low expression level of MDR1, MRP1 and MRP2. MDCKII has
been well characterized as a good host cell line for transfection.
Overexpressing transporter cell lines
The overexpressing transporter system is an effective tool for studying the
activity of individual transport processes. It brought into perspective the
possibility to investigate transporter interaction with substrate on monolayer.
Usually, the difference between efflux ratios on the transfected and parental cell
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lines is regarded as transporter mediated active uptake or efflux process (van
Herwaarden et al., 2007; Zhou et al., 2008; Lagas et al., 2009b). To date,
overexpressing transporter in a host cell line has been a widely accepted
technique. P-gp, MRP2, ABCG2 and other transporters have been
overexpressed in CaCo-2, LLC-PK1 and MDCKI or II for different study
purposes. The expression level and the function of specific transporter can be
characterized and provide some pharmacokinetic insights, however, this method
may not reflect the in vivo condition.
3. Membrane vesicles with transporter protein
Another popular method to study transporter is membrane vesicle of insect or
mammalian cells which also introduces the overexpressing transporter system
into a host cell line. Target transporter can be expressed on membrane of cells
by either stable transfection (heterologously overexpressed) or baculovirusmediated expression in insect cells. In general, stable overexpression is most
often chosen for mammalian cell lines, such as MDCKII, LLC-PK1 and CaCo2
(Burger et al., 2005; de Wolf et al., 2008; Zhao et al., 2009; Zhang et al., 2010).
Although it is possible to perform in insect cell lines (Kohler et al., 2000; Kempf et
al., 2002); however, single insect cells are not easy to grow and the
establishment of a monoclonal cell line is difficult following transfection. Hence,
there is a limited number of studies which include other proteins (such as
receptor) overexpressed in Sf9 insect cells. In most of situations these cells were
used as a population after selection and the percentage of expression cells
would be estimated (Kohler et al., 2000; Kempf et al., 2002).
Baculovirus-mediated expression in insect cells is a well-accepted approach
to produce recombinant transporter protein. It is frequently used because it is
relatively easy to use and the high likelihood of acquiring expected expression
level of heterologous protein and the high probability of obtaining a biologically
active protein. Insect cell is a popular alternative host to bacteria for expression
of recombinant proteins. Several factors contribute to this widespread use,
including the development of vectors with features that provide ease-of-use and
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high expression levels of recombinant protein, post-translational modifications
such as glycosylation and phosphorylation which mimic those modifications in
mammalian cells. Hence, Baculovirus-mediated transporter expressing in insect
cells could be used for mammalian transporter study of qualitative
pharmacokinetic estimates (Pedersen et al., 2008; Lagas et al., 2009b; Vaidya et
al., 2009).
Membrane fractions can be isolated from overexpressing transporter in either
mammalian cells or insect cells. The membrane fraction including functional
transporter would form vesicles. Theoretically, the orientations of these vesicles
are half and half (50% is “inside in” and 50% is “inside out”). Thus, efflux
transporter study can take advantage of “inside out” membrane vesicle where the
ATP binding site is exposed. The technique also changes the efflux study
paradigm to one of vesicle accumulation, so that the experiment can be specific,
ATP dependent and controllable.
I. In vitro models to estimate kinetic parameters of drug transporters

The most common in vitro models to estimate kinetic parameters of drug
transporter are based on transporter overexpressing systems; either membrane
fraction or whole cell system. Both approaches utilize overexpressing transporter
into cell lines (mammalian or insect) to conduct a range of studies to determine
Michaelis-Menten type kinetic parameters and Ki or IC50 values either directly or
indirectly.
1.Transporter ATPase (Km and Vmax)
As mentioned previously, ATPase assay is a cost effective assay to identify
interaction between test compounds and transporters since it is not necessary to
establish a method for each compound. The membrane fractions are isolated
from transporter over-expressing in Sf9 (Feng et al., 2008) or other mammalian
cell lines (Robey et al., 2009; Cai et al., 2010). ATPase activities were calculated
in terms of nanomoles of phosphate per milligram of total vesicle protein per
minute of incubation time. Apparent affinity values (Km) of ATPase, could be
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estimated from the concentration-response data by nonlinear regression (Feng et
al., 2008). Affinities of substrates for transporter can be ranked differently
according to the range of Km of transporter ATPase (Feng et al., 2008). In some
cases, the value of Vmax/Km is used to compare the transport property of different
mutants of transporters (Cai et al., 2010). In addition, the parameter estimation of
transporter ATPase avoids the culture of intact monolayer and basolateral
transport limitation from Transwell. However, Km and Vmax of transporter ATPase
are not equivalent to the Km and Vmax of transporter-substrate complex. They
provide a useful indication of activity of transporter but not real translocation
parameters.
2. Transporter from cellular transport (Km and Vmax)
Intracellular accumulation of substrates is a popular method for the functional
study of transporter to identify either uptake or efflux (Pan et al., 2009; Zheng et
al., 2009; Agarwal et al., 2010; Pan et al., 2010). In some studies intracellular
transport (also called cellular accumulation) is used to determine the kinetic
parameters of efflux transporter, such as Km and Vmax of ABCG2 (Pollex et al.,
2010). In this method, it was assumed that the permeability of empty cell line (as
nonsaturable transport or passive diffusion) was same as in a transporter
overexpressing cell line. Time dependent transport and concentration dependent
experiments were performed. The data were fit into nonlinear regression analysis
to determine Km and Vmax of ABCG2.
The driving forces for this transport process can be described in Figure 1-8.
In this in vitro model there are a passive diffusion, an efflux transport on the
membrane but no paracellular transport between cells. Although there is no
passive diffusion presentation from basolateral as in Transwell model; they do
have passive diffusion exposure on the membrane for efflux transport. The drugs
or substrates to be effluxed out of cell must first diffuse into the cell. It should be
recognized that the donor concentration of substrate is not the driving force for
efflux transport process, but is the cellular concentration. As a result, functional
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qualitative characterization may be acceptable; however, the Km and Vmax of
transporter estimated from accumulation experiment may also be inaccurate.

PSD

PSefflux

Figure 1-8 The model of drug accumulation in cell on plate.

3. Cell monolayers (Km and Vmax)
Transwell is a method used to estimate Michaelis-Menten type kinetic
parameters (Km and Vmax ) of a substrate for a transporter (Breedveld et al., 2004;
Petri et al., 2004). The substrate obtained from the receiver side of the Transwell
is detectable by HPLC or LC-MS. In Figure 1-9, there is an example in which the
K1/2 (Km) of pantoprazole was obtained from Transwell data (Breedveld et al.,
2004) and estimated to be 100-200 µM. However, several issues with this
approach need to be fully understood before the information can be utilized
effectively. First consideration is one of correlating flux with concentration. For
vectorial drug transport from basolateral to apical side or apical side to
basolateral, the driving force for efflux transporters is the drug concentration in
the cell, not donor concentration. Second consideration, is the realization that as
with any process, the overall flux rate is controlled by the slowest step in a series.
Permeability associated with diffusion across the basolateral side (PSD) may be
the limiting step controlling the appearance of drug in the apical compartment,
thus masking the apical flux process. Bentz et al reported the steady-state
Michaelis-Menten analysis of P-glycoprotein mediated transport through a
confluent cell monolayer cannot predict the correct Michaelis constant (Km)
(Bentz et al., 2005). Kalvass and Pollack demonstrated that PSD on the
basolateral membrane limits the apical directional transport of substrate so that
ERA (the apical efflux ratio can be defined as the ratio of the initial rate of flux in
the B-to-A direction in overexpressing cell line divided by the initial rate of flux in
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the B-to-A direction in parent cell line ) of substrate in Transwell should not
exceed 2 (Kalvass and Pollack, 2007). Therefore, understanding the mechanism
of drug transport in Transwells is a critical step to estimating Michaelis-Menten
type kinetic parameters (Km and Vmax) of transporter using this approach.

Figure 1-9 Saturation kinetics of pantoprazole transport by Bcrp1 in the MDCKII cell line.
The difference in transport of pantoprazole in MDCKII-Bcrp1 and MDCKII-Parental cell
lines at t = 4 h is plotted against the pantoprazole concentration (in μM). Inset,
Lineweaver-Burk transformation of these results. The apparent K1/2 value at t = 4 h is
0.1–0.2 mM (Breedveld et al., 2004)

4.Kinetic parameters (Km and Vmax) from Sf9 vesicles

PSD
PSefflux

Figure 1-10 The model of efflux transporter in Sf9 membrane vesicle.
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As described previously, Baculovirus-mediated expression in insect cells has
become well-established for the production of recombinant transporter proteins
(Figure 1-10). Overexpressing transporter in Sf9 cells is convenient, fast and
controllable. For efflux transporters, inside-out Sf9 membrane vesicles expose
ATPase site of transporter and substrate concentration directly so that ATP
dependent substrate accumulation can be quantitiated. Because of these
advantages, estimation of Km and Vmax for efflux transporters from Sf9 vesicles
has been widely used (Breedveld et al., 2004). The disadvantage of Sf9 vesicle
experiment is assay limitation. The amount of substrate accumulation in vesicle
is very low and hence, requires highly sensitivity of assay. The samples from
vesicle experiment are difficult to detect by HPLC or even LC-MS methodology.
As a result, a radiolabeled substrate is frequently used for the detection of
uptake. However, most target substrates are not commercially available as
radiolabeled. Some investigators use inhibition experiments to indirectly
characterize parameter values such as the inhibition constant (KI) (Lagas et al.,
2009b). Another consideration is the lipophilicity of the compound. For highly
lipophilic drugs, the ability to discern the affinity of compound could not be
uniquely defined because of the high background accumulation due to diffusion.
In those cases as well, competition experiments may be employed as an indirect
estimate of affinity, as in the estimation of gimatecan affinity for human ABCG2
(Marchetti et al., 2007).
J. The understanding and mathematical model of efflux in Transwells

Since the initial paper using a monolayer flux model was published in 1980’s,
Transwells have been extensively employed in many studies for individual
purpose. The discussion about the underlying mechanism of drug transport
across cell monolayers has greatly deepened our understanding (Lentz et al.,
2000; Tam et al., 2003; Kalvass and Pollack, 2007). A large number of Transwell
studies have focused on P-gp substrate screening using the CaCo-2 system. The
various complex observations associated with Transwell experiments have
caused investigators to consider a number of factors involved in kinetic
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processes and establish the kinetic models to understand the Transwell model
(Roerig et al., 2004; Janneh et al., 2009). Naruhashi et al have examined
whereas the unstirred water layer can be the rate-limiting step for transport of
drugs with high membrane permeability in Caco-2 cells and affect the apparent
permeability of drug transport (Naruhashi et al., 2003). Therefore, investigators
should be cautious in evaluating the contributions of a transporter in the case of
drugs with high apparent permeability.The passive permeability may also have
influence on results of drug transport mediated by P-gp. Some compounds, such
as nicardipine, may pass through the cell membrane faster than P-gp can
transfer it. Thus, the high passive diffusion can mask drug flux across the apical
membrane via P-gp and resulted in that efflux ratio does not affect active
transport (Lentz et al., 2000). Also Liu et al indicated that the filter membrane is a
permeability barrier for the low mass balance compounds (Liu et al., 2009). It is
very important to define the hydrodynamic conditions in these small chambers
with use of in vitro experimental apparatus (Transwell or Snapwell) for transport
experiments (Naruhashi et al., 2003). To date, a relatively comprehensive
approach to explain flux in monolayer system has been presented as a kinetic
efflux model (Kalvass and Pollack, 2007) and Caco-2 cell monolayer theoretical
model (Sun and Pang, 2008).
1. Kalvass and Pollack kinetic model

Figure 1-11 Kalvass’s three-compartment model consistent with efflux attenuating the
initial rate of flux in the A-to-B direction. PSA,inf and PSA,eff, represent the passive
permeability–surface area product of the apical membrane, whereas, PSB,inf and PSB,eff
represent the passive permeability–surface area products of the basolateral membrane.
PSefflux represents the permeability–surface area product of efflux activity. It is assumed
PSA,inf = PSA,eff = PSA and PSB,inf = PSB,eff = PSB (Kalvass and Pollack, 2007).
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Kalvass et al (Kalvass and Pollack, 2007) constructed the three
compartments kinetic model based on the efflux transporter P-gp in monolayer
system (Figure 1-11). Compared with previous P-gp kinetic models (Lentz et al.,
2000; Adachi et al., 2001), it is a system with relative complete and derived from
first principles. It considers all the interactions in the system, such as passive
diffusion on both membranes (apical and basolateral) and efflux on apical side,
the role of cellular concentration in determination of Km, the relationship between
various efflux ratios (ERA: apical efflux ratio (PS0,B→A/PSB→A) or steady-state
(CA,0/CA); ERB: basolateral efflux ratio (PSI,A→B/PSA→B ) or steady-state (CB,I/CB);
ERα : asymmetry efflux ratio (PSB→A/PSA→B) or steady-state (CA/CB) and ERC:
cellular efflux ratio (PSI,A→C/PSA→C ) or steady-state (CC,I,/CC))and efflux activity.
Permeability-surface area product was introduced to the mathematic model.
It derived the theorectical relationships between PSefflux and experiment
parameters, such as Michaelis-Menten constant (Km), 50% inhibitory
concentration (IC50) and the degree of efflux inhibition (Φi). This model is helpful
in illuminating our interpretation of the apical efflux in the monolayer Transwell
model. Overall, it makes the following points:
1). Apical efflux would attenuate the basolateral directional flux and enhances the
apical directional flux. However, neither attenuation nor enhancement of flux is
proportional to the efflux activity.
2). The flux should not be used to calculate the Km or IC50 directly since the
substrate concentration and inhibitor concentration do not relate to flux directly
and the flux is not proportional to PSefflux.
3). Measuring the effect of efflux on permeability in the B to A is uninformative
because it is minimally sensitive to PSefflux by passive diffusion on basolateral
side. Therefore, the maximal ERA is approaching to 2. ERA is not a right
parameter to estimate the efflux activity.
However, some assumptions upon which this model is based may produce a
significant bias of observation significantly: (1) it did not consider the effect of
paracellular permeability (PSPC) on the kinetic parameters and assumed the
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PSPC can be ignored; (2) it did not consider the effect from unstirred water layer
and filter permeability. For P-gp substrates with high lipophilic property, the high
passive permeability and unstirred water layer may become limiting step or mask
the active flux on the membrane. While insightful, the model of Kalvass and
Pollac (Kalvass and Pollack, 2007) has some shortcomings that came to light
while analyzing the pantoprazole – ABCG2 flux data and compelled us to explore
a more complex mechanistic model.
2.Theoretical Caco-2 model
Caco-2 is widely accepted for assessment of permeability to oral drug
absorption. Usually it is used to test whether compounds are substrates of efflux
transporter, especially P-gp (Sun and Pang, 2008). As mentioned earlier, Caco-2
also expresses various CYP 450 isoforms and phase II enzymes, so the
theoretical model of Caco-2 cell monolayer is a comprehensive system which
described both the kinetic parameters from transporter as other monolayer
systems (MDCKII or PK-LLC) and also metabolic contribution from cellular
enzymes (Sun and Pang, 2008).

Figure 1-12 Sun’s three compartment CaCo-2 model. Schematic presentation of the
Caco-2 cell-based system by a catenary model comprising the basolateral (baso), cell,
and apical (ap) compartments. V, f, and C denote volume, unbound fraction, and the
concentration of drugs of each compartment, respectively; M denotes formed
metabolite(s). CLd1 and CLd2,CLd4, and CLd3 denote the influx and efflux and passive
diffusion clearance on the basolateral and apical membrane, respectively. CLinflux and
CLefflux represent the transporter-mediated influx and efflux intrinsic clearances on the
basolateral membrane; CLabs and CLint,sec denote transporter-mediated intrinsic
clearances of absorption and efflux on the apical membrane, respectively; CLint,met is the
metabolic intrinsic clearance. Under nonlinear conditions, CLinflux,CLefflux,CLabs and
CLint.sec, and CLint,met may be replaced by the Vmax/(Km + Cu), where Cu is the unbound
drug concentration(Sun and Pang, 2008).
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In Sun and Pang’s three compartment Caco-2 model (Figure 1-12), apparent
permeability, Papp (is called effective permeability in the paper) and efflux ratio
ERα (is called EfR in the paper) were also introduced as in Kalvass’s kinetic
model. They added two more detailed elements to the model, volume and
unbound fraction of each compartment. Also, a parameter, clearance was used
to represent the drug “in or out ” the cell membranes either by transporters
mediated efflux or influx, or cellular enzymes mediated metabolic intrinsic
clearance. Compared with other kinetic models, this Caco-2 system considered
both sink and nonsink conditions; no assumptions were made for nonsink
condition. They established an “improvised equation” which reflects the
relationship between flux and passive diffusion and active transport; also Vmax,
Km and the number of binding site were also introduced to express active
transport. The effect of high or low passive diffusion on apparent permeability
and efflux ratio was discussed in the paper. However, there was no consideration
of paracellular permeability either in this model. In the improvised equation, the
donor concentration but not cellular concentration of substrate was used to
calculate Vmax and Km. The cellular concentration of substrate is significantly
different from donor concentration so this calculation can result in deviation from
the right value. For the efflux ratio, they conducted same implication equation as
Kalvass’s model (Eq. 1-2 is equal to Eq.1-).

Eq.1-2

Eq.1-3

In this CaCo-2 model the cellular metabolism was another factor which
contributes to the observation of drug efflux or influx on either direction. Briefly,
cellular metabolism can affect the apparent permeability of each direction but the
effects on both directions (AB and BA) are same, so the efflux ratio remains
unchanged.
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Overall, both Kalvass and Sun’s theoretical models were based on the efflux
transporters, P-gp, and both provided insights into flux across a monolayer
system in Transwell. Both recognized that the Transwell monolayer model is not
just a single barrier but two barriers in series; and both utilized a three
compartment model to better reflect the interaction between substrate and
membrane barriers. The description of apparent permeability, efflux ratio, passive
diffusion, active transport, intracellular metabolism and saturation process
indicated the complexities of the system. Due to the large number of parameters
to be ascribed and that saturation may involve in more than one process
(transporter and enzymes), these models are typically limited to theoretical
considerations and are difficult to fit actual observations.
K. Chirality and effect on drug disposition

1.Molecular chirality
In 1848, Louis Pasteur separated the first isomers of fasfasic acid into its lefthanded (levo-tartaric acid) and right-handed (dextro-tartaric acid) forms by using
a hand lens and a pair of tweezers. This experiment established the theory of
chirality in chemical molecules: the compounds contain chiral center and one is
related to another as non-superimposable mirror images. Ten years after Pasteur
first discovered enantiomers of tartaric acid, he indicated that the mold
Penicillium glaucum destroyed two enantiomers of ammonium tartrate differently
and established that enantioselectivity is exist in biological environment and
proteins can recognize the molecular asymmetry (DE, 1993). Since then,
stereoselectivity of compounds has been documented to give rise to differences
in drug metabolism, pharmacokinetics and toxicity (Prost and Thormann, 2003;
Ha and Follath, 2004; Afshar and Thormann, 2006; Sun and Scott, 2009).
By definition, enantiomeric compounds are composed of the same chemical
entity and have the same structural formulas, but differ with respect to their threedimensional structure. Some stereoisomers could have two or more chiral
centers which have 4 or more non-superimposable mirror images, such as
diastereoisomers. Chirality exists not only in chemical molecules, but also in the
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biological world. Many endogenous substances, such as proteins and amino
acids have chirality feature. The recognition between two enantiomers of
endogenous or exogenous substances and chiral macromolecule, such as an
enzyme, receptor or transporter, could result in different outcomes. In some
situations stereoselectivity is required for biological function and the higher
affinity enantiomer dominates the reaction, or the metabolic or transport pathway.
2. Effect of chirality on drug disposition
It has been estimated that about 50% of therapeutic drugs are currently
administered as a racemate, a mixture of equal proportions of two enantiomers
(Andersson and Weidolf, 2008). When administered as a racemate, two
enantiomers can display a qualitative and quantitative difference in
pharmacokinetic processes (absorption, distribution, metabolism and excretion).
Molecular chemical properties, such as lipophilicity, total hydrogen bond strength
and dipole/polarize-ability are related with passive diffusion. The passive
transcellular membrane transport is generally identical between two enantiomers
(Sugano et al., 2010). By contrast, the active transport tends be significantly
affected by chirality. The interaction of three dimensional structures of active
transporter and chiral substrates can cause different transport profiles.
To date, a large number of studies have focused on enantiomer drugs
stereoselective interaction involving CYP450 in many drug pharmacokinetic,
pharmacodynamic and toxicology areas (Campo et al., 2009; Choong et al.,
2010; Schmitz et al., 2010; Tenberken et al., 2010). Steroselective interactions
may make some drug utilization problematic (e.g., antiarrhythmics), especially
drugs that have a narrow therapeutic index. Drug response is dependent on
many processes including administration route, first-pass effect, inhibition of
enzymes and polymorphisms, receptor sensitivity, etc. Stereoselectivity
contributes to the problem of individual variability to many of these processes (Ha
and Follath, 2004) .
In recent years, the studies have shown that steoroselective interactions not
only occur with metabolic enzymes (Gunaratna and Kissinger, 1998), but also
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with transporters (Bhatia et al., 2008). For example, efflux transporters P-gp and
MRPsexhibit enantioselectivity in the absorption and efflux of cetirizinein in
CaCo-2 monolayer. The results indicated that enantiomers interaction with P-gp
and MRP2 caused potential drug-drug interaction and might significantly
changed the cetirizine pharmacokinetics (He et al., 2009). Moreover, several in
vitro and in vivo evidences indicated an enantioselective drug transport at the
human blood-brain barrier and implied that significant enantioselective activity of
P-gp might be clinically relevant (Choong et al., 2010). As an important efflux
transporter, ABCG2 is involved in the disposition of many drugs in body and has
a significant impact on drug pharmacokinetic and pharmacodynamic profile.
However, to date, there are no reports demonstrating steroselective interaction
between substrate drugs and ABCG2.
L. Pantoprazole

Pantoprazole (Protium and Protonix) is a proton pump (H+/K+-ATPase)
inhibitor (PPI) which binds specifically and irreversibly to the proton pump to
reduce gastric acid secretion [150]. Pantoprazole is a prodrug which is more
stable than other substituted benzimidazole PPI drugs in neutral to moderately
acidic environment and is active and tends to accumulates in an acid
environment (Sachs, 1997). It is more effective than H2-antagonists in the
treatment of moderate to severe gastro-oesophageal reflux disease (GERD)
(Schoenfeld et al., 1999; Scott et al., 2002). The mechanism of action of
pantoprazole on proton pump is shown in Figure 1-13. The prodrug form is
ampholytic in that three nitrogen atoms can accept or donate protons. Briefly,
pantoprazole accumulates under an acidic environment; then is catalysed and
converts to active principal, cyclic sulfenamide. This active principle has an ability
to react with key cysteines present in the gastric acid pump (Kohl et al., 1992;
Huber et al., 1995).
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Figure 1-13 Acid activation of pantoprazole and inhibition of the gastric proton pump by
binding of the active principle to a cysteine SH group of the enzyme (Huber et al., 1995).

Pantoprazole is completely metabolized to inactive metabolites M1, M2 and
M3 by the cytochrome P450 isoforms CYP2C19 (> 80%) and most of rest of
them by CYP3A4 (Andersson, 1996; Noubarani et al., 2010) and rest of them by
a conjugating enzyme, a cytosolic sulfotransferase (Meyer, 1996). The time
course of covalent interaction of pantoprazole with the acid pump is prolonged
compared to the time the compound is in plasma (Huber et al., 1995).
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Pantoprazole is rapidly eliminated from plasma and almost completely
metabolized in the human liver. The initial metabolic step is oxidation via CYP450
system and then it undergoes further metabolism as shown in Figure 1-14. M2,
the main metabolite of pantoprazole, is formed by demethylation at the 4-position
in the pyridine ring to give a hydroxyl group, then conjugated with sulphate. Both
M1 and M3 are sulphate conjugates in an analogous fashion to M2. There are
additional oxidation and reduction of the sulphoxide group to sulphone for
forming M1 and M3 (Figure 1-15). None of these metabolites are active (Huber et
al., 1995).

Figure 1-14 Pattern of pantoprazole metabolites in human plasma (M2: main metabolite;
pantoprazole sulphone: minor metabolite: relative plasma concentrations: M2>M1>M3>
sulphone) (Huber et al., 1995).
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Figure 1-15 Biotransformation of pantoprazole in the human liver (Huber et al., 1995).

Figure 1-16 The structure of pantoprazole isomers.

Pantoprazole is a typical ABCG2 substrate that has been widely used as a
specific inhibitor of ABCG2. PAN is a chiral benzimidazole sulfoxide (Figure 116). Currently it is administered as a racemic mixture. In human study, the
pharmacokinetics of PAN enantiomers was different in extensive metabolizers
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(EMs) and poor metabolizers (PMs). In EMs, the serum concentrations of (-)PAN were slightly higher than (+)-PAN. In PMs, the concentrations of both PAN
isomers were higher than in EMs. The half life of (+)-PAN is 2.67-3.77 times
longer than that of (-)-PAN (Tanaka et al., 1997). It demonstrated a
stereoselective interaction between pantoprazole enantiomers and metabolic
enzymes. In rat pharmacokinetic study, the mean area under the curve value of
(-)-PAN was 1.5 times greater than (+)-PAN after oral administration of racemic
PAN. It suggested stereoselective pharmacokinetics of pantoprazole isomers are
due to the steroselective metabolism that contributed by all the metabolic
pathways (Xie et al., 2005). In addition, the chiral inversion was observed after
administration of (+)-PAN in rat but not (-)-PAN (Masubuchi et al., 1998).
M. Summary

Breastfeeding is considered to be the best choice of nutrition for most infants,
with numerous benefits to infant, mother and society. Drug use during
breastfeeding is common. Limited information on drugs disposition in lactation
adds uncertainty and concern for both lactating mother and caregiver. Most
drugs and their metabolites readily diffuse into milk; however, some drugs are
actively transported into milk, leading to accumulation in milk. To fully understand
drug accumulation into milk as a critical first step in risk assessment, it is
necessary to establish experimental paradigms and mathematical models to be
able to put observations into a more integrated form. ABCG2 is an efflux
transporter on the apical side of epithelial cell in lactating mammary gland that is
responsible for drug active transport into milk. Clinical studies and knockout mice
studies have confirmed the role of ABCG2/Abcg2 in nitrofurantoin, cimetidine,
Phip(toxin 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and other
xenobiotics accumulation in milk. In this dissertation we propose to investigate
the possible role of interaction between substrate and transporter on drug
accumulation in milk using both in vivo and in vitro experimental paradigms
focusing on the following aspects:
a) To determine the role of Abcg2 in drug accumulation in rat milk.
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b) To establish a “chemical rAbcg2 knockout” for drug active transport
into milk.
c) To understand the stereoselective interaction between ABCG2 and
substrate by in vitro and in vivo experiments.
d) To fully understand cell monolayer flux data by using a mechanistic
mathematic model.
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CHAPTER 2:The plan of study and hypothesis
ABCG2/Abcg2 appears to play a major role in the bioavailability and
systemic clearance as well as contribute to the active transport into milk for a
number of drugs. The following hypothesis and specific aims are designed to fully
understand the interaction of substrates with ABCG2/Abcg2 and its role in drug
accumulation into milk.
Overall Hypothesis: ABCG2 substrates accumulate in milk, resulting in high M/S
ratios
Hypothesis 1: Drugs which are rAbcg2 substrates will accumulate in rat milk.
To validate the rat as a suitable animal model for assessing the role of Abcg2 in
drug transfer into milk, the following three aims will be pursued:
Specific Aim 1a: Quantitate the expression and localization of Abcg2 in
lactating mammary gland in rat compared to non-lactating mammary gland
or other organs (kidney and liver).
Specific Aim 1b: Characterize the transport of nitrofurantoin in a rAbcg2MDCKII cell line.
Specific Aim 1c: Validate an in vivo model in lactating rat using
GF120918, a chemical inhibitor of ABCG2, to block the transfer of
nitrofurantoin into milk.
Genetic knockout mice have been used to confirm the role of ABCG2 in drug
accumulation in milk. The benefits of using the rat as an animal model for drug
development also apply to understanding drug accumulation in milk (e.g., similar
drug accumulation in milk between rat and humans, ease of sample collection
and the potential compensatory mechanisms associated with genetic knockout
mice). To establish a clear role for Abcg2 in drug accumulation in rat milk and to
validate the chemical knockout rat Abcg2 model could be valuable tools for drug
development.
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Hypothesis 2: ABCG2 substrates accumulate in milk with high M/S ratio and
interact stereoselectively with ABCG2/Abcg2.
To further challenge the use of the rat as a suitable animal model and to
explore the stereoselectivity of ABCG2, the following three aims will be pursued:
Specific Aim 2a: Characterize the M/S ratio of pantoprazole isomers in
lactating rats.
Specific Aim 2b: Test the ability of a passive diffusion model to predict the
M/S ratios of pantoprazole isomers in rat.
Specific Aim 2b: Utilize the “chemical knockout” Abcg2 rat model to
characterize the differential influence of Abcg2 on the distribution of
pantoprazole isomers into milk.
ABCG2 is highly expressed in mammary gland of mice, cows and humans
during lactation, and is responsible for the active secretion of clinically and
toxicologically important substrates. Pantoprazole, a typical ABCG2 substrate
has been used as a competitive inhibitor to identify other ABCG2 substrates.
However, pantoprazole has a very low M/S at 0.022 in one clinical report (Plante
et al., 2004). Pantoprazole is an ABCG2 substrate that exists as a racemic
mixture. Although chirality has been described as an important characteristic for
a number of enzymes and receptors, there have been few reports of
stereoselective interactions with transporters. The objective of this series of
experiments is to determine if there is a stereoselective interaction between
pantoprazole and ABCG2 and, if present, does the stereoselectivity manifest
itself in the M/S ratios of pantoprazole isomers.
Hypothesis 3: Pantoprazole transport properties are consistent across species
(rat and human).
To fully assess interspecies differences ABCG2 transport, the following two
aims will be pursued:
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Specific Aim 3a: Characterize pantoprazole isomers transport in
ABCG2/Abcg2-expressing MDCKII cell line.
Specific Aim 3b: Compare transport property parameters of rat Abcg2 and
human ABCG2.
To effectively utilize animal model data to predict human exposure, a clear
understanding of similarities and differences across species is warranted. We
have advocated for the use of the rat as an animal model, hence a comparison of
transporter kinetic parameters is required. In addition to kinetic assessments, it
is also of interest to compare the extent to which stereoselective differences
between enantiomers exist across species.
Hypothesis 4: Drug transport in ABCG2-MDCKII monolayer in Transwells can
predict drug accumulation in milk.
To fully develop an overall conceptual framework for pantoprazole interaction
with ABCG2, the following two aims will be pursued:
Specific Aim 4a:

Develop a mechanistic model and characterize the

impact of assumptions of the model with respect to cell monolayer flux
data (Transwell).
Specific Aim 4b: Evaluate the parameters from Transwell such as PSD,
PSPC, ERα, ERA, Km, Vmax, IC50 and Ki based on mathematical three
compartments model.
In general, there is no broadly accepted in vitro exposure system to mimic in
vivo environment. However, several in vitro methods offer the unique possibility
to focus the question and derive a more specific inference as to the role of a
specific drug characteristic or protein (e.g., transporter) feature. Although the
use of cell monolayers of transporter transfected cell lines grown on Transwell is
widespread, a clear understanding of parameters from such data remains a
challange. The purpose of this section of the thesis is to build a mechanism
based model and explore the limits and implications of the model utilizing
pantoprazole isomers as model substrates.
Copyright © Lipeng Wang 2010
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CHAPTER 3: GF120918 as a chemical Abcg2 knockout
model to study nitrofurantoin transfer into milk
3.1 Summary
Genetic knockout mice studies suggested ABCG2/Abcg2 translocates
nitrofurantoin at the mammary – blood barrier resulting in drug accumulation in
milk. The purpose of this study was to establish the role of Abcg2 in nitrofurantoin
accumulation in rat milk using GF120918 as a “chemical knockout” equivalent.
The inhibitory effect of GF120918 was verified in MDCKII cells stably expressing
rat Abcg2 with Hoechst 33342 and nitrofurantoin flux in transwells. Nitrofurantoin
was infused (0.5 mg/h) in the absence and presence GF120918 (10 mg/kg in
DMSO) to Sprague Dawley lactating female rats using a balanced crossover
design. Administration of GF120918 increased nitrofurantoin concentration in
serum (from 443±51 to 650±120 ng/ml) and decreased concentration in milk
(from 18.1±0.9 to 1.9±1.2 μg/ml), resulting in corresponding mean values for M/S
of 41.4±19.1 vs. 3.04±2.27 in the absence and presence of GF120918 (p<0.05),
respectively. There was a decrease in the systemic clearance with GF120918
(2.8±0.5 L/h/kg) compared to vehicle controls (4.1±0.5 L/h/kg; p<0.05). Western
blot analysis revealed good expression of Abcg2 and no P-gp expression in
mammary gland while immunohistochemistry confirmed the apical expression of
Abcg2 in lactating mammary gland epithelia. Nitrofurantoin active transport into
rat milk can be inhibited by GF120918 resulting in a 10-fold lower M/S. Although
GF120918 inhibits both Abcg2 and P-gp, the high expression of Abcg2 and the
absence of detectable P-gp expression in lactating mammary gland validates an
important role for Abcg2 in nitrofurantoin accumulation in rat milk. GF120918 is
particularly useful as a rat “chemical knockout” model to establish ABCG2’s role
in drug transfer into milk during breastfeeding.
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3.2 Introduction
Most xenobiotics are transferred into milk by passive diffusion and the extent
of their accumulation in milk (as measured by milk to serum concentration ratio,
(M/S)) can be predicted by in vitro measurements of drug binding and ionization
in milk and serum as well as lipid partitioning into milk (Fleishaker et al., 1987;
Fleishaker and McNamara, 1988a). Such an approach successfully predicted
the M/S for a number of drugs (Fleishaker and McNamara, 1988b); however, this
approach was unable to estimate the large M/S observed for drugs like
nitrofurantoin (Gerk et al., 2001a). In fact, the observed ratios for nitrofurantoin in
the human and rat were 20 and 100 times greater (Gerk et al., 2001a; Oo et al.,
2001), respectively than could be accounted for by passive diffusion alone,
clearly implicating an active transport process.
The transport of nitrofurantoin across a murine mammary epithelial cell
culture model has been shown to be saturable and sodium dependent in the
basal-to-apical direction (Toddywalla et al., 1997; Gerk et al., 2002). Merino et
al described that nitrofurantoin was efficiently transported by murine Bcrp1 and
human BCRP by using polarized cell lines (Merino et al., 2005b). Importantly,
they also demonstrated that the milk-to-plasma ratio of nitrofurantoin was almost
80 times higher in wild-type compared with Bcrp1 knockout lactating female mice
(Merino et al., 2005b). Nitrofurantoin, therefore, was identified as an excellent
BCRP/Bcrp1 substrate that is translocated at the blood–mammary barrier
resulting in its accumulation in milk.
A growing number of studies have shown compensatory mechanisms in
genetic knockout mouse models. The most impressive evidence was from recent
literature. In Bcrp (-/-) mice, several transporters, like Abca5, Abcb4, Abcc2, and
Abcc4, were significantly up- or down-regulated, the most pronounced differential
expression observed with Abcg5 and Abcg8, which showed a 20- to 100-fold upregulation in Bcrp (-/-) mice (Huls et al., 2008). Therefore, compensatory
mechanisms in transport function in genetic knockout mice may complicate the
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interpretation of drug metabolism and disposition studies as well as active
transport into milk.
In present study, we systematically evaluated the role of Abcg2 (Bcrp) in
nitrofurantoin accumulation in rat milk. GF120918 pretreatment was administered
to generate a “chemical knockout” equivalent of Abcg2 in lactating rat and
nitrofurantoin was employed as the prototypical Abcg2 substrate. The results
obtained from these studies provide new insights into the utility of the rat model
for ABCG2 substrates in drug active transport into milk and other drug
metabolism and disposition studies.
3.3 Materials and Methods
Chemicals
Nitrofurantoin and furazolidone were purchased from Sigma Chemical Co.
(St. Louis, MO). N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) was
a gift from GlaxoSmithKline (Research Triangle Park, NC). Hoechst-33342 was
from Invitrogen (Carlsbad, CA). All organic solvents (HPLC grade) and PEG400
were purchased from Fisher (Pittsburgh, PA) and all other chemicals were
obtained from Sigma (St. Louis, MO) unless specified otherwise.
Animals
Five adult female lactating Sprague-Dawley rats (250 to 350 g) with 1 or 3
day old pups were purchased from Harlan Laboratories (Indianapolis, IN).
Animals were maintained under a 12 h/12 h light/dark cycle and had access to
food and water during the experiments. The rats were acclimatized for at least 1
week before the experiment. All procedures were approved by the University of
Kentucky Institutional Animal Care and Use Committee.

48

Expression and Functional Characterization of Rat Abcg2 in MDCK-II
Cells
Total RNA was isolated from a frozen liver of a Sprague Dawley rat using
RNAeasy kit (Qiagen, Valencia, CA) and reverse transcribed to cDNA using oligo
dT primers and Thermoscript RT PCR kit (Invitrogen, Carlsbad, CA). Rat Abcg2
cDNA was amplified using forward (5’CCGCTCGAGGCATAGATCCTAAAGATGTCTC-3’) and reverse 5’CTAGTCTAGAGGAGTACTATCAATAGTCCTTTC-3’) primers and Phusion DNA
polymerase enzyme (NEB, Ipswich, MA). The PCR product was cloned into the
pcDNA3.1 vector (Invitrogen) between XhoI and XbaI restriction sites. The
Abcg2 sequence in this vector was confirmed (Davis Sequencing, Davis, CA)
and it had 100% homology with the published rat Abcg2 sequence (Gene Bank
accession number AB105817). MDCKII cells were maintained in MEM with
Earle’s salts (Mediatech, Manassas, VA) with 5% FBS (GIBCO/Invitrogen) and
1X Penicillin Streptomycin (Invitrogen) at 37ºC in 5% CO2. Cells were transfected
with pcDNA3.1 or pcDNA3.1-rAbcg2 using Fugene 6 transfection reagent (Roche
Diagnostics, Indianapolis, IN) according to the manufacturer’s instructions. After
48 hours, cells were selected with 800 μg/ml G418 (Invitrogen) for 10 days.
Abcg2 expression was confirmed by Western blot analysis with polyclonal
anti-ABCG2 antibody from Kamiya Biomedical Company (Seattle, WA). Rat
Abcg2 function was assessed using the Hoechst-33342 (10 µM) accumulation
assay (Leggas et al., 2006). Single clones were isolated by fluorescenceactivated cells sorting (FACS) (MoFloTM, DakoCytomation, Fort Collins, CO) on
the basis of reduced accumulation of the Hoechst 33342 dye. The clone with the
highest functional activity was chosen for in-vitro studies.
Inhibition of rAbcg2 by GF120918
To assess the utility of GF120918 as a chemical inhibitor of rat Abcg2, first,
we incubated MDCKII-rAbcg2 cells with Hoechst 33342 in the presence and
absence of 1 µM GF120918. Briefly, cells were incubated with dye-containing
medium at 37°C for 45 minutes. GF120918 was added at the indicated
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concentrations 10 minutes before the dye incubation. All flow cytometry assays
used 10 µM Hoechst 33342 (Leggas et al., 2006). Secondly, the effect of
GF120918 on nitrofurantoin directional transport was evaluated using MDCKII
cells expressing rat Abcg2 or empty vector (pcDNA3.1). Cells were seeded on
microporous membrane filters (3.0-µm pore size, 24-mm diameter; Transwell
3414; Corning Glassworks, Corning, NY) at a density of 1.0×106 cells per well.
Cells were grown for 4 days to achieve TEER (transepithelial electrical
resistance) >200 Ω∙cm2 and medium was replaced every other day. Prior to the
experiment, the medium at both the apical and basolateral side of the monolayer
was replaced with 2 ml of OpitiMEM medium (Invitrogen) without serum, and
either 1 µM GF120918 or vehicle-only (0.1% DMSO) with 10 µM nitrofurantoin
containing 0.2 µCi/ml [3H]-Mannitol. Cells were incubated at 37oC in 5% CO2. To
ensure the tightness of each monolayer, 50 µl aliquots were collected to assess
the paracellular flux of [3H]-Mannitol into the opposite compartment. We required
that layers restricted mannitol transport to <1% of the total radioactivity per hour.
For nitrofurantoin transport, 140 µl aliquots were taken at 0.5, 1, 2 and 3 hours.
Samples were stored at -80 oC until the time of analysis by HPLC assay.
In-vivo Studies
The jugular and femoral veins of Sprague-Dawley lactating female rats were
cannulated under ketamine/xylazine anesthesia on day 10 to 12 post partum.
After a day of recovery, each dam (n = 5) was randomized to receive an
intravenous infusion of nitrofurantoin in PEG400 (0.5 mg/0.25ml/h) for 5 hours
either with pretreatment of the inhibitor (GF120918, 10 mg/kg in DMSO) or with
equivalent volume (about 0.15 ml DMSO) of vehicle administered intravenously
over 10 min and crossed over on the second day to complete both phases (Gerk
et al., 2001b; Edwards et al., 2005). One ml normal saline was given hourly to
prevent dehydration during infusion. The dams were separated from the pups
prior to the infusion. Blood samples were drawn hourly for the last 4 h of the
infusion. The blood samples were protected from light, allowed to clot,
centrifuged to harvest serum, and frozen at -80°C until analysis. Milk samples
were obtained by manual manipulation under light anesthesia (ketamine) at the
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end of the infusion, protected from light, and also frozen at 80°C until analysis.
Mammary gland and kidney samples were harvested from a separate group of
lactating rats on day 16 to18 post partum, frozen in liquid nitrogen, and stored at
-80°C until analysis.
Nitrofurantoin HPLC Analysis
To each aliquot (70 µl) of serum, 15 µl of a 5 µg/ml furazolidone HCl was
added as an internal standard and was precipitated with 85 µl of cold methanol,
vortexed for 5 min, and then centrifuged at 16,000g for 10 min at 4°C. Fifty
microliters of the supernatant plus 50 µl mobile phase was mixed for 10 seconds
and injected onto the HPLC. To each aliquot of milk, 25 µl of a 25 µg/ml
furazolidone HCl was added as an internal standard to 50 µl milk sample and
was precipitated with 200 µl of cold methanol, vortexed for 5 min, and then
centrifuged at 16,000g for 10 min at 4°C. Then, 50 µl of the supernatant was
mixed with 50 µl mobile phase and injected onto the HPLC. The HPLC system
consisted of a Lichrosorb 5 RP18 125 × 4.0-mm column (Phenomenex,
Torrance, CA) and eluted with 20% acetonitrile: 80% 25 mM potassium
phosphate buffer (pH 3.0) at 1.0 ml/min. UV absorbance was measured at
366 nm. Peak height ratios (nitrofurantoin/furazolidone) were used for
comparison with the standard curve. The standard curve range for nitrofurantoin
in serum was 62.5 to 4000 ng/ml. The milk samples were diluted if the
concentration was greater than the linear range for the standard curve (0.725 to
29 µg/ml). Aliquots of nitrofurantoin in OptiMEM medium were directly injected
onto the HPLC. The standard curve range was 7.8 to 2000 ng/ml. All standard
curves demonstrated an intra- and inter-day variability of less than 10% and r2
>0.99.
Western Blot Analysis for P-gp and Abcg2
Crude membrane fractions were prepared from lactating mammary gland
and kidney. Briefly, the tissue samples were homogenized in Dounce Buffer (Tris
buffer pH 7.6 at 4ºC, 0.5 mM magnesium chloride) with protease inhibitors
(Complete Mini EDTA-free tablets, Roche Diagnostics, Indiapolis, IN) and the
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tonicity restored to 150 mM with sodium chloride. Following centrifugation at
1200 g for 5 min at 4ºC, the supernatant was removed and EDTA was added to a
final concentration of 5 mM. The sample was then centrifuged further at 100,000
g for 1 hour at 4ºC to pellet the crude membrane fractions. Pellets were
resuspended in resuspension buffer (0.2 M mannitol, 0.07 M sucrose, 50 μM Tris
HCl, 1 μM EDTA). Rat Abcg2- and pcDNA3.1 (empty vector)-MDCKII cell pellets
were resuspended in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40,
0.5% deoxycholate, 0.1% SDS, protease inhibitor cocktail), rotated for 30
minutes at 4oC, then centrifuged at 13000 rpm for 20 minutes at 4ºC.
Supernatants were collected for immunoblot. Protein concentrations were
measured using the BCA Protein Assay kit (Pierce, Rockford, IL). PNGase F
(New England Biolabs, Ipswich, MA) was used for deglycosylation of rat Abcg2
following manufacturer instructions. Briefly, 60 μg (lactating mammary gland),
100 μg (kidney) and 7 μg (pcDNA3.1 expressed MDCKII cell and Abcg2
expressed MDCKII cell) of membrane fractions were incubated with 10X
denaturing buffer supplied and PNGase F (4 μl) at 37 °C for 2.5 h. Then the
samples were mixed with 2X SDS-loading buffer and reducing buffer at 37°C for
30 minutes as the non-PNGase treatment group. Western blotting was performed
as described previously (Edwards, 2005). P-gp expression was determined using
the C219 (mouse anti-human P-gp; 1:100) monoclonal antibody which was
obtained from Signet Laboratories (Dedham, MA) and Abcg2 was determined
using the PC-138 (1:1000) antibody which was obtained from Kamiya Biomedical
(Seattle, WA). Antibody binding was detected using a horseradish peroxide
linked IgG (H+L) (goat anti-rabbit) and IgG (H+L) (rabbit anti-mouse) antibodies
(1:20000) obtained from Pierce, Inc. (Rockford, IL). The bands were visualized
using a SuperSignal Pico Chemiluminescent substrate detection kit (Pierce,
Rockford, IL).
Immunohistochemistry for Abcg2 localization in lactating mammary
gland
Six-micrometer sections of paraffin blocks were cut using microtomy. After
deparaffinization and rehydration, endogenous peroxidase was blocked with
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H2O2 in methanol for 20 min. The sections were blocked using an avidin biotin
blocking kit (Vector Laboratories, Burlingame, CA), and PC-138 (1:1000) was
applied for kidney and lactating mammary gland. For non-specific staining
control, rabbit IgG (Invitrogen) was applied to the slide instead of PC-138
(1:1000). The sections were incubated overnight at 4oC with amplifier.
Subsequently, the slides were washed in PBS-T and then incubated with
biotinylated anti-rabbit antibody (1:600 dilutions) and HRP-conjugated avidinbiotin-complex (Vector Laboratories, Burlingame, CA). The antibody binding sites
were visualized by incubation with DAB-H2O2 solution to develop a brown color
and counterstained with hematoxylin, dehydrated, and coverslipped.
Pharmacokinetic calculations and statistical analysis
Systemic clearance was calculated using the following formula.

Eq.3-1
Where Cs is the average concentration of nitrofurantoin in serum from 3 to 5
hours.

M/S was calculated by:

Eq. 3-2
Where Cm is concentration of nitrofurantoin in milk at 5 hours.

All data are expressed as mean ± standard deviation (SD). Analyses were
performed to estimate intergroup differences using the One-way ANOVA. A p
value of <0.05 was considered statistically significant.
3.4 Results
Functional characterization of rat Abcg2 expressed in MDCKII cells and
GF120918 as an inhibitor of rat Abcg2
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The full-length rat Abcg2 complementary DNA was expressed in MDCK-II
cells. The functional activity of Abcg2 was characterized and high activity clones
were selected using FACS based on the ability to limit the accumulation of the
prototypical human and mouse ABCG2 substrate, Hoechst 33342. Rat Abcg2
clone was selected and validated as shown (Figure 3-1 A). The phenotype of
this clone could be reversed with GF120918 (Figure 3-1 B). Furthermore, the
effect of GF120918 on the transport of nitrofurantoin by rat Abcg2 was
investigated in MDCKII-rat Abcg2 and MDCKII-empty cells. These MDCKII-rat
Abcg2 cells demonstrated 7.5-fold increase in apically directed transport and a
55% decrease in basolateral transport of nitrofurantoin (Figure 3-1C), which was
largely reversed by GF120918 treatment (Figure 3-1D). These results show the
creation of a MDCKII–rat Abcg2 expressing cell line was successful and that
GF120918 is an inhibitor of rat Abcg2.
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Figure 3-1 Functional characterization of MDCKII-rat Abcg2 expressed cells. The
Hoechst 33342 accumulation of MDCKII cells with either empty vector (black unfilled) or
rAcbg2 clone cells (shaded) (Panel A). Cells were analyzed by flow cytometry following
incubation of the ABCG2 substrate Hoescht 33342 in presence (black unfilled) and
absence (shaded) of 1 µM of the ABCG2 inhibitor, GF120918 (Panel B). The amount of
nitrofurantoin appearing in the receiver compartment across MDCKII-empty vector and
MDCKII-rAbcg2 monolayers grown on Transwells (Panels C and D). Panel C depicts
the flux of nitrofurantoin from the basolateral to apical (●■); apical to basolateral (○□) in
MDCKII-empty (●○) and MDCKII –Abcg2 (□■); Panel D depicts the transport of
nitrofurantoin from the basolateral to apical in MDCKII-empty (●○) and MDCKII –Abcg2
(□■) in MDCKII-

Expression of rAbcg2 and P-gp in lactating mammary gland and rAbcg2
expressed MDCKII cells
Abcg2 and P-gp expression in rat lactating mammary gland were assayed by
Western blot. In contrast to the kidney (positive control), P-gp was not detected in
lactating mammary gland (Figure 3-2A). Abcg2 expression was detected in
lactating mammary gland, kidney and Abcg2 expressing MDCKII cell line (Figure
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3-2B and 3-2C); however, the native Abcg2 bands were different sizes in the
mammary gland (~72kd), rat Abcg2 expressing in MDCKII cell line (~80kd) and
the kidney (~80kd). Following deglycosylation (Figure 3-2B and 3-2C), all of the
native bands were reduced to approximately 60 kDa. Immunohistochemistry
showed the localization of Abcg2 in rat lactating mammary gland (Figure 3-3).
Abcg2 was strongly expressed on the apical side of epithelial cells in lactating
mammary gland. As a positive control, Abcg2 staining was mainly observed in
the renal proximal tubules in kidney. Abcg2 staining was not found in the
nonspecific staining control.
Infusion Studies
Results from the nitrofurantoin infusion study in lactating rats are shown in
Figure 4. The concentration of nitrofurantoin in serum reached steady-state at 2
hours following the initiation of the infusion and was maintained through 5 hours.
Linear regression revealed that the slope (plasma concentration versus time)
was not significantly (p<0.05) different from zero over this timeframe, however
there was a trend for the GF120918 treatment to increase nitrofurantoin
concentration with time. The presence of GF120918 resulted in a higher
concentration of nitrofurantoin in serum (Figure 3-4A). The systemic clearance of
nitrofurantoin in lactating rats was 4.12 ± 0.5 L/h/kg and was significantly
decreased to 2.78 ± 0.5 L/h/kg (p<0.05, Figure 3-4B) by coadministration with
GF120918. Higher nitrofurantoin serum concentrations and lower milk
concentrations (Figure 3-4A) in GF120918 treated group resulted in a
substantial reduction (93%) in the M/S of nitrofurantoin from 41.5 ± 19.1 to 3.04 ±
2.27 (Figure 3-4C).
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Figure 3-2 Western blot analysis of P-gp and Abcg2 expression. Crude membrane
fractions were prepared for all the samples. P-gp expression in rat kidney and lactating
mammary gland (Panel A). The expression of native and deglycosylated rAbcg2 in
lactating mammary gland, kidney (Panel B), vector (pcDNA3.1), and rAbcg2 expressed
MDCKII cell line (Panel C).
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Figure 3-3 Immunohistochemical detection of Abcg2 (magnification, 63x) in rat lactating
mammary gland (nonspecific staining control) (Panel A), rat kidney (positive control)
(Panel B) and rat lactating mammary gland (Panel C).

Figure 3-4 Concentration versus time profile (Panel A) for serum (●■) and milk (○□)
following nitrofurantoin infusion (0.5 mg/hr) in GF120918 (10 mg/kg) treated (□■) or
control lactating rats (●○). Nitrofurantoin systemic clearance (Panel B) and M/S (Panel
C). Asterisks represent data points that are significantly different from control. * P<0.05.
Data is presented as mean ± SD).
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3.5 Discussion
In the present study, we have utilized GF120918 as an inhibitor of Abcg2 in
order to assess its role in drug transfer into rat milk. GF120918 was originally
developed as a second-generation P-gp inhibitor (Tan et al., 2000). It belongs to
the family of acridone carboxamide derivatives (Warmann et al., 2002;
Boumendjel et al., 2007) and has an IC50 value of ~30 to 300 nM on the cellular
accumulation of phosphine technetium complexes by human P-gp in Sf9 cells
(Luker et al., 1997). GF120918 is also a potent ABCG2 inhibitor with IC50 values
of ~300 nM on efflux or accumulation in cell lines transfected with human ABCG2
(Ahmed-Belkacem et al., 2005; Pan et al., 2007). Based on our results,
GF120918 (1 μM) appeared to effectively inhibit the efflux of Hoechst 33342 and
nitrofurantoin from rAbcg2 expressing MDCKII cell line, thus confirming that
GF120918 is an effective in vitro inhibitor of rat Abcg2.
Following a 10 mg/kg dose, GF120918 significantly increased the serum
concentrations of nitrofurantoin by decreasing its systemic clearance. Previous
investigators have noted the systemic clearance of nitrofurantoin to be mediated,
in part, by Abcg2-dependent processes (Merino et al., 2005b; Wang and Morris,
2007). Following oral and intravenous administration of nitrofurantoin, the area
under the concentration time curve in Bcrp1 knockout mice was 4-fold and 2-fold
higher, respectively, than in wild-type mice (Merino et al., 2005b), due to reduced
first pass and hepatobiliary excretion of nitrofurantoin. Zhang et al have also
shown that Bcrp1 limited the fetal distribution of nitrofurantoin and had a minor
effect on the systemic clearance of the drug in the pregnant mouse (Zhang et al.,
2007).
In previous work in our lab, the P-gp substrate, nelfinavir, was dosed to
lactating rats with GF120918 (Edwards et al., 2005). GF120918 had no effect on
M/P (the ratio of drug concentration in milk to in plasma) but did change brain to
plasma ratio. Nelfinavir, like other human immunodeficiency virus protease
inhibitors are well established substrates of P-gp (Kim et al., 1998; Lee et al.,
1998; Washington et al., 1998). These protease inhibitors have been shown to
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be inhibitors, but not substrates of Abcg2 (Gupta et al., 2004). This evidence
suggests that P-gp does not play a role in drug transfer into rat milk. By contrast,
nitrofurantoin has not been shown to be a substrate of other major efflux
transporters, such as P-gp, Mrp1 and Mrp2 (Merino et al., 2005b; Wang and
Morris, 2007). Hence, the affect GF120918 on the clearance and M/S of
nitrofurantoin is not mediated by P-gp, but due largely to Abcg2 inhibition. It
should be noted, however, a study of membrane transporters in MDCKII-hMDR1
using GF120918 to inhibit digoxin and loperamide efflux implicated a possible
basolateral transporter(s) which could be inhibited by GF120918 (Acharya et al.,
2008). The identity or function of basolateral transporter(s) on lactating
mammary epithelial cells and their potential impact on M/S has not been
established.
Consistent with mammary gland expression in other species (Merino et al.,
2005b), our western blotting results show Abcg2 is highly expressed in the
lactating rat. P-gp appears to be transcriptionally down-regulated during lactation
(Alcorn et al., 2002) and protein expression was not detectable in the lactating rat
mammary gland (Figure 2A). All of the native Abcg2 bands were reduced to
approximately 60 kDa following deglycosylation. This observation is consistent
with the result previous work suggesting that ABCG2 contains N-linked
oligosaccharides, probably at both of the putative glycosylation sites (Litman et
al., 2002). The native Abcg2 bands in kidney and rAbcg2 - MDCKII cell line had
a larger size (approximately 80 kd) than the mammary gland (approximately
70kd), suggesting rat Abcg2 may have tissue or cell specific patterns of
glycosylation.
Consistent with the Western blot analysis, immunohistochemistry clearly
indicated that Abcg2 is strongly expressed on the apical side of epithelial cells in
lactating mammary gland. Apical expression also confirms the role of Abcg2 in
actively transporting nitrofurantoin out of the epithelial cells and into rat milk.
The rat is a frequently used animal model in drug development and may be a
better animal model under certain experimental paradigms (e.g., multiple
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samples, crossover study design). Furthermore, drugs identified as
accumulating in rat milk by active transport are consistent with human literature
(McNamara et al., 1991; McNamara et al., 1992a). Hence, evidence gathered to
date suggest that the rat is a good model for identifying which drugs might
undergo active transport into human milk.
As noted in the introduction, genetic knockout models are useful tools to
demonstrate transporter function with the assumption that the only difference
from wild-type is the abolishment of expression of the intended protein.
However, knockout models have been found to undergo additional changes
which might further complicate interpretation. For example, brain microvessels
from Mdr1a deficient mice express 3 times more Abcg2 RNA than microvessels
of wild-type mice (Cisternino et al., 2004). Although the accumulation of Abcg2
substrates, mitoxantrone and prazosin was significantly increased in the
presence of GF120918 in both wild-type and P-gp deficient mice there was
significant difference between them (Cisternino et al., 2004). Whether or not this
increased expression and activity of Abcg2 is a compensatory mechanism for the
lack of Mdr1a at the mouse blood-brain barrier remains to be elucidated.

There

are other compensatory functions which also may be present in genetic knockout
animals. In Mrp2 (-/-) mice, Mrp4 mRNA and protein expression in liver and
kidney were increased approximately 6- and 2-fold, respectively (Chu et al.,
2006). In Mrp2-deficient rats [TR (-)], Mrp3 was significantly up-regulated in the
liver (approximately 6-fold) and kidney (approximately 3.5-fold) compared with
wild-type controls. Likewise, the expression of the Ugt1 enzyme was increased
in the liver and kidney of TR (-) rats by approximately 3.5- and 5.5-fold (Johnson
et al., 2006). Therefore, alterations in drug disposition using knockout animals
must be interpreted cautiously because of the possibility of compensatory
changes in other transport proteins.
The inhibition of Abcg2-associated nitrofurantoin accumulation by GF120918
in the lactating rat (“chemical knockout”) provides support for the use of this
alternative to the genetic knockout model for establishing the role of Abcg2 in
drug active transport into milk. GF120918 has been tested in phase I clinical
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trials and was confirmed to have little toxicity (Planting et al., 2005; Kuppens et
al., 2007). Various studies have shown that GF120918 can be tolerated in
humans and animals at concentrations sufficient to inhibit ABCG2. Hence,
GF120918 is suitable for in vivo animal and perhaps even clinical studies (Mao
and Unadkat, 2005).
In summary, Abcg2, but not P-gp is expressed in lactating mammary
epithelia and appears to be responsible for nitrofurantoin active transport into rat
milk. The rat appears to be a good animal model for identifying those drugs that
would accumulate in human milk. GF120918 appears to be an effective in vivo
inhibitor (“chemical knockout”) tool for confirming the role of Abcg2 in milk
transfer. These data are especially valuable for the design of studies of ABCG2
substrates during breastfeeding using the rat as animal model.
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CHAPTER 4: Stereoselective drug accumulation in milk:
ABCG2 interaction with pantoprazole
4.1 Summary
Drug active transport into milk is a major concern in breastfeeding. Recent
evidence has confirmed Abcg2, a xenobiotic transporter, plays a critical role in
drug transfer into rat milk which is consistent with human study. Although it is
estimated that about half of all therapeutic agents are chiral, there have been few
reports of stereoselective interactions with transporters. The purpose of this
study is to investigate the interaction of pantoprazole isomers with Abcg2 in drug
accumulation in milk by in vitro and in vivo experiments. For in vitro experiments,
Abcg2/vector-MDCKII cells were seeded in Transwell. Pantoprazole isomers (30
µM) were loaded on apical/basolateral side and pantoprazole flux was analyzed
by HPLC. Jugular and femoral veins of Sprague-Dawley lactating rats were
cannulated and each dam (n = 5) received an i.v. infusion of pantoprazole
mixture in saline for 8h with/out Abcg2 inhibitor (GF120918) and crossed over on
the second day. Samples were analyzed by LC-MS with chiral column. The
results indicated pantoprazole isomers were transported in an identical fashion in
empty-MDCKII cell lines, whereas a significant difference in flux was observed in
Abcg2-MDCKII cell line. In the in vivo experiments, the steady state was
achieved after 2 hour infusion and the administration of GF120918 apparently
increased both pantoprazole isomer concentrations in serum, but no statistical
difference was observed. (+)-PAN (0.57±0.1) had a higher systemic clearance
than (-)-PAN (0.44±0.12) (p<0.01). Milk to serum ratio of (-)-PAN (1.36±0.20) was
almost 3 times as great as that of (+)-PAN (0.54±0.09). Administration of the
Abcg2 inhibitor (GF120918) decreased M/S of (-)-PAN to 0.50±0.08 (p<0.001)
and (+)-PAN to 0.38 ±0.07 (p>0.05). Abcg2 interacts stereoselectively with
pantoprazole isomers in both in vitro and in vivo studies. Pantoprazole
stereoselectivity for Abcg2 appears to be responsible for a difference in the
accumulation of substrate isomers in milk and may have consequences for other
aspects of stereoselective drug disposition.
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4.2 Introduction
Chirality is a central feature of biology and its existence is essential for many
life processes. Specific three dimensional structure-activity relationships in the
environment of living systems are required for effect (e.g., enzymes, receptors,
transporters, and DNA) (Smith, 2009), which implies that enantiomers of drugs or
substrates may elicit a different response or outcome. It is estimated that about
half of marketed therapeutic agents are chiral with most available as 50/50
mixtures of their enantiomeric forms (Andersson and Weidolf, 2008). The final
decision to market a drug as an enantiomerically pure form or a racemic mixture
is made following consideration of all the medical, financial and social risk
benefits (Nunez et al., 2009).
Stereoselective metabolism, the transport of chiral drugs as well as genetic
polymorphisms of CYP450 and receptors complicate drug dosing and influence
pharmacokinetics, pharmacodynamics, and toxicity (Katsuki et al., 2001; Tateishi
et al., 2008; Miura and Uno, 2009). It is especially critical for those drugs that
have a narrow therapeutic index (e.g., warfarin) (Takahashi, 2008). Additionally,
there is a report that two enantiomers of chiral drug can have reverse
stereoselective regulation on transporter expression (Shen et al., 2007). As a
result of these revelations of the significance of chirality on pharmacodynamic
and pharmacokinetic profiles, there has been increasing concern over the use of
racemates, and other steroisomeric mixtures, as drugs.
As a widely distributed efflux transporter in such tissues as kidney, liver,
blood-brain barrier, placenta, stem cells and mammary gland, ABCG2 (ATP
binding cassette transporter isoform G2) exhibits a broad substrate specificity
transporting hydrophobic, anionic, and cationic drugs (Mao and Unadkat, 2005).
It can significantly influence the absorption, distribution, elimination and toxicity of
substrate drugs (Oostendorp et al., 2009).
The role of ABCG2 in xenobiotic distribution into milk has been identified
(Jonker et al., 2005; Merino et al., 2006b). A working hypothesis of the present
work provides that all ABCG2 substrates accumulate in milk resulting in relatively
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high M/S ratios (the ratio of drug concentration in milk to serum); higher than that
predicted by simple diffusion. However, a clinical case report with pantoprazole
(PAN) would appear to challenge this hypothesis (Plante et al., 2004). PAN has
been described as a typical ABCG2 substrate (Breedveld et al., 2004), and yet,
the authors found an M/S value of 0.022 for racemic PAN in one volunteer
(Plante et al., 2004). It is unclear whether the low M/S ratio for PAN is a result a
more limited ability of PAN to act as a substrate for ABCG2, PAN’s rapid diffusion
across membranes, PAN’s extensive serum protein binding, or some other
explanation.
PAN undergoes enantioselective hepatic metabolism in both humans and
rats (Tanaka et al., 2001; Xie et al., 2005). Poor metabolizers of S-mephenytoin
(a CYP2C19 substrate) were less able to metabolize (+) PAN than (–) PAN
(Tanaka et al., 2001). There are no reports of PAN isomers interacting with
transporters (e.g., ABCG2). Moreover, there do not appear to be any reports on
stereoselective drug accumulation in milk.
A chemical knock-out Abcg2 rat model, in which the function of Abcg2 is
inhibited by GF120918, has been established (Wang et al., 2008). The major
goals of the present work was to take advantage of this unique model to
investigate the stereoselective interaction in pantoprazole enantiomers active
transport in milk and to further examine the ABCG2 substrate milk accumulation
hypothesis by comparing that to predicted M/S from passive diffusion model.
4.3 Materials and methods:
Chemicals Protonix I.V (Pantoprazole sodium, 50:50 stereo mixtures) was
obtained from Altana (Konstanz, Germany) and zonisamide sodium was
purchased from Sigma-Aldrich (St. Louis, MO). The isomers of PAN were
obtained from Altana Pharma AG (Konstanz, Germany). GF120918 was a gift
from GlaxoSmithKline (Research Triangle Park, NC). All the organic solvents
[high-performance liquid chromatography (HPLC) grade] were purchased from
Thermo Fisher Scientific (Waltham, MA).
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Animals
Five adult female lactating Sprague-Dawley rats (250–350 g) with 1- or 3day-old pups were purchased from Harlan Laboratories (Indianapolis, IN).
Animals were maintained under a 12/12-h light/dark cycle and had access to
food and water during the experiments. The rats were acclimatized for at least 1
week before the experiment. All the procedures were approved by the University
of Kentucky Institutional Animal Care and Use Committee.
Flux study
Rat Abcg2 and empty vector (pcDNA3.1) expressed in Madin-Darby Canine
Kidney II Cells has been established in our lab (Wang et al., 2008). Cells were
seeded on microporous membrane filters (3.0-µm pore size, 24-mm diameter;
Transwell 3414; Corning Inc., Corning, NY) at a density of 1.0 x 10 6 cells/well.
Cells were grown for 4 days to achieve transepithelial electrical resistance >200
· cm2, and media was replaced every other day. Before the experiment, the
media at both the apical and basolateral side of the monolayer was replaced with
2 ml of OptiMEM media (Invitrogen, CA) without serum and either the apical or
basolateral side was loaded with 25 µM PAN isomers containing 0.2 µCi/ml
[3H]mannitol (Perkin Elmer, Norton, OH). Cells were incubated at 37°C in 5%
CO2. To assess tight junctions of each monolayer, 50 µl aliquots were collected
to assess the paracellular flux of [3H] mannitol into the opposite compartment.
For PAN isomers transport, 140-µl aliquots were taken at 1, 2, 3 and 4 h.
Samples were stored at -80°C until the time of analysis.
In vitro M/S.
M/S ratios for PAN isomers transfer into milk is governed by passive diffusion
and can be predicted from an in vitro passive diffusion model (Fleishaker et al.,
1987; Fleishaker and McNamara, 1988b):

Eq.3-1
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where fu is the unionized fraction of drug in serum or milk, f is the free fraction of
drug in serum or milk, W/S is the ratio of the drug concentration in whole milk to the drug
concentration in skim milk, and the subscripts s and m represent serum and milk,
respectively.

The S/W ratios, a measure of the milk fat partitioning of PAN isomers, were
determined following LC-MS analysis of the each PAN isomer concentrations in
blank rat whole milk and skim milk into which isomer had been added. The
unionized fraction in serum and skim milk, a measure of the pH partitioning of
drug between serum and milk, was calculated from the pKa of each isomer and
from the pHs of serum (pH 7.45) and milk (pH 6.8)(Alcorn and McNamara, 2002).
The unbound fraction of PAN isomers in milk and serum were determined by
equilibrium dialysis of these fluids against a 0.133 M phosphate buffer (milk pH
6.8 and serum pH 7.45) in plexiglass dialysis cells (single place, 0.5 ml cells).
After 8 hours equilibrium at 37oC, samples were taken from both donor and
recipient sides. These concentrations were determined by LC-MS.
In vivo studies
The jugular and femoral veins of Sprague-Dawley lactating female rats were
cannulated under ketamine/xylazine anesthesia on days 10 to 12 postpartum.
After 24 hours of recovery, each dam (n = 5) was randomized to receive an i.v.
infusion of PAN in saline (0.4 mg/ml/h) for 8 h either with pretreatment of the
inhibitor (GF120918, 10 mg/kg in DMSO) or with equivalent volume
(approximately 0.15 ml of DMSO) of vehicle administered i.v. 10 minutes before
infusion and all animals were crossed over on the second day to complete both
phases (Wang et al., 2008). One milliliter of normal saline was given hourly by
i.v. infusion to prevent dehydration during infusion. The dams were separated
from the pups 4 hours before the infusion. Blood samples were drawn every 2
hours during the infusion. The blood samples were protected from light in
separator tubes (BD Microtainer, Franklin Lakes, NJ), centrifuged to harvest
serum, and frozen at -80°C until analysis. Milk samples were obtained by manual
manipulation under light anesthesia (ketamine) at the end of the infusion,
protected from light, and also frozen at -80°C until analysis.
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Sample preparation
To each aliquot (50 µl) of serum, 10 µl 0.2 M NaOH and 20 µl of 10 µg/ml
zonisamide sodium (internal standard) were added and the proteins were
precipitated with 1ml Ethyl acetate, vortexed for 1 min, and then centrifuged at
2,400 rpm for 15 min at room temperature. The clear layer was collected into
another clean glass tube (~0.8 ml) and dried under nitrogen in a 40oC water bath.
Samples were then reconstituted in 50 ul mobile phase (15% Acetonitrille and
85% water but without formic acid). To each aliquot of milk, the same amount of
NaOH and zonisamide sodium were added to 25 µl of milk sample, protein was
precipitated with 1 ml of cold methanol, vortexed for 30 seconds, and then
centrifuged at 14,000g for 10 min at 4°C. The clear layer was collected to a clean
glass tube (~0.9ml) and dried under nitrogen in a 40°C water bath. Samples
were reconstituted in 200 µl water and mixed very well. Then 1 ml ethyl acetate
was added, the samples were vortexed and centrifuged (same as serum samples
extraction). The collected clear layers were dried under nitrogen in a 40oC water
bath and reconstituted in 50 µl mobile phase. This method was adapted from
Bharathi (Bharathi et al., 2009). PAN isomers in phosphate buffer samples from
in vitro predicted M/S ratio experiment were reconstituted in 1 ml water and 2 ml
ethyl acetate, vortexed and centrifuged at 2400rpm for 15 minutes. The 1.8 ml
organic layer was collected and dried under nitrogen at 40oC water bath and
reconstituted in 50 µl mobile phase.
Pantoprazole HPLC analysis
Concentrations of total PAN were assayed by HPLC on a Luna RP18 125 x
4.0-mm column (Phenomenex, Torrance, CA) and eluted with 40%
acetonitrile/60% 10 mM potassium phosphate buffer, pH 7.2, at 0.5 ml/min. UV
absorb at 290 nm. Aliquots of PAN in Opti-MEM medium were directly injected
onto the HPLC. The standard curve range was 7.8 to 2000 ng/ml. All the
standard curves showed an intraday and interday variability of <10% and r2 >
0.999.
Pantoprazole isomer analyses by LC-MS
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A Varian 1200L Triple Quadrupole mass spectrometer (Walnut Creek, CA)
equipped with an electrospray ionization (ESI) source and a Varian MS
Workstation (6.42) data system was employed. The interface was adjusted to the
following conditions: positive ion mode; spray needle voltage, 5000V; shield
voltage, 600V; capillary voltage, 40V; drying gas (Nitrogen) temperature,
300oC. MS/MS spectra were obtained for selected precursor ions through
incidental collision with neutral gas molecules (Argon) at 2.0mTorr in the collision
cell of the mass spectrometer. The collision energy was set at 8.50V. The
parameters of the selected reaction monitoring transitions for the [M+H]+ to
selected product ions were optimized with the following typical values for the
analytes and internal standard: PAN m/z 384 to 200 and the internal standard
zonisamide m/z 213 to 132. The LC conditions were as follows. The column was
a Lux 5 µl Amylose-2 150 x 4.60-mm Chiral column (Phenomenex, Torrance,
CA). The initial mobile phase consisting of acetonitrile: water: formic acid
(15%:85%:0.02%) was delivered by dual Varian ProStar 210 pumps (Walnut
Creek, CA), at a flow rate of 0.3 ml/min. A gradient program was utilized; the
acetonitrile phase was increased to 90% over 12 minutes and held constant for
an additional 6 minutes. The acetonitrile phase was returned to 15% over 1
minute and held constant for an additional 11 minutes for a total run time of 30
minutes. Twenty microliters of the sample was injected onto the LC-MS. Serum
and milk concentrations of PAN were quantified according to standard curves.
Pharmacokinetic Calculations and Statistical Analysis. Systemic clearance
was calculated using the following formula:

Eq.3-2

where CS is the average concentration of PAN in serum from 2 to 8 h. M/S
was calculated by:

(
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Eq.3-3

where CM is concentration of PAN in milk at 8 h.
All the data are expressed as mean ± S.D. Analyses were performed to
estimate intergroup differences using two-way ANOVA analysis of variance with
Bonferroni Post test for multiple comparisons. A p value of <0.05 was considered
statistically significant.

4.4 Results
Pantoprazole isomers transport in rat-Abcg2 expressed in MDCKII cell
line.
The expression level and function of rat Abcg2-MDCKII were confirmed by
Western blot, flow-cytometry and nitrofurantoin transport in previous studies
(Wang et al., 2008). At 25 μM, the flux for both isomers and in both directions
approached steady-state after 3 hour in empty vector and Abcg2-MDCKII cells.
Initial rates were calculated during first hour. The flux for both PAN isomers in
both directions was identical in empty MDCKII cells (Figure 4-1A). The
asymmetry efflux ratios (ERα) of (+)- and (-)- PAN in parent cell line at the one
hour time point were 0.90 and 0.95, respectively. In Abcg2-MDCKII cell line, the
initial flux rate for basolateral to apical flux was considerably greater than the flux
in the opposite direction. The mass transport of (+)-PAN from basolateral to
apical side across monolayer appeared greater than (-)-PAN (Figure 1B),
whereas the flux from apical to basolateral was greater for the (-)-PAN relative to
the (+)-PAN. The ERα of (+)- and (-)-PAN at the one hour time point were 5.15
and 1.51, respectively in Abcg2-MDCKII cell line. These stereoselective
differences in initial rates were maintained as the profiles approached steady
state of (+)-and (-)-PAN were 3.82 and 1.77, respectively.
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Figure 4-1 The amount (mean±SD, n=3) of PAN isomers appearing in the receiver
compartment of MDCKII-empty vector and MDCKII-rAbcg2 monolayers grown on
Transwells at donor concentration of 25 uM. PAN isomers: minus (open symbol) and
plus (closed symbol) from the basolateral to apical (squares) and apical to basolateral
(circles) in MDCKII-empty (panel A) and MDCKII-rAbcg2 (panel B)

Predicted M/S ratios of pantoprazole isomers
Table 4-1 contains individual parameter estimates that contribute to the
diffusion model prediction of M/S (M/Spredicted) of the PAN isomers. The fraction of
unionized approximated 1 for both PAN isomers since their pKa is lower than the
pH of both rat milk (6.8) and serum (7.45). The free fractions of PAN isomers
were determined by equilibrium dialysis using serum concentrations in rat
infusion study. The serum free faction of (+)-and (-)-PAN were 2.33% and
2.38%, respectively. PAN isomers have lower binding in skim milk (74% and
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73%, respectively). The fat partitioning of each isomer was reflected in the S/W
ratio which was 0.75 and 0.77 for the (+)- and (-)-PAN, respectively. M/S ratio
predicted by the diffusion model was 0.12 for (+)-PAN and 0.11 for (-)-PAN.
Table 4-1 M/S Ratio Observed M/S Ratio Predicted for PAN isomers in lactating SpragueDawley rats.* P<0.01. Data is presented as mean.

M/S Ratio and property or rat no.

(+)-PAN

(-)-PAN

Diffusion Model Parameters
pKa

3.9

3.9

u

~1

~1

u

~1

~1

f serum (%)

2.33

2.38

f milk (%)

25.96

27.08

S/W ratio

0.75

0.77

Predicted M/S (M/S Predicted)

0.12

0.11

200% M/S Predicted

0.24

0.23

50% M/S Predicted

0.06

0.06

(M/S Observed)/(M/S Predicted)

4.43*

11.95

1

0.45

1.22

2

0.43

1.34

3

0.62

1.68

4

0.64

1.40

5

0.54

1.17

Mean

0.54*

1.36

SD

0.10

0.20

Lower 95% Cl of mean

0.42

1.11

Upper 95% Cl of mean

0.65

1.61

f ,serum
f ,milk

Observed M/S (M/S Observed)
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In vivo study-pantoprazole isomers accumulate in rat milk.
The lactating rats were infused with racemic PAN and each isomer
concentration in serum and milk were measured by LC-MS. Chromatographs of
PAN isomers and zonisamide are shown in Figure 4-2. The standard curve was
linear from 80 to 5,000 ng/ml in serum, 10 to 5000 ng/ml in milk and 25-1000
ng/ml in phosphate buffer. All the standard curves showed an intraday and
interday variability of <10% and r2 > 0.99 (Appendix D-2) .

IS

(+)-PAN (-)-PAN

A
B
C
D

IS

Figure 4-2 Enantiomeric separation of PAN (156 ng/ml) and internal standard
zonisamide (4 µg/ml). Panels A and C represent a chromatogram of internal standard
alone in one PAN standard serum (156 ng/ml) and blank serum respectively. Panels B
and D represent a chromatogram of PAN isomers in one PAN standard serum (156
ng/ml) and blank serum (lower attenuation), respectively.

The mean PAN isomer concentration time profiles in serum are shown in
Figure 4-3. In the dosing vehicle treatment, both PAN isomers appeared to
achieve steady-state serum concentrations by 2 hour time point in the
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intravenous infusion protocol with (-)-PAN (1,625 ng/ml) slightly higher than (+)PAN (1,204 ng/ml). The treatment of GF120918 appeared to increase the
serum concentration of both PAN isomers, in particular for (-)-PAN which
increased 37%. In the control group, (+)-PAN (0.57±0.1) had greater systemic
clearance (Figure 4-4) than did (-)-PAN (0.44±0.12). The two-way ANOVA
analysis of variance indicated a significant isomer and treatment effect, but no

PAN concentration in serum
(ug/l n=5 mean+/-SD )

interaction.

4

DMSO
GF120918

(-)-PAN

(+)-PAN
3
2
1
0
2

4

6

8

2

4

6

8

Time(hour)
Figure 4-3 PAN isomer concentrations (Mean±S.D., n=5) in serum in lactating SpragueDawley rats at 2, 4, 6 and 8 hour infusion (0.4 mg/ml/h) following administration of
dosing vehicle alone (DMSO) or GF120918 (10 mg/kg)

PAN isomers were distributed differently into milk in the rat. At 8 hours, the
milk concentration of (-)-PAN (2,260 ng/ml) was considerably higher than (+)PAN (644 ng/ml). The milk concentrations were lower for both isomers and the
difference between the isomers diminished [(-)-PAN (1,098 ng/ml) and (+)-PAN
(525 ng/ml)] following GF120918 administration. The M/S ratios for PAN
isomers are shown in Figure 4-5. In control (DMSO) group, M/S ratio of (-)-PAN
was nearly 3 times that of (+)-PAN. Administration of GF120918 decreased M/S
ratios of (+)-PAN from 0.54±0.09 to 0.38 ±0.07 and (-)-PAN from 1.36±0.20 to
0.50±0.08. The two-way ANOVA analysis of variance indicated a significant
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isomer and treatment effect, as well as a significant interaction between isomer
and treatment. The mean observed M/S was 4.43 fold for (+)-PAN and 11.95 fold
for (-)-PAN greater than the M/S Predicted (Table 4-1) and the 95% confidence
intervals around the M/S did not overlap the 50 to 200% range of the M/S
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M
SO

Systemic Clearance (L/hr/kg)

predicted.

(+) PAN

(-) PAN

Figure 4-4 The systemic clearance of PAN isomers following administration of dosing
vehicle alone (DMSO) or GF120918 (10 mg/kg). Data are presented as paired values
from individual rats.
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Figure 4-5 The M/S ratios of PAN isomers following administration of dosing vehicle
alone (DMSO) or GF120918 (10mg/kg). Data are presented as paired values from
individual rats.

4.5 Discussion
ABCG2 is a widely distributed efflux transporter and plays an important role
protecting body against endogenous or exogenous xenobiotics. The role of
transporter on absorption, distribution, metabolism and excretion (ADME) of
drugs has been documented in ABCG2 substrate flux studies (Kruijtzer et al.,
2002). There is a growing concern regarding the role of ABCG2 in drug-drug
interactions as well (Giacomini et al., 2010; Huang and Woodcock, 2010).
ABCG2 is also found on the apical surface of lactating mammary epithelial
cells (Jonker et al., 2005). The physiological function of ABCG2 in lactation is
uncertain; however, riboflavin has been shown to be a substrate and ABCG2
may be functioning as a nutrient transporter (van Herwaarden et al., 2007). A
number of investigators have demonstrated the importance of this transporter in
76

the accumulation of drugs in milk (Jonker et al., 2005; Perez et al., 2009).
Nitrofurantoin and cimetidine, both ABCG2 substrates, accumulates in human
and rat milk (Oo et al., 1995; McNamara et al., 1996; Gerk et al., 2001a; Oo et
al., 2001). Others have clearly demonstrated the role of mAbcg2 in drug transfer
into milk using knockout mice (Jonker et al., 2005; Merino et al., 2005b). Other
ABCG2 substrates which appear to accumulate in milk include: topotecan,
acyclovir, dietary carcinogens, ranitidine and ciprofloxicin (Jonker et al., 2005;
Merino et al., 2005b; Merino et al., 2006a; van Herwaarden et al., 2007; Vlaming
et al., 2009)
A testable supposition would hold that all ABCG2 substrates accumulate in
milk, resulting in relatively high M/S ratios, greater than that predicted by simple
diffusion. A clinical case report with PAN would appear to challenge the premise
(Plante et al., 2004). PAN is highly protein bound (>98%) in human serum
(Andersson and Weidolf, 2008) and rat serum (Xie et al., 2005). Data in the
current work confirms that the protein binding of both PAN isomers in rat serum
is extensive. PAN has a modest octanol to water partitioning (Badwan, 2002)
and hence, the fat partitioning is higher (reflected in a lower S/W value) than
many drugs. The unionized fractions were assumed to be identical for the two
isomers. As a result, M/S ratios predicted by diffusion for both isomers were low
and virtually identical. The observed M/S were 4.4 fold [(+)-PAN] and 12.5 fold [
(-)-PAN] higher than predicted by diffusion and the 95% confidence intervals
around the observed M/S did not overlap the 50 to 200% range of the predicted
M/S (Table 4-1) clearly suggesting a potential role of a transporter for PAN
accumulation in milk. We have previously utilized this approach as a predictor for
a significant role of a transporter in drug accumulation in milk (Alcorn and
McNamara, 2002; Edwards et al., 2003). The observed M/S ratios of (+)-PAN
and (-)-PAN in the rat were 20-60 times higher than the M/S from the lone human
report (Plante et al., 2004). The explanation for the species difference remains
unclear.
Stereochemistry is an important aspect of biology and plays a role in many
aspects of drug disposition (Bhatia et al., 2008) and yet there are few studies
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examining stereoselective transport of drugs. PAN is marketed as a racemic
mixture whose stereoselective disposition has been characterized (Masubuchi et
al., 1998; Tanaka et al., 2001); however, the interaction of its isomers with
transporters (e.g., ABCG2) has not been described. It is unclear whether
differences in stereoselective disposition could play any role in the distribution of
PAN into milk. The present work characterized PAN isomer flux using rat Abcg2
in vitro models as well as PAN isomer distribution into rat milk.
Previously our laboratory had established a stably expressed rat Abcg2 in
MDCKII cell line, a cell line commonly used in transport studies (Bartholome et
al., 2007; Marchetti et al., 2007; Weinglass et al., 2008). MDCKII cells are
believed to express fewer endogenous xenobiotic transporters compared to
Caco-2 cells, although some research groups have demonstrated that several
xenobiotic transporters are present in MDCKII cells, such as p-gp and MRP2 (Su
et al., 2004). Hence, a number of substrates, including nitrofurantoin exhibit
directional transport in parent cell line (Kim et al., 1998; van Herwaarden et al.,
2007; Wang et al., 2008). Interestingly the PAN isomers transported from apical
to basolateral or from basolateral to apical overlaped completely in MDCKII
empty cell line; the ERα values were close to unity for both PAN isomers. This
would suggest that PAN was not a substrate for any of the endogenous
transporters in MDCKII; hence, PAN may serve as a model ABCG2 substrate for
a certain mechanistic flux studies.
As a typical ABCG2 substrate, PAN has been used as a competitive ABCG2
inhibitor to identify other ABCG2 substrates or to study drug-drug
interaction(Breedveld et al., 2004; Yokooji et al., 2007; Adkison et al., 2009) Our
in vitro experiment demonstrated a rat Abcg2 mediated apically directed
transport of PAN and indicated pantoprazole is a substrate of rAbcg2, which is
consistent with the reports that pantoprazole is a substrate for human and mouse
ABCG2/Abcg2 (Breedveld et al., 2004; Breedveld et al., 2005; Suzuki et al.,
2009). Furthermore, in rat expressing MDCKII cell line, Abcg2 demonstrated
stereoselective interaction with pantoprazole. The flux of the (+)-PAN appears to
be greater than the (-)-PAN isomer (Figure 4-1B). However, a more detailed
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analysis of the in vitro transport data (Chapter 5) suggests that the (-) isomer is,
in fact, the better ABCG2 substrate; possessing a greater affinity and overall
apical efflux permeability (PSAE) for rAbcg2. The greater flux of (+)-PAN arises
due to the interplay between the two membranes (basolateral and apical) in
determining the overall flux. At lower concentrations, PAN (both isomers) flux
across the apical membrane (due to rAbcg2) is so rapid that the overall rate
limiting step is diffusion across the basolateral membrane. At 25 µM
concentration, the higher affinity (-)-PAN isomer saturates rAbcg2 at the apical
membrane, slowing overall flux across the monolayer. Hence, (+)-PAN
appeared to be a better rAbcg2 substrate than (-)-PAN (Figure 4-1) when in
reality the opposite is true. A more insightful, mechanistic model is required to
fully interpret flux data (theoretical part, Chapter 6) and such an analysis reveals
(-)-PAN to be a better rAbcg2 substrate (Chapter 5: in vitro model).
In the chemical Abcg2 knockout rat model, co-administration of GF120918
decreased the systemic clearance of nitrofurantoin (Wang et al., 2008). In the
present study of PAN isomers, (-)-PAN had a slightly lower systemic clearance
compared to (+)-PAN but there was no statistical difference. This observation is
consistent with the report that (-)-PAN had relative longer serum elimination halflife and mean residence time in rat study (Masubuchi et al., 1998). The
administration of GF120918 had no significant effect on PAN isomer systemic
clearance, which would indicate that Abcg2 does not play a major role in the
elimination for the systemic clearance of PAN. In a human study, roughly 80%
of an oral or intravenous dose is excreted as metabolites in urine; the remainder
is found in feces and appears to originate from biliary secretion (Huber et al.,
1996a). The parent drug is predominantly metabolized by CYP2C19 and to a
lesser extent by CYP3A (Radhofer-Welte, 1999). The pharmacokinetics of PAN
is unaltered in patients with renal failure, but the rate of metabolism was
significantly decreased with severe liver cirrhosis patients (Huber et al., 1996b),
which indicates systemic clearance of PAN is largely determined by hepatic
metabolism of PAN.
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The metabolism of PAN isomers in mammary epithelial cell appears to be
minimal (no evidence of metabolism in milk samples). The in vivo M/S of (+)PAN was almost 1/3 that of (-)-PAN in DMSO group and the in vivo M/S of both
isomers converged to a similar value (0.4-0.5) following the administration of
GF120918, suggesting Abcg2 contributes to PAN distribution in rat milk with
Abcg2 serving as a major contributor for (-)-PAN accumulation.
Based on the results of in vitro and in vivo studies, we confirmed that Abcg2
recognizes three dimensional structure of PAN. This difference may play a role
in the tissue distribution profile for PAN. However, it is likely that such
differences would result in minimal differences in the overall pharmacodynamic
profiles of PAN. PAN is an acid gradient dependent accumulation prodrug and
both isomers are converted to the same active principle, planar sulphenamide.
Cyclic sulphenamide has an ability to react with key cysteines present in the
gastric acid pump (Huber et al., 1995). The chirality is lost in the conversion from
prodrug to active form; hence, for PAN, stereoselective differences in disposition
may have limited pharmacologic or clinical effects.
In conclusion, the present work has demonstrated a clear difference in the
transport of the isomers of PAN by rAbcg2 with (-)-PAN a better substrate than
(+)-PAN. Moreover, PAN stereoselectivity for Abcg2 appears responsible for a
difference accumulation of substrate isomers in milk and may have
consequences for other aspects of stereoselective drug disposition. The current
work also supports the hypothesis that ABCG2 substrates will accumulate in
milk, but does not explain the previous clinical observation of a low M/S ratio.
Additional studies will be needed to clarify this apparent species difference.
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CHAPTER 5: Data based efflux transport transwell
model: pantoprazole interaction with rAbcg2/ABCG2
5.1 Summary
CaCo-2 and efflux transporter over-expressing cell lines seeded in Transwell
have been broadly used for new molecule entity screening (NME), drug
disposition and drug-drug interaction studies which involved efflux transporters,
such as P-gp, ABCG2 and MRP2. The interactions between compound and
monolayer in Transwell as a NME screening tool have driven more attention than
before. In recent years, investigators have employed mathematical models to
explain the various experimental observations. Kalvass’s efflux theoretical model
and Sun’s CaCo-2 model expanded our understanding of Transwell flux data and
have identified the limitation of some parameters. However, these models also
have their limitations as well.
In this section, we characterize the interactions between pantoprazole
isomers and rat Abcg2/ human ABCG2 in Transwell system. Both pantoprazole
isomers are Abcg2/ABCG2 substrates. There were stereoselective transport of
pantoprazole isomers in monolayer of both Abcg2 and ABCG2 expressed in
MDCKII cell lines with (-)-PAN having a greater affinity. There was a modest
difference observed in kinetic transport parameters between rat Abcg2 and
human ABCG2. (-)-pantoprazole is a better substrate than (+)-PAN for both
species. The observation of PAN isomers transport in Abcg2 expressing in
MDCKII cell line is consistant with the in vivo result from rat study in Chapter 4.
Having identical chemical properties (diffusion controlled), the pantoprazole
isomers provide an ideal platform to compare the kinetic parameters derived from
Transwell experiments. It is important to use cellular concentration instead of
donor concentration to estimate kinetic parameters of transporters, e.g., PS A,E,
Km and Vmax. The theoretical mechanistic model provided a comprehensive
understanding of pantoprazole isomers transport in Abcg2/ABCG2, verified the
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theory behind the experimental paradigm and helped reinforce our understanding
of the monolayer flux experiments.
5.2 Introduction
Efflux transporters such as P-gp, MRP2 and ABCG2 are localized in
numerous tissues throughout the body and play important roles in drug
absorption, distribution, metabolism and excretion (Giacomini et al., 2010).
These transporters can be major determinants of the pharmacokinetic, efficacy
and safety profiles of drugs. In order to identify transporter substrates from new
discovery libraries or investigate the impact of drug-drug interaction on drug
metabolism and pharmacokinetic of marketed drugs or those in development, an
in vitro method is required that is convenient, specific, high-speed and cost
effective.
Flux across a Caco-2 or P-gp-overexpressing polarized epithelial cell lines
have become one of the most popular in vitro methods to characterize substrate
– transporter interactions. Experimental monolayer models produce an
environment that mimics the in vivo state, permitting cultured cells to polarize and
grow on porous membranes that provide an independent access to apical and
basolateral plasma membrane domains. Vectorial transport across cell
monolayers has been well established and used routinely in pharmaceutical
industries world-wide (Balimane et al., 2004; Balimane and Chong, 2005).
However, a mechanistic explanation and quantitative description of transport or
inhibition data from transwells remains limited (Kalvass and Pollack, 2007). The
US Food and Drug Administration and the International Transporter Consortium
are trying to develop guidance to assist drug development scientists in
conducting informative in vitro and follow-up clinical studies, for example, to
establish decision trees for the study of P‑glycoprotein or BCRP substrate
interactions and inhibitor interactions (Zhang et al., 2008; Huang and Woodcock,
2010).
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Our laboratory has studied the transfer of drugs into milk in rats, rabbits and
humans. While diffusion plays a major role in drug appearance in milk, so does
ABCG2. ABCG2 is found on the apical surface of lactating mammary epithelial
cells (Jonker et al., 2005) and ABCG2 facilitates the accumulation of drugs in
milk including: nitrofurantoin, cimetidine, topotecan, acyclovir, dietary
carcinogens, ranitidine and ciprofloxicin (Oo et al., 1995; McNamara et al., 1996;
Gerk et al., 2001a; Oo et al., 2001; Jonker et al., 2005; Merino et al., 2005a;
Merino et al., 2006b; van Herwaarden et al., 2007; Vlaming et al., 2009).

It is

unclear if all ABCG2 substrates will accumulate in milk. A clinical report involving
pantoprazole (PAN) reported a very low M/S (0.022) which would question the
predictability of this generalization (Plante et al., 2004). In a companion chapter,
the disposition of PAN in rat milk was explored and revealed a clear
stereoselective difference associated with rAbcg2. PAN is marketed as a
racemic mixture (Figure 5-1) and differences in the overall disposition of the two
isomers have been reported both in man (Tanaka et al., 2001) and in rats (Xie et
al., 2005). It is unknown if the interaction of PAN with ABCG2 is stereoselective
or if it could explain the human M/S report.
In this paper, the transport of PAN isomers in monolayers consisting of rat
(rAbcg2) and human ABCG2 expressed in MDCKII cell line was examined. The
first objective was to establish whether any difference in the interaction between
PAN isomers and rAbcg2/ABCG2 was present. Secondly, a model was
proposed to quantify these stereoselective differences in kinetic parameters in
order that they might be related to in vivo disposition studies. A third objective
was to examine the interspecies difference since the rat is frequently used as an
animal model.
5.3 Material and methods
Chemicals and materials
PAN mixture (50:50) was purchased from Wyeth (Philadelphia, PA) and the
isomers of PAN were obtained from Altana Pharma AG (Konstanz, Germany).
Cell culture mediums were obtained from Invitrogen (Carlsbad, CA). All the
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organic solvents [high-performance liquid chromatography (HPLC) grade] were
purchased from Thermo Fisher Scientific (Waltham, MA), and all of the other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless specified.
Over-expressing rAbcg2/ABCG2 in MDCK-II cell lines were used in the
transport studies. The establishment of rat Abcg2 or empty vector (pcDNA3.1)
alone in MDCKII was described previously (Wang et al., 2008). Human ABCG2
or empty vector (pcDNA3.1) alone in MDCKII was previously established in our
laboratory (Phil Empy Thesis). The pcDNA3 plasmid construct alone (empty
vector) and the pcDNA3 plasmid containing wild-type ABCG2 were prepared for
transfection. MDCKII cell transfection was performed at 50% confluence with the
lipid-based FuGENE 6® transfection reagent at a 3:1 ratio per manufacturer’s
protocol. Success of transfection was initially evaluated at 48 h by Western blot
analysis of cell lysates for ABCG2 following procedures described in the Western
blot on page 37. Transfected cells were then selected through the addition of
800 μg/mL genecitin to the parent cell line media (MEM containing glutamax, 5%
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin) (From Phil Empey’s
dissertation).

Figure 5-1 The structure of pantoprazole isomers.
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PAN isomers transport in rat Abcg2 or human ABCG2 in MadinDarby Canine Kidney II cells.
Briefly, rat /human ABCG2 or empty vector in MDCKII cells were seeded on
microporous membrane filters (3.0-µm pore size, 24-mm diameter; Transwell
3414; Corning Inc., Corning, NY) at a density of 1.0 x 106 cells/well. Cells were
grown for 4 days to achieve transepithelial electrical resistance >200

· cm2, and

medium was replaced every other day. Before the experiment, the medium at
both the apical and basolateral side of the monolayer was replaced with 2 ml of
OptiMEM medium (Invitrogen) without serum and either apical or basolateral
side was loaded with 3, 10, 30, 50 and 200 µM PAN isomers containing 0.2
µCi/ml [3H]mannitol (Perkin Elmer, Hebron, KY). Cells were incubated at 37°C in
5% CO2. 50-µl aliquots were collected to assess the paracellular flux of [3H]
mannitol into the opposite compartment; layers restricted mannitol transport to
<1% of the total radioactivity per hour. For PAN isomers transport, 140-µl aliquots
were taken at 0.5 and 1 h. Samples were stored at -80°C until the time of
analysis by HPLC assay.
PAN HPLC
Concentrations of PAN were assayed by HPLC on a Luna RP18 125 x 4.0mm column (Phenomenex, Torrance, CA) and eluted with 40% acetonitrile/60%
10 mM potassium phosphate buffer, pH 7.2, at 0.5 ml/min. UV absorb at 290
nm. Aliquots of PAN in Opti-MEM medium were directly injected onto the HPLC.
The standard curve range was from 7.8 to 2000 ng/ml. All the standard curves
showed an intraday and interday variability of <10% and r2 > 0.999.
Permeability
The observed permeability (PObs, (μL/hr)/cm2) of PAN isomers or paracellular
marker was determined by calculating its initial transfer rate ( , pmol/hr) across
the cell layer and dividing by the surface area (A, cm 2) of the Transwell and the
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initial concentration (C0, pmol/mL) in the donor chamber. PAN isomers transport
data in rat Abcg2 or human ABCG2 were expressed as mean ± S.D.
Eq. 5-1

Figure 5-2 Three compartment model of flux across monolayer on Transwell
system. PSD: passive diffusion; PSPC: permeability of paracellular transport; PSABCG2:
active efflux mediated by ABCG2 on apical side.
A three compartment kinetic model of transcellular flux across a monolayer
system (e.g., ABCG2 – MDCKII) is shown in Figure 5-2 and has been recently
developed to facilitate the interpretation of flux data (Theoretical part). Briefly,
the driving force for drug efflux from basolateral to apical side includes passive
diffusion (PSD) across both basolateral and apical membranes, paracellular
transport (PSPC) between cells and active transport efflux on apical side (PSAE)
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associated with the transporter. The model assumes the substrate does not
interact with endogenous transporters, passive diffusion permeability (PSD) is the
same across both membranes, there is no cellular metabolism, and rapid
intracellular diffusion. Substrate flux rates in three compartments can be
described by the following set of differential equations (Eq.5-2, Eq.5-3 and Eq.54).

Eq. 5-2

Eq. 5-3

Eq.5-4

where XB, XA and XC are the mass of drug in the basolateral, apical and cellular
compartment; CC, CB and CA are the concentration of drug in the cellular,
basolateral and apical compartment, respectively; PSAE , PSD and PSPC are the
permeability-surface area products for active apical efflux, passive diffusion and
paracellular pathways, respectively.
Equation 5-2 and 5-3 can be further refined (Chapter 6) to describe the initial
permeability from B to A (

) or A to B (

)

Eq.5-5

Eq. 5-6

Paracellular permeability of mannitol was used as a surrogate for PAN PS PC.
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PSD was estimated from the PAN flux in parent MDCKII (PSAE=0) by rearranging
Equation 5-5 (or 5-6) as
Eq. 5-7

Permeability associated with ABCG2 apical efflux (PSAE) was estimated from B
to A or A to B PAN flux in rAbcg2/ABCG2 - MDCKII rearranging Equation 8 or 9,
respectively.

Eq. 5-8

Eq.5-9

Initial transfer flux of from B to A (assuming CA=0) or A to B can be rewritten
(Chapter 6) and used to solve for CC as Eq. 5-10

Eq. 5-10

ERα is defined as the ratio of the initial rate of B to A flux divided by the initial rate
of A to B.

Eq. 5-11

Kinetic Parameter (KM and TMax) Estimation
The saturation kinetics of PAN isomers apical efflux transport by rAbcg2 or
ABCG2 (PSAE) as a function of estimated cellular concentrations (Equation 5-10)
can be modeled by Eq. 5-12 where Tmax is the maximum transport rate and Km
the Michaelis constant, inversely reflecting binding affinity of substrate for
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transporter. Non-linear regression using GraphPad Prism (5.02) was employed
to determine Km and Tmax in Equation 5-12 from PSAE

Eq. 5-12

5.4 Results
Pantoprazole isomers transported in rAbcg2 or ABCG2. The expression
level and function of transport study of stably expressing rat Abcg2/ human
ABCG2 cDNA or vector alone in MDCKII cell lines has been tested in a previous
study (Wang et al., 2008) and unpublished data (Phil Empey’s Thesis). The mass
transport of PAN isomers was studied in empty-MDCKII and rAbcg2-MDCKII
cells as shown in Figure 5-3. There was no difference observed for flux in either
direction (A to B or B to A) or isomer-related flux in PAN isomer transport in
empty-MDCKII monolayers at any of the five concentrations examined. In
contrast, the transport of PAN isomers exhibited directional flux in rAbcg2MDCKII cell line. There were marked transport differences between the PAN
isomers at 30 and 50 μM for both directions. At lower (3 and 10 μM)
concentrations, the difference between the isomers became negligible. At the
highest donor concentration (200 μM) both isomers collapsed to flux identical to
the empty-

89

Empty-MDCKII

Rat Abcg2-MDCKII
3 M
PAN transferred (pmol)

PAN transferred (pmol)

3 M
4000

(-)-PAN A to B
(-)-PAN B to A
(+)-PAN A to B
(+)-PAN B to A
2000

0
0.0

0.5

1.0

4000

2000

0
0.0

12000

PAN transferred (pmol)

PAN transferred (pmol)

6000

6000

0
0.0

1.0

17500

1.0

35000

17500

0
0.0

Time (Hour)

30000

1.0

60000

30000

0
0.0

Time (Hour)

200 M

1.0

200 M
180000

PAN transferred (pmol)

PAN transferred (pmol)

0.5

Time (Hour)

180000

90000

0
0.0

1.0

50 M
PAN transferred (pmol)

PAN transferred (pmol)

50 M

0.5

0.5

Time (Hour)

60000

0
0.0

1.0

30 M
PAN transferred (pmol)

PAN transferred (pmol)

30 M
35000

0.5

0.5

Time (Hour)

Time (Hour)

0
0.0

1.0

10 M

10 M
12000

0.5

0.5

Time (Hour)

Time (Hour)

0
0.0

(-)-PAN A to B
(-)-PAN B to A
(+)-PAN A to B
(+)-PAN B to A

0.5

1.0

Time (Hour)

90000

0
0.0

0.5

1.0

Time (Hour)

Figure 5-3 Mean (± SD, n=3) PAN isomer transport in pcDNA3.1-MDCKII (left panels) or
rAbcg2-MDCKII cells (right panels) at 3, 10, 30, 50 and 200μM.
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Figure 5-4 Mean (± SD, n=3) PAN isomer transport in pcDNA3.1-MDCKII (left panels) or
human ABCG2-MDCKII cells (right panels) 3, 10, 30, 50 and 200μM.
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MDCKII. Parallel results were observed in empty-MDCKII and human ABCG2MDCKII cell line transport study (Figure 5-4). The directional transport of the two
isomers confirmed that PAN is a substrate for both human and rat ABCG2.
Permeability parameters (PSobs, PSD and PSPC) and asymmetry efflux
ratios (ERα). Apparent permeability for PSobs, PSD, PSpc and asymmetry efflux
ratios (Table 5-1 and 5-2) were obtained for both rat and human ABCG2. Using
PSobs of PAN transport in empty-MDCKII, PSD was estimated from Equation 5-7
at different concentrations and both directions were very close (Table 5-1 and 52). Assuming the transport permeability of mannitol is similar to PAN isomer
transport across paracellular pathway, PSpc values were small and consistent
across studies. PSpc values were lower for ABCG2-MDCKII compared to emptyMDCKII. PSobs of PAN isomers in empty-MDCKII cell lines were very similar for
both directions at different concentrations resulting in ERα values approximating
unity for all of the experiments. By contrast, the PSobs of both PAN isomers in the
transfected cell lines were very different with respect to direction, favoring strong
basolateral to apical directional flux at lower PAN concentration. The apparent
flux were similar, but with subtle differences. At the lowest PAN concentration,
the ERα(s) of (-)-PAN was nearly double that of (+)-PAN. Flux was decreased
from basolateral to apical side in Abcg2/ABCG2-MDCKII and increased from
apical side to basolateral as donor concentration increased (Table 5-1 and 5-2).
As a result, the ERα(s) of PAN isomers in both rat and human ABCG2
transfected cell lines decreased with increasing donor concentration (Table 5-1
and 5-2). The direct driving force of transport is cellular concentration of
substrate not donor concentration.
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rAbcg2-MDCKII

Isomer Parameter Direction
Minus
A->B
PSobs
B->A
ER
Plus
A->B
PSobs
B->A
ER
PSD (Both Isomers)
PSPC (Mannitol)
Minus
A->B
PSobs
B->A
ER
Plus
A->B
PSobs
B->A
ER
PSPC (Mannitol)

3uM
118
120
1.02

10uM
123
130
1.06

30uM
116
123
1.07

50uM
121
126
1.04

200uM
130
135
1.04

Mean
121
127
1.05

SD
5
6
0.02

116
117
1.01

114
121
1.07

110
116
1.06

123
135
1.09

142
140
0.98

121
126
1.04

13
11
0.05

231
2.30
7.4
253
34.0

242
1.14
30.1
224
7.44

226
3.54
92.5
151
1.63

251
0.72
109
137
1.26

271
1.39
127
136
1.07

244
1.82

18
1.12

12.8
238
18.7

20.9
229
11.0

33.5
206
6.16

79.1
194
2.46

126
162
1.29

0.51

0.88

3.44

0.72

1.59

n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
1.43

1.20
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Empty-MDCKII

Table 5-1 The asymmetry efflux ratios (ERα) and permeability parameters (PSobs, PSD and PSPC) of PAN isomers transport in empty
vs rat Abcg2-MDCKII as a function of PAN donor concentration (PS units: (μL/hr)/cm2).

Huamn ABCG2

Isomer Parameter Direction
Minus
A->B
PSobs
B->A
ER
Plus
A->B
PSobs
B->A
ER
PSD (Both Isomers)
PSPC (Mannitol)
Minus
A->B
PSobs
B->A
ER
Plus
A->B
PSobs
B->A
ER
PSPC (Mannitol)

3uM
126
128
1.01

10uM
143
155
1.08

30uM
140
150
1.08

50uM
137
146
1.06

200uM
152
151
0.99

Mean
140
146
1.04

SD
9
11
0.04

140
149
1.06

140
157
1.13

137
156
1.14

136
149
1.09

159
166
1.04

142
155
1.09

10
7
0.04

267
2.30
16.9
254
15.0

291
3.29
31.6
255
8.06

289
1.22
67.6
211
3.12

277
3.44
109
156
1.44

309
2.29
132
132
1.00

287
2.51

16
0.90

30.0
258
8.61

42.2
246
5.81

43.6
240
5.50

79.6
195
2.45

126
179
1.42

1.00

1.03

0.76

0.78

0.71

n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
0.86

0.15
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Table 5-2 The asymmetry efflux ratios (ERα) and permeability parameters (PSobs, PSD and PSPC) of PAN isomers transport in empty
vs human ABCG2-MDCKII as a function of PAN donor concentration (PS units: (μL/hr)/cm2).

Cellular concentration profile Simulated cellular concentrations of PAN
isomers corresponding to donor concentrations are presented in Figure 5-5 as
estimated from Equation 5-10 for both rAbcg2 and ABCG2-MDCKII based on
initial estimates of permeability parameters (PSobs, PSD and PSPC) of PAN
isomers and apparent PSAE values. At low donor concentration (3 M), cellular
concentration is estimated to be 3.2% of donor concentration for (-)-PAN and
5.6% for (+)-PAN for rAbcg2 and 5.5% for (-)-PAN and 11% for (+)-PAN for
ABCG2. At high donor concentration (above 50 M), cellular concentration is
predicted to approach ½ of donor concentration (Figure 5-5).
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Cellular Conc ( M)

100
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1
0.1
0.01
0.1
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1000
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Figure 5-5 Predicted cellular concentration of PAN (Equation 5-10) relative to donor
concentration based on PSD and PSPC described in Table 5-1 and 5-2 as well as fitted
parameters TMAX and KM (Table 5-3) were used. Squares indicate (+)-PAN, circles
represent (-)- PAN, open symbols indicate rAbcg2-MDCKII and closed symbols
represent ABCG2-MDCKII. The line of identity is also illustrated.

Kinetic parameters Km and Tmax for rat Abcg2 and human ABCG2. The
profile of apparent PSAE (both directions) as a function of estimated cellular PAN
concentration is presented in Figure 5-6. Kinetic parameters for the two
isomers interaction with Abcg2 and ABCG2 are shown in Table 3. The (-) isomer
of PAN has an 8-fold lower KM compared to the (+)-PAN for both rAbcg2 (0.25 vs
1.85 µM) and ABCG2 (0.6 vs 5.32 µM), indicating a higher affinity of
rAbcg2/ABCG2 for the (-) isomer. The (+) isomer of PAN has a 3-fold higher
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TMAX compared to the (-)-PAN for both rAbcg2 (7.86 vs 2.49 nmol/hr*cm2) and
ABCG2 (10.2 vs 3.29 nmol/hr*cm2). rAbcg2 had a lower KM (a higher affinity) for
the PAN isomers compared to human ABCG2, but comparable T Max values. The
overall permeability (transport clearance at low PAN concentrations, PS AE)
associated with rAbcg2 and ABCG2 was twice that for the (-) isomer compared to
the (+) isomer of PAN.
Modeling overall Permeability (PSObs). Utlizing the PSD values from the
empty –MDCKII (Table 5-1 and 5-2) as well as PSpc from the transfected cell
lines (Table 5-1 and 5-2) and the ABCG2 related kinetic parameters (Table 5-3)
the overall PS was modeled as a function of donor concentration (Figure 5-7).
Donor concentrations were back calculated from the intercellular concentrations.
The comprehensive relationships (Equations 5-5 and 5-6) were effective in
modeling PAN flux in both directions of (-)- PAN (r2= 0.979) and (+)-PAN (r2=
0.988) in ABCG2-MDCKII and (-)-PAN (r2= 0.985) and (+)-PAN (r2= 0.986) in
rAbcg2-MDCKII.
Table 5-3 The permeability parameters (PSD, PSPC and PSAE) and fitted mean (± SE)
kinetic parameters (Km and Tmax) in both human ABCG2 and rat Abcg2.
Parameters

Km

Tmax
PSAE
[Tmax / Km]

Unit

Rat Abcg2

Human ABCG2

Mean

Mean

(+) PAN

1.85 ± 0.66

5.32 ± 1.62

(-) PAN

0.25 ± 0.06

0.6 ± 0.12

(+) PAN

7.86 ± 2.20

10.2 ± 2.43

(-) PAN

2.49 ± 0.41

3.29 ± 0.48

(+) PAN

4,250

1,920

(-) PAN

9,960

5,480

Isomer

μM

nmol/hr*cm

2

μL/hr*cm2
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Figure 5-6 Apparent apical efflux permeability (PSAE, Equation 5-12) as a function of
simulated PAN cellular concentration (Equation 5-10). Panel A: rat Abcg2; panel B:
human ABCG2-MDCKII cell monolayer; Squares indicate (+)-PAN, circles represent (-)PAN, open symbols indicate basolateral to apical PSAE and closed symbols represent
apical to basolateral PSAE. The initial estimates of parameters TMAX and KM (Table 5-3)
were used to generate cellular concentration (Equation 5-10) and these concentrations
were used in the final estimation process. Both axes were log transformed for easier
visualization; fitting was performed using untransformed pooled data from both
directional PSAE. The solid and dashed lines are the fitted results for the (-)- and (+)PAN isomers, respectively.
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Figure 5-7 Overall permeability (PSobs) as a function of PAN donor concentration. Panel
A: rat Abcg2; panel B: human ABCG2-MDCKII cell monolayer; Squares indicate (+)PAN, circles represent (-)-PAN, open symbols indicate basolateral to apical and closed
symbols represent apical to basolateral flux. The simulation line represents Equation 55 and 5-6 for basolateral to apical and apical to basolateral flux, respectively. Fitted
parameters TMAX and KM (Table 5-3) were used to generate cellular concentration
(Equation 5-10) and simulation of overall PSobs together with PSD and PSPC as described
in Table 5-1 and 5-2. Model limits for basolateral to apical (PSD + PSPC), apical to
basolateral (PSPC) and empty cell line flux are presented as reference. The small square
box presents the range of PAN concentration in serum in rat or pharmacological
concentration in human, respectively.
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5.5 Discussion
Transporters can play a role in the absorption, distribution, metabolism and
excretion as well as a pharmacological effect of a variety of drugs. A recent
white paper raised several key issues for drug discovery and development,
including which transporters are clinically important in drug absorption and
disposition, and which in vitro approaches are predictive for studying drug
interactions involving these transporters (Giacomini et al., 2010). Flux across a
Caco-2 or P-gp overexpressing polarized epithelial cell lines was one of the
prominent in vitro methods proposed in the paper. Recently, our laboratory has
described some of the limitations and interpretations of flux across a monolayer
using a theoretical model (Chapter 6). The impetus for the model arose, in part,
from the PAN isomer flux data presented herein. PAN isomers have almost
identical physiochemical properties. PAN isomers transported in ABCG2
overexpressing MDCKII provided a simplified experiment model to compare
important kinetic parameters from Transwell.
The apparent permeabilities (PSapp) of PAN isomers transport in empty
MDCKII cell line (parent cell line) at five different concentrations were virtually
identical (Table 5-1 and 5-2). There was no directional transport difference
observed at any concentration; indicating no interaction of PAN isomers with
endogenous transporters in the parent MDCKII cell line. This observation is
consistent with other reports from literature (Breedveld et al., 2004) and suggests
that PAN is a model substrate for this commonly used polarized epithelial cell
line. PAN has been commonly used as an ABCG2 inhibitor in drug-drug
interaction or ABCG2 substrate identification studies (Breedveld et al., 2004;
Adkison et al., 2009; Oostendorp et al., 2009). In the present study, PAN was
transported by human ABCG2 and rat Abcg2; it is particularly evident at 30 and
50 μM (Figure 5-3 and 5-4). The results confirm that both PAN isomers are
rAbcg2/ABCG2 substrates.
The stereoselective interaction of PAN with rAbcg2/ABCG2 was evident at
30 and 50 μM but was not evident at lower (3 μM and 10 μM) or higher
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concentrations (200 μM). The model provides for a clearer interpretation of the
isomer flux. The rate limiting steps for PAN flux are associated with diffusion
(PSD and PSPC) and not rAbcg2/ABCG2 associated PSAE under these
concentrations. Only at the intermediate donor concentrations when
rAbcg2/ABCG2 become saturated is a change in flux observed. Flux studies,
including those examining stereoisomer differences, are carried out at low
substrate concentrations in high expressing clones to optimize the opportunity for
observing a response. It should be noted that under such conditions, it is
unlikely that stereoselective interactions would be reported since diffusion
pathways dominate overall flux.
Taken together the flux data from empty and rAbcg2/ABCG2-MDCKII cell
lines were consistent with the three compartment kinetic model shown in Figure
5-2, in which the passive apparent permeability on either apical or basolateral
side (PSD), paracellular apparent permeability through tight junction between
cells (PSPC) and the active apparent permeability of ABCG2 on apical side (PSAE)
as shown. Isolating the various parameters (PSD, PSPC, VMax and KM) allowed
the overall PSObs to be successfully modeled (Figure 5-7). PAN flux in the B to A
direction at low PAN concentration was very rapid across the apical membrane
and overall flux was limited by the rate of diffusional flux across the basolateral
membrane plus diffusion via the paracellular pathway. PAN flux in the A to B
direction was limited paracellular diffusion since the counter flux associated with
PSAE was so efficient that virtually none of the drug which entered the cell from
the apical surface fluxed transcellularly to the basolateral compartment.
Relating kinetic parameters (VMax and KM) to donor concentrations was
problematic. Initial attempts to fit flux to permutations of the Micahelis Menton
equation as a function of donor concentration resulted in fits which did not mimic
the observed data. Fitting flux to donor concentrations would suggest an
apparent cooperative interaction with the transporter (Hill coefficient)(Pan et al.,
2007). Clearly the driving force for an apical efflux transporter such as
rAbcg2/ABCG2 is intracellular not donor concentration. The apparent
cooperativity simply reflects the fact that there is relatively more cellular drug
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concentration as donor concentration increases due to saturation of the efflux
transporter (Figure 5-5). Intracellular concentrations were not measured in the
current study, but were predicted by the model (Figure 5-5) using the apparent
PSAE as well as estimates of PSD and PSPC. These intracellular concentrations
were then used to estimate VMax and KM. The estimated KM values ranged from
0.25 to 5.3 μM), whereas the donor concentrations around the inflection point
(Figure 5-7) were in the 20 to 100 μM range. The (-)-PAN had a KM value that
was 10% of the (+) isomer indicating (-)-PAN had an almost 10 fold higher affinity
for ABCG2 as well as rAbcg2. The capacity (VMax) was 60% lower for (-)-PAN
for ABCG2 and rAbcg2. For normal therapeutic dosing, serum unbound
concentrations are likely to be below 0.1 μM, hence cellular concentrations are
also expected to be well below the KM. The effective permeability (PSAE listed in
Table 5-3) would be more than two fold greater for (-)-PAN compared to the (+)
isomer. In the companion Chapter 4, the M/S for (-)-PAN in rats was 1.36 and
decreased markedly in response to GF120918 (an inhibitor of rAbcg2/ABCG2)
when compared to 0.54 for (+)-PAN (Chapter 4). Hence, the stereoselective
effect of PAN and rAbcg2 in vitro did manifest itself in a measureable in vivo
difference in disposition.
There may be differences in the human M/S for the two PAN isomers. The
current in vitro or rat data does not provide sufficient insight to explain the
observed clinical report of a low M/S for pantoprazole (Plante et al., 2004).
Differences in the overall disposition of the two isomers have been reported;
however most of this difference appears to be related to differences in
metabolism. The stereoselective metabolism of (+)-PAN was impaired to a
greater extent than (-)-PAN in the poor metabolizers of S-mephenytoin 4'hydroxylase (CYP2C19) (Tanaka et al., 2001) The stereoselective metabolism
via sulfoxide oxidation, 4'-O-demethylation, and 6-hydroxylation results in
enantioselective pharmacokinetics; the area under the curve value of (-)-PAN
was 1.5 times greater than that of (+)-PAN (Xie et al., 2005). Moreover, it should
be realized that both isomers are converted to a common metabolite before
achieving pharmacological activity, hence, the ultimate clinical effect of
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stereoselective differences in disposition may be limited. As our in vivo rat milk
studies demonstrate, stereoselective differences in disposition attributed to
ABCG2 can result in tissue concentrations being higher despite comparable
systemic concentrations.
In conclusion, there was stereoselective transport of PAN isomers in
monolayers of both rat (rAbcg2) and human ABCG2 expressed in MDCKII cell
line with the (-) isomer possessing a greater affinity. A mechanism based model
was used to quantify differences in kinetic parameters between the two isomers.
These kinetic parameters provided insights as to the extent of differences that
might arise for in vivo studies. The current work also provided insights into the
species difference in ABCG2 transport.
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CHAPTER 6:Theoretical framework for

transcellular flux across a monolayer system
6.1 Summary
In-vitro cell models are utilized to assess the role of transporter proteins on the
vectorial transfer of drug across a polarized epithelial cell monolayer. A
mechanistic model is presented to challenge and verify the underlying concepts
and boundaries of this approach. Previous investigators have demonstrated the
limitations of the apical efflux ratio (ERA), and proposed the use of the
asymmetrical efflux ratio (ER ) as a more robust parameter. However, the
assumption of a nonexistent paracellular transport pathway confounds parameter
estimation and gives rise to an underestimation of the contribution of apical efflux
(PSA,E). Use of donor (and not cellular) concentration gives rise to an apparent
positive cooperativty in kinetic parameters. Neither observed permeability
(PSobs) nor ER plotted as a function of substrate (or inhibitor) concentration
provide an accurate estimation of KM or KI. Greater appreciation of the
consequence of using high expressing clones and the transition of rate limiting
steps (from basolateral alone to apical and basolateral processes) provides
insight into the interpretation of flux kinetic data (TMax or KM) as well as inhibition
profiles (KI). The concepts presented in this paper provide a framework for
interpreting transcellular flux across a cell monolayer and have implications for
the assessment of drug-drug interactions involving transporters.
6.2 Introduction
Approximately 50 efflux and 360 uptake transporter proteins have been identified
in mammalian species. These proteins are localized both in intracellular
membranes as well as on the cell membrane. They appear to play key roles in
homeostasis through their selectivity for ions and larger endogenous molecules,
but they also interact with exogenous substances and drugs. Their orientation on
either apical or basolateral faces of epithelium or endothelium can greatly control
and facilitate substrate passage across biological membranes. This interaction
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has led to the realization that transporter proteins can play an important role in
the pharmacokinetics and pharmacodynamics of drugs. Initially, much of the
interest in transporter–drug interactions was sparked by the role of ATP-binding
cassette (ABC) efflux transporters, such as p-glycoprotein (P-gp), multidrug
resistance associated proteins (MRPs) and breast cancer resistance protein
(BCRP) in resistance to chemotherapy. More recently, the role of select efflux
and uptake transporters, which polarize on opposite sides of the same cell and
have common substrates, has also been recognized for their capacity to
selectively control drug transfer across a variety of epithelial and endothelial
blood-tissue barriers.
In the context of drug development, in-vitro expression models are being used
extensively to characterize transporter-drug interactions. From a regulatory
perspective, these analyses are warranted by concerns that interindividual
variation in transporter function and drug interactions may influence
pharmacokinetics and ultimately pharmacodynamics (Zhang et al., 2008; Zhang
et al., 2009). As a result, transporter effects have been included in the drug
labeling requirements (Zhang et al., 2008; Zhang et al., 2009). Currently, efforts
are ongoing in the industry and at the FDA to develop and evaluate models for
predicting the relevance of interactions between drugs and efflux or uptake
transporters. These efforts are focused on classifying individual drugs as
transporter substrates, inhibitors, and inducers and on providing quantitative
measures that will prompt further in-vivo studies for rigorous evaluation of clinical
relevance.
Widely accepted systems for such studies include cells that polarize (e.g.,
MDCKII) and overexpress a cloned transporter. Ideally, this model system has
tight junctions and no endogenous transporters that would interact with the drug
of interest. While qualitatively useful for identification of substrates, using these
expression systems for quantitative assessments should be carefully considered
(Kalvass and Pollack, 2007) before making conclusions based on mathematical
modeling of the transport data.
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Although Michaelis-Menten type relationships analysis is often used to assess
drug-transporter interactions, there are multiple assumptions, which if not
carefully considered could potentially yield misleading results. Some of the
assumptions include minimum contribution by physical barriers such as the
unstirred water layer, minimum contribution by passive diffusion, and minimum
paracellular transport. Here we examine how these assumptions can potentially
influence the quantitative assessments of transport parameters obtained using
these monolayer systems and offer insights and guidelines for analyzing vectorial
transport data.
Comprehensive Model for Transport Pathways across a Transwell System
Flux across a cell monolayer grown on a support filter (e.g., Transwells) can be
represented by a series of sequential and parallel barriers (Figure 6-1, Panel A).
The barriers include permeability across the unstirred water layer at surfaces
(PSUWL), permeability across the filter (PSF) and ultimately permeability across
the monolayer itself (PSM).
An equation can be written to describe overall permeability (PS Overall) that
includes consideration of the properties of filter itself as well as flux across the
parent cell model monolayer (assuming no active uptake or efflux processes
present at basolateral or apical membranes) such that
6-1
Experimentally it is difficult to discern permeability through the unstirred water
layer and the filter and these terms are generally combined to yield
6-2
The contribution of diffusion through the porous filter to overall permeability is
rather negligible. However, diffusion across the unstirred water layer may present
a significant barrier for more lipophilic drugs, whereas the cell monolayer itself is
the rate limiting step in the overall permeability for more hydrophilic drugs.
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The monolayer presents two distinct parallel pathways through which drug can
pass, transcellular (PSTC) and paracellular (PSPC) as shown in Figure 6-1, Panel
B.
6-3
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Figure 6-1 Panel A: Model of flux across monolayer on Transwell system, depicting permeability-surface area clearance
across unstirred water layers (PUWL), the filter (PSF) and the cell monolayer itself (PSM). The subscripts A and B denote
the apical (AP) or basolateral (BL) compartments. Panel B: Model of flux across a model cell monolayer with all possible
active transport processes. The model depicts the processes governing the transfer of drug from the basolateral to apical
compartments across the MDCKII (cellular) compartment. Transfer processes include diffusion (PS D), active uptake on
the basolateral and apical membranes (PSB,U and PSA,U, respectively), active efflux on the basolateral and apical
membranes (PSB,E and PSA,E, respectively) as well as paracellular diffusion (PSPC). Transcellular transport processes are
denoted as PSTC.
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A

The latter depends largely on the molecular size and the integrity of tight
junctions. The former is comprised of two distinct barriers, the basolateral and
apical membranes, with each containing multiple pathways that restrict or
facilitate passage. At a minimum, diffusion occurs across both membranes (PSD)
and drug must cross these barriers in series.
6-4

Careful consideration must be given to passage across the unstirred water layer
since it may present the rate limiting barrier for some drugs. While the above
analysis is restricted to diffusion (i.e., parent cell line), there are implications for
expression systems as well. The observations of Balakrishnan et al
(Balakrishnan et al., 2007) suggest that a similar phenomena may occur for less
lipophilic drugs for which flux across empty or parent cell monolayers is
controlled by diffusion. Their flux in overexpression systems, however, may be
so rapid that the unstirred water layer becomes rate limiting. Hence, variation in
transporter expression or substrate affinity can readily influence which barrier is
rate limiting (Balakrishnan et al., 2007).
For the remainder of the paper, the contribution of the unstirred water layer will
be assumed to be negligible.
Integrated Monolayer Model
While the resistance approach is simple and direct, there are limitations in its
application and a broader model is warranted to explore the contributions of the
two membranes to overall flux. Assuming no endogenous transporters, passive
diffusion permeability (PSD) is the same across both membranes, no cellular
metabolism, and rapid intracellular diffusion, a kinetic model (Figure 6-1, Panel
B) can be described by the following set of differential equations.
Substrate flux into and out of the basolateral compartment, B, can be described
by the following equation
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6-5

where XB is the mass of drug in the basolateral compartment; CC, CB and CA are
the concentration of drug in the cellular, basolateral and apical compartment,
respectively; PSB,E , PSB,U and PSPC are the permeability-surface area products
for basolateral efflux, basolateral uptake and paracellular pathways, respectively.
Substrate flux into and out of the cellular compartment, C, can be described by
the following equation

6-6

where XC is the mass of drug in the cellular compartment; PSA,U and PSA,E are
the permeability-surface area products for apical uptake and apical efflux
pathways, respectively.
Substrate flux into and out of the apical compartment, A, can be described by the
following equation

6-7

where XA is the mass of drug in the cellular compartment.
Flux Across an Untransfected Cell Line
Assuming the absence of both active uptake into and efflux out of the cell, initial
permeability for the basolateral to apical direction in the parent untransfected cell
line (

) can be written as
6-8
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An identical equation can be written for flux in the apical to basolateral direction.
Fluxes via parallel pathways, like diffusion through the cell
cells

and between

are summed, while flux via pathways in series (i.e., diffusion across

basolateral and apical membranes) is the reciprocal of the sum of the
reciprocals

.

Initial Rate of B-to-A flux across a Monolayer
For most experiments, an initial directional flux rate is often used. The initial flux
or appearance in the apical compartment for drug transferred from B→A
(assuming CA=0), Equation 6-7 can be written as
6-9
If rapid equilibrium between the basolateral and cellular compartment is
assumed

, then Equation 6 can be rewritten as

6-10
Substituting Equation 10 into Equation 9 yields

6-11
Hence, the initial permeability for the basolateral to apical direction (

) can

be described by the following equation

6-12
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Initial Rate of A-to-B flux across a Monolayer
Likewise the directional flux rate in the apical to basolateral direction (assuming
CB=0) can be written as
6-13
Assuming rapid equilibrium between the apical and cellular compartments
, Equation 6-6 can be rewritten as

6-14
Substituting Equation 6-14 into Equation 6-13 yields the initial permeability for the
apical to basolateral direction (

)

6-15

Flux Across a Transfected Cell Line
In order to understand the limitations of models describing flux across a
monolayer, a broadly encompassing model that includes all of the flux processes
can be utilized (Figure 6-1, Panel B). Such an approach may be required to
explore the relative contributions of the two membranes to overall transcellular
flux as well as the contribution of paracellular flux. However, this paper will focus
attention on the most frequent analysis and on what is the current focus of the
Drug-Drug Interaction Draft Guidance at the FDA; a monolayer in which an apical
efflux transporter (i.e., P-gp, ABCG2, MRPs) has been expressed. Table 6-1
contains various scenarios to describe flux across such a model system.
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In a single transfected system like ABCG2 (or MRPs), the other pathways are
assumed to be negligible

and Equation 6-12 can be

rewritten as

6-16

Table 6-1 Scenario 2 describes the PSObsl for the ABCG2 transfected cell line in
which passage across both membranes and between cells are contributing to the
overall flux.
PSA,E is determined by the properties of the substrate and the transporter, and
can be written as in Equation 6-17
6-17

where TMax is the maximum transfer rate associated with the active transport
process, KM is the Michaelis-Menten constant (inversely related to affinity) for the
transporter substrate complex and CC is the intracellular drug concentration
available to interact with the transporter.
As defined, PSA,E can vary according to inherent substrate characteristics (KM
and TMax) or due to transporter expression level (scaling of TMax). During the
development of transfected cell lines, clones with high transporter expression
levels are selected in order to develop a positive response model for identifying
substrates and predict the role of the transporter in the drug’s disposition (i.e.,
significant change in B→A rate). Thus, this process is inherently biased for
selecting clones that can achieve a much greater PSA,E (e.g., 10-fold) than PSD.
Hence,

increases with increasing PSA,E until it achieves a maximal flux
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that is the upper boundary (PSD + PSPC), as defined by Equation 6-18, which
evaluates Equation 6-16 at high PSA,E values relative to PSD.
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Table 6-1 Models depicting initial flux rates for parent and cloned cell model with diffusion across membranes (PSD), diffusion via paracellular
pathway (PSPC) and active transport via an apical efflux transporter (PSAE) as well as the determinants of overall permeability (PS) for parent cell
line as well as low and high expressing clones.
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1. Empty or
Parent Cell
Line

A→B Flux

Basolateral

B

Upper Boundary
Apical membrane ceases to
be a barrier; passage across
basolateral membrane is rate
limiting for transcellular flux.

Cellular

Apical

C

A

PSD

PSD
PSA,E

PSPC
Tight
Junction

Lower Boundary
All drug entering the cell is
pumped back into apical
compartment; only drug
appearing in B is associated
with paracellular pathway.

6-18
In this limiting case, it becomes increasingly difficult to distinguish the role of
PSA,E in the overall transport. Flux across the apical membrane becomes so
rapid such that overall vectorial flux across the monolayer is controlled by
diffusion through the basolateral membrane (PSD) as well as by the paracellular
pathway (Table 6-1, Scenario 3). Clearly the B→A flux rate has a fixed dynamic
range (2 fold) which is bounded and scaled by PSD.
In a similar fashion, A→B flux for single transfected system like ABCG2
(Equation 6-15) can be rewritten as

6-19
Likewise as PSA,E increases, flux in the A→B direction reaches a lower limiting
value.
6-20
All drug mass that enters the cell by diffusion across the apical surface is
pumped back into the apical compartment and does not cross the basolateral
membrane (Table 6-1, Scenario 3). Hence, only drug diffusing via the
paracellular pathway reaches the basolateral compartment.
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Figure 6-2 Panel A: Effect of increasing permeability-surface area clearance attributed to apical efflux (PSA,E) on observed flux
(PSobs). B to A flux increases as PSA,E increases to a maximum of diffusion across the basolateral membrane (PSD) and paracellular
pathway (PSPC). A to B flux (dX/dt) decreases as PSA,E increases to a minimum of diffusion across the paracellular pathway (PSPC).
As the apparent permeability and permeability-surface area product are proportional to flux, substituting any of these parameters on
the y-axis would yield the same relationship. Panel B: The influence of PSA,E relative to PSD on permeability flux (PSobs) for
situations where PSD is two (squares), five (diamonds) or greater than 10 times (circles) the paracellular flux (PSPC). Panel C: Data
from Panel B is normalized by adjusting for the dynamic range; all of the data from B to A (open circle) or A to B (closed circle)
collapse to the identical line.

Numerous published reports utilize the initial B→A vectorial transfer of drug
to determine the influence of an apical efflux transporter. While a logical
approach, its limitations as a quantitative tool are rarely appreciated (Kalvass and
Pollack, 2007). From a practical perspective it is useful to consider those
conditions under which an apically expressed transporter contributes to the
overall flux of a series of drugs (or a given drug in a series of clones that vary in
expression levels of the transporter). Figure 6-2 Panel A shows the influence of
PSA,E (relative to PSD) on the mass transfer of drug across a monolayer. As
PSA,E increases, the directional flux reaches an upper (B→A) and lower (A→B)
boundary that is controlled by the diffusion properties of the basolateral
membrane and paracellular passage. Such data could experimentally arise due
to clonal selection, i.e., comparing transcellular flux of one drug in different
clones (PSA,E varies due to increasing transporter expression) or in comparing
various drugs in a single clone (varied PSA,E or PSD). For either situation, overall
flux (PSObs) is bounded between the flux observed in the parent cell line
(Equation 6-8) and the flux observed in the clone when PSA,E>>PSD (Equation 618). At lower PSA,E to PSD ratios (PSA,E / PSD < 0.2), contributions of active efflux
is less apparent. The appearance of drug in the apical compartment is governed
by diffusion across both basolateral and apical membrane with contribution from
paracellular diffusion. At much higher PSA,E to PSD ratios ((PSA,E / PSD > 20.),
flux approaches the boundary (i.e., diffusion across the basolateral membrane
and paracellular pathway become rate limiting). Figure 2 Panel B further
illustrates this phenomena by plotting the measured flux as a function of PSA,E
normalized to PSD. Kalvass and Pollack (Kalvass and Pollack, 2007) presented
a similar figure (Figure 6-2 in their reference) however, their model assumed
paracellular to be nonexistent (PSPC=0). For drugs which have poor diffusion
permeability (PSD<10*PSPC) it is clear that paracellular flux cannot be ignored. If
the observed permeability surface area product (PSobs) is normalized for the
dynamic range (influenced by PSPC) then all of the curves in Figure 6-2 Panel B
collapse into a one B→A and one A→B flux graph can be seen as in Figure 6-2
Panel C. The inflection point in PSObs (50% in A to B and 150% for B to A)
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occurs when PSAE / PSD = 2.

When this ratio is much less than 2, both

basolateral and apical membranes contribute to controlling the appearance of
drug in the receiver side. When the ratio is much greater than 2, passage
across the apical membrane ceases to be a barrier for B→A flux and drug
appearance in the donor side is controlled by diffusion across the basolateral
membrane and diffusion via paracellular route. For A→B flux (PSA,E / PSD >> 2)
the drug appearance in the receiver side is limited to drug arriving via
paracellular passage. Hence, the region near the inflection point is the most
sensitive to changes in PSAE and has important implications when considering
clonal selection, saturation and inhibition of the transporter (changes in apparent
PSAE) and these concepts will be utilized later on in the paper. Normalization
(Figure 6-2 Panel C) provides a more universal application (a single graphical
representation); however, it may also be somewhat misleading. Data
transformation as advocated by a number of groups (Kalvass and Pollack, 2007;
Giacomini et al., 2010; Lumen et al., 2010), including efflux ratios (ERA, ER ) or
the ratios of ratios (ER

inhibitor /

ER

inhibitor)),

can distort the experimental error

and may result in a loss of critical insight between the experimental observation
and its determinants, e.g., role of PSPC in parameter estimation (see below).
While PS has its limitations (Kalvass and Pollack, 2007), PS, like systemic
clearance, can be more readily related to underlying principles (i.e., rate limiting
steps).
ERA
Frequently the rate of flux in B→A direction in the transfected cell line is
compared to the parent cell line to quantitate the contribution of an apically
expressed transporter. This ratio is termed ERA and is estimated by
6-21
Substituting Equation 6-16 and 6-19 and assuming
yields
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, Equation 21

6-22
Equation 6-22 would imply that this ratio is independent of the very parameter of
interest, namely PSA,E.
Moreover, as PSPC approaches 0 (or is low relative to PSD), ERA approaches a
limit
6-23
This limitation was pointed out in the work by Kalvass and Pollack (Kalvass and
Pollack, 2007). Table 6-2 illustrates this point with ERA for both murine (Abcg2)
and human (ABCG2) derived from the literature. ERA approaches the limitation
of 2 for most drugs, especially for the Abcg2 clones and supports the earlier
assumption that for many of these substrates

largely due to the

high transporter expression level for these clones. Hence, ERA is not a
discriminating parameter since it has limited dynamic range and the numerical
value is independent of ABCG2 flux (PSA,E). Rather ERA reflects the fact that
flux across the system has changed from one controlled by diffusion across two
barriers arranged in series (PSD/2) to diffusion across one barrier (PSD), the
basolateral membrane.
ER
In contrast to ERA, a more robust parameter is the ratio of the rate of flux in one
direction (B→A) over the opposite flux (A→B) in the transfected cell line (Kalvass
and Pollack, 2007). This ratio is termed the asymmetrical ER (ER ) and is
estimated by
6-24
Equation 6-24 can be rewritten using Equations 16 and 18 and experimentally
setting
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6-25

Moreover, as PSPC approaches 0 (or is low relative to PSD), ER approaches a
limit
6-26
It would appear that ER can be more readily related to PSA,E (Equation 27) and
this relationship has been explored in the work of Kalvass and Pollack (Kalvass
and Pollack, 2007).
6-27
The magnitude of ER estimates obtained in mouse and human ABCG2
expressing cells is much greater; hence, it appears to be more discriminating
compared to ERA (Table 6-2). The ER for the empty or parent cell is close to
unity (+/-20%) for most substrates suggesting that endogenous transporters in
MDCKII cells are playing a minor role in the flux of these molecules. Exceptions
to this assumption would include cimetidine, estradiol, nitrofurantoin, riboflavin
and topotecan; indicating a likely interaction with endogenous MDCKII
transporters.
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Table 6-2 Comparison of the ERA and ERα of several Abcg2/ABCG2 substrates in
murine and human Abcg2/ABCG2-transfected MDCKII cell lines in the literature. Apical
efflux ratios (ERA), asymmetry efflux ratios (ERα), and the ratio of the asymmetry ratios in
Abcg2/ABCG2-transfected vs. empty vector-transfected cells (ERα Ratio) in mouse
(mAbcg2) or human (ABCG2) transfected MDCKII cells were calculated using flux data
compiled from the literature. Drugs where the mean of ERα Empty was not within 20% of
unity were identified (shaded rows).

Empty

mAbcg2

ABCG2

Substrate

Reference
ERα

ERA

ERα

ERA

ERα

Aflatoxin

1.12

1.58

9.32

1.15

1.91

(van Herwaarden et al.,
2006)

Albendazole

1.14

1.70

18.3

1.36

2.11

(Merino et al., 2005a)

Cimetidine

1.26

3.01

7.14

2.44

3.11

(Pavek et al., 2005)

Ciprofloxacin

0.88

2.52

4.37

1.18

2.13

(Merino et al., 2006a)

Estradiol

0.68

-

-

0.83

0.66

(Pavek et al., 2005)

Imatinib

1.03

2.39

35.3

-

-

(Breedveld et al., 2005)

IQ

1.09

1.84

16.7

1.30

2.47

(van Herwaarden et al.,
2006)

Nitrofurantoin

0.64

2.63

8.70

2.66

3.21

(Merino et al., 2005b)

Norfloxacin

0.91

2.92

3.26

1.29

1.32

(Merino et al., 2006a)

Ofloxacin

0.90

2.22

6.17

1.29

1.56

(Merino et al., 2006a)

Oxfendazole

1.14

2.35

5.70

0.87

1.17

(Merino et al., 2005a)

Pantoprazole

1.00

1.34

5.05

-

-

(Breedveld et al., 2004)

PhIP

1.20

1.27

16.43

1.89

12.7

Riboflavin

0.13

2.33

1.65

-

-

Topotecan

2.23

3.13

14.85

1.46

5.79

Trp-P-1

1.09

2.89

4.25

1.64

1.39

(van Herwaarden et al.,
2003; Pavek et al., 2005)
(van Herwaarden et al.,
2007)
(Breedveld et al., 2004;
Pavek et al., 2005)
(van Herwaarden et al.,
2006)

While valuable, there are limitations to the use of ER . In order to use ER as
depicted in Equation 6-26, PSPC was assumed to be negligible. In our lab (as in
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others), PSPC in MDCKII cells is relatively low, but not zero (1-2% of the amount
initially in the donor per hour). PSPC contributes significantly to passage of drugs
with lower lipophilicity, the very drugs for which transporters would appear to be
most critical. As indicated by the ratio of Equations 6-18 and 6-20, at the limit
(i.e., assuming that PSA,E>>PSD when clones are overexpressing the
transporter), ER , much like ERA, reflects the ratio of fluxes that are independent
of the transporter protein (Equation 6-28).

6-28
Hence, evaluating the vectorial transport of high affinity substrates in
overexpressing clones may generate ER values that do not correlate with PSAE.
The influence of PSPC on ER is demonstrated in Figure 6-3 Panel A. When
PSPC is zero there is a linear relationship between the ER and PSA,E regardless
of the PSD value.

However, in the presence of a typical PSPC there is a

deviation from linearity such that ER is no longer proportional to PSA,E. The
deviation becomes more problematic as PSD decreases since the paracellular
pathway contributes more to the overall flux in either direction. At high ratios of
PSAE / PSD ER reaches the experimental boundary defined by Equation 6-28.
The impact of PSPC on the estimation of PSAE (Equation 6-27) is illustrated in
Figure 6-3, Panel B. As PSPC approaches zero then PSA,E is accurately
estimated. However, in the presence of a typical PSPC, estimates of PSA,E
diverge from their true values, and substrates with the lower PSD are most
affected.
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Figure 6-3 Panel A Asymmetrical flux ratio (ERα) as a function of increasing PSA,E relative to PSD (10, 25, 50 and 250 uL/hr*cm2)
when PSPC is 1.5 uL/hr*cm2. Dashed line represents the case for all values of PSD when PSPC is 0. Panel B Estimated apical efflux
permeability (PSA,E ; Equation 27 ) relative to the true value of PSA,E as a function of increasing PSA,E relative to PSD (10, 25, 50 and
250 uL/hr*cm2) when PSPC is 1.5 uL/hr*cm2. Dashed line represents the case for all values of PSD when PSPC is 0.

Saturable PSA,E
A number of investigators have characterized the influence of increasing donor
concentration on the basolateral to apical flux of drug across a cell monolayer
when characterizing an apical efflux transporter (Breedveld et al., 2004; Kitamura
et al., 2008). The interpretation of such analysis has several limitations.
If PSA,E is assumed to be a saturable process (Equation 6-17), then Equation 16
can be rewritten to describe the flux of drug from basolateral to the apical side

6-29

As similar fashion, flux from apical to the basolateral side, Equation 6-19, can be
written as

6-30
In order to assess an accurate KM the concentrations to be characterized are
cellular and not donor concentration (basolateral or apical compartment). These
concentrations are not equivalent; nor is the relationship between them fixed for
a saturable efflux system. Earlier in considering the initial flux rates, it was
assumed that the cellular concentration comes to rapid equilibrium and can be
defined by the model parameters as in Equation 6-10 for (B→A flux) and
Equation 6-14 (A→B flux); hence, it is possible to simulate CC for the initial rate
calculation. For a single transfected apical efflux transporter model examining
B→A flux (as well as A→B flux), the relationship for CC approximates the
following.

6-31
A more complex relationship arises when considering saturation of the efflux
transporter as in Equation 6-32
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6-32
that can be rearranged to yield an expression which equates donor concentration
(CB) to a given cellular concentration
6-33
Hence, simulations using cellular concentrations can be performed and donor
concentrations derived from Equation 6-33. A much greater challenge is to
assess cellular concentrations in an experimental setting; nonetheless
simulations provide useful insights that guide experimental design and
interpretation of the results.
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Figure 6-4: Panel A Internal cellular concentration (CC) as a function of external donor concentration (CD) for a drug modeled in
which PSD is fixed at 250 uL/hr*cm2, TMax is fixed at 5,000 pmol/hr/cm2and KM varies from 0.05 M to 5 M (hence, PSAE varies from
100,000 to 1,000 uL/hr*cm2, respectively). Dotted line represents line of unity. Panel B Concentration relationship between apparent
PSobs and cellular (CC, open symbols) or donor (closed symbols) concentration for a drug with PSD of 250 uL/hr*cm2, PSPC of 1.5
uL/hr*cm2,TMax of 5,000 pmol/hr/cm2 and KM of 0.5 M. The simulation was performed using CC and equations 29 and 30.
Subsequently corresponding donor concentrations were solved for using the influence of saturating the apical efflux transporter
(Equation 33).

Figure 6-4 Panel A illustrates the predicted relationship between cellular (CC)
and basolateral donor concentration (CD) for a model system containing an apical
efflux transporter. At low donor concentrations, the intercellular concentration is
considerably lower for larger PSA,E (i.e., when KM is smaller) since drug is
pumped out of the cell more effectively. At higher donor concentrations, the
transporter becomes saturated and the cellular concentration approaches a limit
of half the donor concentration (i.e., same concentration achieved in parent cell
line). While intuitively obvious, the full impact of this observation is realized when
examining the Panel B in Figure 6-4 which illustrates the relationship between
observed flux and cellular or donor concentration. The nonlinear function relating
cellular and donor concentration causes the relationship between flux and donor
concentration (squares Panel B Figure 6-4) to be steeper than a simple
saturation model. Without an appreciation for the need to model cellular
concentration, a saturable model with a positive Hill coefficient (estimated near
2.5) would need to be invoked in order to describe the relationship between flux
and donor concentration. If the cellular concentrations could be used, a simple
saturation model is sufficient to characterize the model (circles Figure 6-4 Panel
B).
Another limitation of this type of data is the interpretation of the inflection point on
the plot of apparent PS and concentration (donor or cellular). As described
earlier (Figure 6-2, Panel B) the 50% (A→B flux) and the 150% (B→A flux)
value of the PSObs occurs when the value of PSA,E approaches twice that of PSD.
Typically this inflection point (CC,inf pt) has been interpreted as being
representative of KM; however, this is inaccurate for flux across a monolayer.
The concentration corresponding to this inflection point, CC,inf pt can be defined as

6-34

which can be rearranged to yield
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Figure 6-5 Apparent permeability-surface area clearance (PSobs) A→B directional flux
(Panel A and C) and ER (Panel B and D) as a function of substrate concentration
(cellular: open symbols; donor: closed symbols). PSPC is 1.5 uL/hr*cm2 and PSD is 50
uL/hr*cm2 . Panel A and B Substrates vary in KM with both substrates having a TMax of
2.500 pmol/hr/cm2. Substrate 1 (circles) has a KM of 0.2 M and Substrate 2 (squares)
has a KM of 2.0 M. Panel C and D Substrates vary in TMax with both substrates having
a KM of 0.2 M. Substrate 1 (circles) possessing TMax of 2.500 pmol/hr/cm2, and
Substrate 3 (squares) has a TMax of 10,000 pmol/hr/cm2.

As evident from Equation 6-17, PSAE (at low CC) is the ratio of TMax to KM.
6-36
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Hence, the greater the ratio of apical active efflux to diffusion permeability
(PSA,E/PSD>>2) the greater CC,infpt will deviate from KM. The mechanistic
understanding of this deviation can be illustrated for the apical efflux transporter
scenario depicted in Table 6-1. For high affinity transporter substrates tested in
high expression cell monolayers, flux across the apical membrane at 1/2 PSA,E
(when CC = KM) results in apical flux which is many fold greater than PSD.
However, flux across the apical surface will not be rate limiting under those
conditions. PSA,E will only begin to approach 2PSD when the CC is much greater
than KM as defined by Equation 6-36. Figure 6-5 Panel A illustrates the change
in A→B flux as a function of cellular and donor substrate concentration. [To
simplify presentation, only A→B flux is depicted; however, B→A flux is a mirror
image of A→B flux relative to the location of the inflection point]. The inflection
point of PSObs (A→B or B→A) as a function of CC does not correspond to KM
(Figure 6-5 Panel A). The cellular CC, infpt values were virtually identical at close
to 25 M for the two substrates despite the tenfold difference in K M (0.2 and 2.0
M, respectively). As predicted by Equation 6-36, the inflection point for PSObs
occurs at a cellular concentration which is much larger than the KM (125-fold for
Substrate 1 and 12.5-fold for Substrate 2). Moreover, the corresponding donor
concentrations (plotted in most flux experiments) were close to 100 M for both
substrates and the steepness of the relationship is again evident. Kalvass and
Pollack (Kalvass and Pollack, 2007) advocate using ER rather than PSObs to
estimate kinetic parameters. As can be seen in Figure 6-5 Panel B the
inflection point is closer to KM when plotting ER as a function of concentration;
however, it is not equivalent to KM even if the cellular concentrations were known
(open symbols). The overall flux rate (or ratio of fluxes, ER ) is dominated by
the slow step, i.e., diffusion across the basolateral membrane. For the two
examples depicted in Figure 6-5 (Panel A and B) flux across the apical
membrane at CC=KM is 10 to 100 greater than flux across the basolateral
membrane. This influence of PSA,E/2PSD on inflection point for apparent PS can
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also be seen in Figure 6-5 Panel C, in which KM is common, but TMax differs for
the substrates. The cellular CC,infpt values were different at 25 and 95 M for the
two substrates despite having identical KM values (0.2 M). Equation 36
predicts an inflection point which would be 125-fold greater than KM for Substrate
1 and 500-fold for Substrate 4 under the specified conditions. Again, the
inflection point is closer to KM when plotting ER as a function of concentration
(Figure 6-5 Panel D) but far from identical. Again, the saturation of the apical
efflux transporter becomes evident only when its flux rate slows considerably and
approaches the diffusion permeability of the drug. Interpretation of monolayer
flux data must be done with considerable appreciation for the limitations of the
system and an understanding of those factors controlling flux.
Parameter Estimation for Saturable PSA,E
Given the complexity of the donor to cellular concentration relationship (Figure 64, Panel A) and the fact that PSObs is a hybrid parameter, estimation of kinetic
parameters from Transwell flux data is problematic, but not intractable. Table 63 outlines an approach that can provide estimates of TMax and KM using
Transwell flux data. Several key assumptions underpin the analysis such as (1)
paracellular flux of the drug can be modeled using the flux of a marker substrate
(e.g., mannitol or sucrose), (2) no endogenous transport processes, (3) no
cellular metabolism and (4) cellular concentration can be modeled as described.
Our laboratory has investigated the interaction of pantoprazole isomers with
ABCG2 in a transfected MDCKII cell model using this approach (Wang and
McNamara, 2010). Pantoprazole isomers exhibited many of the properties
illustrated in the current analysis; i.e., boundaries illustrated in Figure 6-4 Panel
B at low and high pantoprazole donor concentrations, inflection point related to
TMax not KM, kinetic analysis with donor concentrations suggesting positive
cooperativity. Using the approach outlined in Table 6-3, reasonable parameter
estimates were obtained (Wang and McNamara, 2010).
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Table 6-3 Iterative approach for the estimation of TMax and KM using transcellular flux data.
Substrate/Cell

Eq

Rearranged to

Comments

Paracellular
Permeability

Mannitol (or
sucrose) / Parent
cell line

6-8

1. Solve for PSPC using mannitol data.
2. Assume that paracellular flux is similar
for drug and marker (mannitol or
sucrose).

Diffusion
Permeability

Drug / Parent cell
line

6-8

Transcellular
Permeability

Drug / Transfected
cell line

3. Confirm drug is not a substrate for
endogenous transporter, ER is unity
for parent cell line.
4. Solve for PSD using drug data and PSPC
from mannitol data.
5. Solve for transcellular permeability
PSTC,B→A.
6. Similar case for A to B flux

Apparent
Apical Efflux
Permeability

Drug / Transfected
cell line

6-16

Apparent
Apical Efflux
Permeability

Drug / Transfected
cell line

6-19

7. Approximate apparent apical efflux
for B to A direction using
, PSD and PSPC).
8. Approximation is more accurate near
the inflection point; error is significant
near the boundaries (contribution of
PSAE is masked).
9. Approximate apparent apical efflux
for A to B direction using
, PSD and PSPC)

Initial Cellular
Concentration

Drug / Transfected
cell line

6-31

10. Approximate initial cellular concentration
(CC) using CD, PSD and
.

Kinetic
Parameters

Drug / Transfected
cell line

6-17

11. Nonlinear regression analysis of PSAE,
apparent as a function of CC to fit the
parameters (TMax and KM).
12. Steps 4-9 may be repeated to refine
estimates of CC and PSAE, apparent
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Parameter

Inhibition of PSA,E
As mentioned earlier, there is considerable interest in assessing drug-drug
interactions involving transporters. Inhibition of transcellular flux has been
advocated as a viable approach for screening, however, there is considerable
concern regarding the ability to compare results obtained using different model
substrates or different cell lines or clones (Giacomini et al., 2010). At low cellular
concentrations of substrate (CC<<KM), the influence of a competitive or noncompetitive inhibitor on permeability-surface area product associated with the
active transport component can be written as:

6-37
where IC is the cellular concentration of the inhibitor and KI is the MichaelisMenten constant (inversely related to affinity) for the transporter inhibitor
complex.
As discussed by Kalvass and Pollack (Kalvass and Pollack, 2007) the use of
B→A flux data or ERA alone can be misleading, resulting in inaccurate estimates
of inhibition constants (KI). Figure 6-6 Panel A illustrates the influence of
increasing inhibitor concentration on the apparent permeability-surface area
A→B flux for a substrate. If the inhibitor is also a substrate for the transporter
then the nonlinear nature of the relationship between cellular and donor
concentration of the inhibitor needs to be considered (Equation 6-33, Figure 6-4
Panel A). As cellular inhibitor concentration increases, the efflux pump
becomes inhibited and the substrate flux returns to that of the parent cell line.
The difference between the two inhibitors (KI values of 0.1 and 0.5 M) is evident
in Figure 6-6 Panel A; however, it should be noted that the inflection point for
these cellular concentration inhibition curves (0.9 and 4.5 M, respectively) do
not correspond to the KI values.
Again as described earlier (Figure 6-2, Panel B) the 50% (A→B flux) and the
150% (B→A flux) value of the PSObs occurs when apparent PSAE approaches a
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value which is twice that of PSD. A drug could be defined as an effective inhibitor
if it causes the flux of a known substrate to decrease to half of its maximum for
B→A (150%) transport or minimum for A→B (50%). The cellular inhibitor
concentration corresponding to this inflection point,CC,inf pt can be defined as

6-38

Rearranging this equation to yield a relationship which defines the concentration
of inhibitor required to cause a 50% decrease in the apparent flux in a
transmembrane system relative to the actual KI and the substrate’s active apical
efflux (PSA,E) and passive diffusion (PSD) characteristics.
6-39
Equation 6-38 would imply that the concentration of inhibitor needed to cause a
substantial change in flux is dependent on the characteristics of the substrate
(PSA,E and PSD) in addition to properties of the inhibitor (KI). Use of ER does
not provide an accurate estimation of KI (Figure 6-6 Panel B) for either donor or
cellular concentration. Again, the influence of an inhibited PS A,E is not evident
until it’s numerical value approaches twice that of PSD.
Figure 6-6 Panel C expands on this issue in that a better efflux substrate (higher
PSAE) is more difficult to inhibit causing a shift to the right of the inhibition profile
(IC,infpt increases from 0.9 to 9.9 M for the tenfold higher PSA,E). In a similar
fashion (Equation 6-39), inhibition of a substrate with a higher diffusion
permeability (PSD) occurs at lower inhibitor concentration (IC,infpt decreases as
substrate PSD increases). Again ER plotted as a function of inhibitor
concentration (donor or cellular) reveals inflection points which are influenced by
PSA,E of the substrate (Figure 6-6 Panel D).
The influence of the BCRP inhibitors FTC and GF120918 on the B→A flux for
nitrofurantoin, cimetidine and PhIP in BCRP-MDCKII cells were examined in our
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laboratory (Philip Empey Thesis, Figure 6-7). At a concentration of 10 M, FTC
was shown to be effective at inhibiting flux of all three substrates; however,
GF120918 (1 M) was effective in inhibiting nitrofurantoin and cimetidine, but did
not inhibit PhIP B→A flux. One interpretation of such data might be that there
are multiple binding sites for BCRP. Giri et al (Giri et al., 2008) suggested that
similar inhibition profiles supported evidence for the involvement of multiple
binding regions for BCRP. In the context of the current model analysis
(Equation 6-38), another interpretation could also be put forth. For the same
inhibitor (same KI), a much higher concentration will be required to see a change
in overall flux rate when substrates have a higher PSA,E to PSD ratio. The
concentration needed to cause the apparent PSObs to decrease by 50% (between
the transfected with no drug and the parent cell flux), is greater than K I. The
greater the PSD at the basolateral surface the less transport at the apical surface
has to change in order for overall PSObs to be altered. Subsequent experiments
in our lab (Philip Empey Thesis, data not shown) revealed that higher
concentrations of GF120918 (10 M) decreased the B→A flux of PhiP. Hence,
this inconsistency in altering flux of different substrates with a common inhibitor
may not be a result of multiple binding sites, but rather a consequence of data
interpretation in light of the complexity of the model system.
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Figure 6-6 Apparent permeability-surface area clearance (PSobs) A→B directional flux (Panel A and C) and ER (Panel B and D) for
a substrate (PSA,E = 500 uL/hr*cm2 and PSD of 25 uL/hr*cm2 at low substrate concentration) as a function of inhibitor concentration
(cellular: open symbols; donor: closed symbols) with a PSPC of 1.5 uL/hr*cm2. Panel A and B Inhibitors vary in KI with both inhibitors
have a PSD, and TMax of 25 uL/hr*cm2 and 500 pmol/hr/cm2 respectively. Inhibitor 1 (circles) and Inhibitor 2 (squares) have KI values
of 0.1 and 0.5 M, respectively. Panel C and D Same inhibitor but substrates vary in PSA,E; both substrates having PSD of 25
uL/hr*cm2. Substrate 1 (squares) has a PSA,E of 500 uL/hr*cm2 and Substrate 2 (circles) has a PSA,E of 5,000 uL/hr*cm2. Inhibitor
has PSD, TMax and KI values of 25 uL/hr*cm2, 500 pmol/hr/cm2 and 0.1 M, respectively.

B

C
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Figure 6-7 Apparent permeability-surface area clearance (PSobs) B→A directional flux for (Panel A) Nitrofurantoin at 10 M, (Panel
B) Cimetidine at 5 M and (Panel C) PhiP at 2 M in MDCKII cells transfected with human ABCG2 in the absence or presence of 1
M GF120918 or 10 M FTC.

Discussion
Interactions between transporters and drug substrates are of great interest in
drug development and in-vitro cell models are constructed to study the
importance of a given transporter protein on the vectorial transfer of drug from
one side of a polarized epithelial cell barrier to the other. An example includes
the use of MDCKII cells into which a transporter gene has been cloned and the
protein is usually expressed at high levels. While the experimental paradigm is
widely utilized, the limitations and interpretations of the results of such studies
are not broadly understood (Bentz et al., 2005; Balakrishnan et al., 2007; Kalvass
and Pollack, 2007; Korjamo et al., 2007; Lumen et al., 2010). An appreciation of
the underlying conceptual framework and assumptions that provide insights into
the mechanisms of drug uptake and efflux when using such in-vitro models is
needed in order to make broader inferences regarding drug absorption,
disposition and for predicting the potential for drug-drug interactions. The goal
of the present analysis was to provide the framework for systematically
examining data from such models. An appreciation of controlling (rate limiting
steps) or boundary conditions provides insights as to the interpretation of
resulting observations.
The work of Kalvass and Pollack (Kalvass and Pollack, 2007) represented an
important conceptual step forward illustrating some of the complexities with
modeling and interpreting vectorial transport data. They clearly demonstrated
the limitations of ERA, recognizing that transporter overexpression on one
surface (e.g., apical) results in diffusion across the opposite surface (i.e.,
basolateral) being the rate limiting transport process across the monolayer.
Hence when studying the role of an apical transporter in B→A flux, in comparison
to the untransfected parent cell line, the ERA metric is an unreliable index for the
magnitude of the transporter’s contribution to the overall flux because this rate
limiting situation yields asymptotic values for a range of affinities. Table 6-2
provides further experimental evidence supporting the concern that ER A is not a
discriminating parameter. ER or the asymmetrical flux, on the other hand, was
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thought to be more robust and would more readily correlate with the extent of
transporter drug interaction. Again, the current analysis (Table 6-2) supports that
ER is a more robust parameter. However, the discriminating power of this
parameter relies on the assumption that the paracellular transport pathway
contributes negligibly to the overall flux across the membrane, which can be
invalid for many experimental paradigms (e.g., MDCKII cell models) and can
confound parameter estimation and the values of ER . The degree to which
paracellular flux influences ER or PSA,E appears to be greatest for those
substrates with lower passive diffusion, i.e., substrates for which a transporter
would seem most critical for membrane flux.
The current analysis suggests that kinetic parameters (e.g., KM) derived from
vectorial flux data must be interpreted with caution. Kitamura et al (Kitamura et
al., 2008) examined the role of multiple transporters in the hepatobiliary transport
of rosuvastatin. The KM values for rosuvastatin uptake into HEK293 cells for
OATP1B1 (0.80 M) was considerably different from those attributed to
OATP1B1 obtained using a double transfected (OATP1B1/MRP2) MDCKII model
(29.9 M), and the authors concluded that the transcellular transport of
rosuvastatin might not be determined solely by the uptake clearance. Breedveld
et al (Breedveld et al., 2004) estimated a K1/2 for the B→A flux of pantoprazole in
an MDCKII-mBcrp model system of 0.1-1.2mM. Experimental work in our
laboratory (Wang and McNamara, 2010) would suggest a much higher affinity
(lower KM) for mBcrp and pantoprazole than might be inferred from the K 1/2 value.
The active site for an efflux transporter is likely to be intracellular, although the
active site for p-GP may be imbedded in the inner membrane itself. Hence, the
driving force for efflux transporters is the concentration in a compartment other
than the donor. The present examination illustrated that the nonlinear
relationship between cellular and donor concentration gives rise to an apparent
positive cooperatively relationship when examining flux as a function of donor
substrate (or inhibitor) concentration. Several groups have reported positive
cooperatively in transcellular flux for p-GP (Keogh and Kunta, 2006b) and BCRP
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(Pan et al., 2007). Clearly an alternative explanation is the differential between
the internal and external concentration gradients. It is likely this phenomenon of
positive cooperatively is also observed for cellular uptake studies.
Giri, et al (Giri et al., 2008) has examined the inhibition of substrate (prozosin,
zidovudine, abacavir and imatinib) flux in BCRP overexpressing MDCKII cells by
a number of inhibitors. At a fixed concentration, Ko143 inhibited the flux of all of
the substrates whereas GF120918, nelfinavir and Pluronic P85 exhibited
differential inhibition depending on the substrate. The authors suggested that
these observations supported evidence for the involvement of multiple binding
regions for BCRP (Giri et al., 2008). Another interpretation of the data might be
related to the relative magnitude of active transport and passive diffusion flux for
the substrates relative to the KI for the inhibitors. Again, parameters arising from
flux experiments needs to be interpreted with caution.
The concepts presented in this paper provide a framework for interpreting
data arising from flux across a cell monolayer. Without the appropriate context,
quantitative and qualitative (mechanistic) errors arise that ultimately can
misinform our understanding of transporter function and their influence on
pharmacokinetics and pharmacodynamics (Zhang et al., 2008; Zhang et al.,
2009).
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CHAPTER 7: Summary and conclusion
Drug accumulation in milk is a rising concern for the strategy of
breastfeeding. Understanding the mechanism of active drug transport into milk is
a key step to provide guidance for drug use in lactation. ABCG2 is highly
expressed in mammary gland during lactation in mouse, cow and human studies
and is responsible for the active transport of some xenobiotics into milk.
In this dissertation, we confirmed that Abcg2, but not P-gp, is highly
expressed in rat lactating mammary gland by western blot and
immunohistochemistry. Abcg2 was upregulated during lactation compared with
non-lactation as shown by Real-time PCR. A rAbcg2-MDCKII cell line has been
characterized as functional one by Flow Cytometry and the transport of
nitrofurantoin. Utilizing GF120918 as an effective inhibitor of rAbcg2, a “chemical
knockout” rat model has been established for milk active transport study. The
M/S for nitrofurantoin was decreased dramatically in this viable alternative to the
genetic knockout mouse model.
Half of all drugs are marketed as chiral substances. While there are some
studies of stereoselective interaction with P-gp transport or chiral metabolism,
there is no report demonstrating stereoselective interaction between drugs and
ABCG2. From our investigation, pantoprazole is a prototypical substrate of
human ABCG2 as well as of rat Abcg2. There is stereoselective interaction
between Abcg2/ABCG2 and pantoprazole as demonstrated in both in vitro and in
vivo experiments. ABCG2 recognizes pantoprazole enantiomers differently which
resulted in significant differences in M/S ratios for the two isomers in the rat
study. M/S ratios of pantoprazole isomers in rat mediated by passive diffusion
were determined and predicted by a passive diffusion model. Since chirality does
not alter basic physical and chemical properties, no difference was observed
between predicted M/S ratios of pantoprazole isomers. The ratios of
(M/SObserved)/ (M/SPredicted) of plus and minus pantoprazole were 4.43 and 11.95,
respectively, which supported a role for a transporter in the high M/S ratios of
pantoprazole isomers. GF120918 decreased M/S ratios of both isomers but had
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a more significant effect on the minus isomer of pantoprazole. Both pantoprazole
isomers form an identical active metabolite that does not have a chiral center, so
the stereoselective interaction between pantoprazole and ABCG2 is unlikely to
result in any significant clinical consequences. However, this stereoselective
recognition may have consequences for other chiral drugs. The M/S ratio of
either isomer of pantoprazole in rat was much higher (25 time or 68 times) than
one human case report (M/S=0.02). The reason for this species difference has
not been resolved.
Five concentrations of pantoprazole isomers were transport by either rat
Abcg2 or human ABCG2. Having identical chemical properties (diffusion
controlled) as well as no interaction with endogenous transporters of the MDCKII
cell line, the pantoprazole isomers provided an ideal platform to compare the
kinetic parameters derived from Transwell experiments, e.g., PSD, PSAE, PSPC,
Km and Vmax. The results demonstrated a consistent trend for pantoprazole
transport across these two species. Km and Vmax of pantoprazole enantiomers in
rat Abcg2 or human ABCG2 were estimated from fitting data with very modest
differences between species.
Cell monolayer flux across Transwell or Snapwell is a broadly used method
for studying drug transporter or for screening new molecule entity in drug
development. Three compartment models instead of a single barrier model have
been established by different groups in order to explain the complex
observations. Transport of pantoprazole isomers in Abcg2/ABCG2
overexpressing MDCKII cell line provided solid evidence for a mathematic model
of the monolayer system. Paracellular transport of a hydrophilic compound may
not be assumed negligible compared with transcellular transport. Cellular
concentration and not donor concentration is the direct driving force of
transcellular transport for an apical efflux transporter like ABCG2. The model
confirmed the importance of assessing the data from the context of rate limiting
barriers in series or in parallel. For good substrates in highly expressing cell
clones passive diffusion on the basolateral side is the limiting step in efflux
transporter on the apical side in a monolayer system, so that the ERA does not
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reflect PSAE. ERα is a more robust parameter than ERA but the expression level
of efflux transporter and cellular concentration can still affect the value of ERα.
Due consideration should be taken when setting up criteria in drug screening
based on the value of ERα. The estimation of Km, Ki or IC50 from monolayer
system is not directly related to a property or function of a transporter, but is
related to the transition from one rate limiting step (flux across the basolateral
membrane) to multiple barriers (flux across both basolateral and apical
membranes).
In conclusion, transporters are broadly expressed in barriers (i.e., blood brain
barrier, intestine epithelial barrier, renal epithelial barrier, mammary gland
epithelial barrier and so on), playing an important biological role for the regulation
of endogenous and exogenous substrate concentrations across cells, tissues
and systems. A mechanistic three compartment monolayer model with
appropriate expression of transporters is critical to our understanding of these in
vivo biological barriers. Specific transporter expressing cell lines grown in
monolayer systems can provide invaluable insights into their function provided
that an appropriate expression level of transporter can be correlated with function
and flux assessment can be put into the context of limitations of the model
system.

142

APPENDICES
Appendix A: List of Abbreviations
A

Membrane surface area

ABC

ATP-binding cassette transporter superfamily

ACV

Acyclovir

ADME

Absorption, Distribution, Metabolism and Excretion

AUC

Area under the concentration-time curve

BCRP

Breast cancer resistance protein

CA

Concentration in the apical (milk) compartment

CB

Concentration in the basolateral (serum) compartment)

CC

Concentration in the cellular (LMEC) compartment

Cmilk, unbound

Unbound concentration in the milk

Cserum, unbound

Unbound concentration in the serum

CDC

The Centers of Disease Control and Prevention

CM

Cimetidine

CP

Ciprofloxicin

DMSO

Dimethyl sulfoxide

ERα

Asymmetry efflux ratio; ratio of the initial rate of B→A flux
divided by the initial rate of A→B flux

FACS

Fluorescence-activated cell sorting

fm

Fraction protein bound in the milk

fs

Fraction protein bound in the serum

GF120918

N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
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NF

Nitrofurantoin

PAN

Pantoprazole

Papp,
(μL/hr)/cm2

The apparent permeability

PDR

The Physician’s Desk Reference

PSAE

Permeability-surface area products of apical efflux

PSD

Permeability-surface area products of passive diffusion

PSPC
MRP

Permeability-surface area products of paracellular flux
between cells
Multiple resistance protein

M/S

Drug concentration in milk to drug concentration in serum

MXR

Mitoxantrone resistance-associated protein

MTX

Methotrexate

NIS

The National Immunization Survey

RER

Rough endoplasmic reticulum

RLMS

Ross Laboratory Mother Survey

RN

Ranitidine

SA

Salicylic acid

TEB

Terminal end buds

XA

The mass of drug in the apical compartment

XB,

The mass of drug in the basolateral compartment

XC

The mass of drug in the cellular compartment
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Appendix B: Glossary
ATP

ATP is a molecule which consists of the nitrogenous base
adenine linked to the sugar ribose and which has a chain of
three phosphate groups attached to the ribose in a linear
fashion. ATP is present in all living cells and serves as an
energy source for many metabolic processes; energy is
released when ATP is hydrolyzed into ADP. It is the single
most important molecule in all living things since it serves as
the currency for energy in biological systems.

ATPase

Enzyme that catalyzes a process involving the hydrolysis of
ATP. A large number of different proteins, including ABC
transporters, have ATPase activity.

Baculovirus
vectors

They are used for expression of foreign genes in insects.

Caco-2

The Caco-2 cell line is an immortalized line of heterogenous
human epithelial colorectal adenocarcinoma cells.
Monolayers of Caco-2 cells are widely used to predict the
absorption of compounds. This tool is also suitable to study
active transport processes.

cDNA

Single-stranded complementary DNA synthesized from an
RNA template by the action of RNA-dependent DNA
polymerase. cDNA (i.e., complementary DNA) is used in a
variety of molecular cloning experiments as well as serving
as a specific hybridization probe.

Cloning,
Molecular

The insertion of recombinant DNA molecules from
prokaryotic and/or eukaryotic sources into a replicating
vehicle, such as a plasmid or virus vector, and the
introduction of the resultant hybrid molecules into recipient
cells without altering the viability of those cells.

DMPK

Drug metabolism and pharmacokinetics

Drug interactions

The action of a drug (termed perpetrator) that may affect the
activity, metabolism, or toxicity of another drug (termed
victim).
Any substance which when absorbed into a living organism
may modify one or more of its functions. The term is
generally accepted for a substance taken for a therapeutic
purpose, but is also commonly used for abused substances.
Synonymous with medicine, pharmaceutical.

Drug
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Efflux transporter
Endogenous

Proteins, located in the cell membrane, which transport
molecules out of the cell.
Produced inside an organism or cell.

Endothelial cell of Monomolecular cell layer separating the blood and brain
the brain
tissue. Play a major role in blocking xenobiotic and some
capillaries
endogenous substances from entering the brain.
Epithelial cells

Cells that line the inner and outer surfaces of the body.

Flow-cytometry

An instrument that allows one to gather information from
single cells by light scattering or fluorescence properties.
These provide information on the size and internal complexity
(forward scatter and side scatter, respectively) as well as
"markers", identified by staining with fluorescent probes such
as conjugated antibodies in the case of immunophenotyping,
or nucleic acid dyes in the case of reticulocyte enumeration
and DNA content analysis.

In vitro

A biological or biochemical process carried out in a test-tube,
culture plate or similar vessel.

In vivo

A biological or biochemical process occurring in a living
organism.
Polymerase chain reaction (PCR) is a rapid, inexpensive and
simple method for producing relatively large numbers of
copies of DNA molecules from minute quantities of source
DNA material--even when the source DNA is of relatively
poor quality. It has rapidly become one of the most widely
used techniques in molecular biology and molecular
pathology.

PCR

Sf9

An insect ovarian cell, Spodoptera frugiperda (Sf9), has been
widely used to express recombinant proteins, as a host cell in
the baculovirus expression system.

Vesicle

A relatively small and enclosed compartment, separated from
the cytosol by at least one lipid bilayer. Vesicles store,
transport, or digest cellular products and wastes.

Xenobiotic

Chemical substances those are foreign to the biological
system. They include naturally occurring compounds, drugs,
environmental agents, carcinogens, insecticides, etc.
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Appendix C: Chemical Structures

1. GF120918

2. Cimetidine

3.Pantoprazole
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4. Methotrexate

5.Nirofurantoin
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6. Riboflavin
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Appendix D: Standard curves for HPLC assay
1. The standard curve of NF in rat serum

Ratio (Height of NF to height of FZ)

Range: 62.5-8000ng/ml; Y=0.0017x; r2=0.9999
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2. The standard curve of NF in rat milk:

Ratio (Height of NF to height of FZ)

Range: 0.725-29 μg/ml; Y=0.6272x; r2=0.9993
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3. The standard curve of NF in cell culture media
Range: 3.9-8000 ng/ml; Y=16.921x; r2=0.9999

The peak height of NF
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4. The standard curve of pantoprazole in cell culture media (this is one
Std curve for 10μM PAN experiment)

The peak height of PAN

Range: 15.6-8000 ng/ml; Y=130.3093x; r2=0.9998
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Appendix E-1: Chromatogram of PAN and internal standard of LC-MS
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1. Chromatogram of PAN in phosphate buffer: A: 1250 ng/ml PAN mixture; B:
1500ng/ml (-) PAN; C: 1500ng/ml (+) PAN; D: blank.

A
B
C
D

(+)PAN

(-)PAN

(-)PAN

(+)PAN
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2. Chromatogram of PAN and internal standard in milk sample: A and B:
1250ng/ml PAN and IS in milk sample; C and D: blank milk sample.

A
B
C
D

IS

PAN(+)

PAN(-)

IS
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3. Chromatogram of PAN and internal standard in serum sample: A: IS; B: PAN
isomers.

A
B

IS

(+) PAN

154

(-) PAN

Appendix E-2: Standard curves for LC-MS assay
E-2-1: The standard curve of PAN isomers in phosphate buffer.

(+) PAN
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(-) PAN
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E-2-2: The standard curve of PAN isomers in milk.

(+) PAN

157

(-) PAN
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E-2-3: The standard curve of PAN isomers in serum.

(+) PAN

159

(-) PAN
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Appendix F: The expression of Abcg2 RNA Ontogeny
Material and Methods
Tissue collection:
Eight adult female Sprague-Dawley rats (four lactating and four non-lactating)
were purchased from Harlan Laboratories (Indianapolis, IN). The mammary
glands were harvested in lactating rats on day 16 to 18 post partum and all
tissues from non-lactating and lactating rats were fresh frozen in liquid nitrogen
and then stored at -80 °C until the time of analysis by real time PCR.
RNA isolation and quantitative PCR
Isolation of total RNA from mammary gland was performed using the RNeasy®
Micro Kit per manufacturer protocol with sample disruption using Qiashredder®
and on-column DNAse treatment. The total RNA concentration was determined
by the measurement of optical density at 260 nm with a small volume UV-Vis
Spectrophotometer (ND-1000, NanoDrop, Wilmingon, DE). Total RNA integrity
was verified by an OD260/OD280 absorption ratio greater than 1.9. Reversetranscription of 1μg RNA to cDNA was performed with the SuperScriptTM FirstStrand Synthesis System for RT-PCR kit following manufacturer’s protocol using
oligo(dT) to prime the reaction preferentially for mRNA. The total cDNA samples
of liver and intestine ontogeny were from Maggie Abbassi (Maggie Abbassi
Thesis).
Quantification of the expression level of rat Abcg2 was performed using the
quantitative polymerase chain reaction (qPCR) on the iCycler Multicolor RealTime PCR Detection System (Bio-Rad, Hercules, CA). The primer sequences
were obtained from published literature and double checked with reference
sequences deposited in NCBI’s Entrez Gene with the software assistance of
Primer3 (Whitehead Institute for Biomedical Research, Cambridge, MA) and
Oligo Tool Kit (Operon, Huntsville, AL). The primers utilized were confirmed to
generate unique products using NCBI’s BLAST. Reference accession numbers,
primer sequences, and product sizes are provided in table 6-1
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Table 0-1 The primer sequences of rat Abcg2 for Qualitative PCR
Gene

Reference
Sequence

Rat
AB105817
Abcg2

Forward Primer (5’→3’)

Prod. Mg Anneal
Size Conc Temp
(bp) (mM) (ºC)

Reverse Primer (5’→3’)
TAT GAG GTT CTT GCC AAG
TGT TAT

181

3.5

60

CTA ACA TGA AGT ACA ATA
AAC AAG

Ref.

(Bergman
et al.,
2005)

qPCR reaction master mixes (50 µL) were made using the SYBR® Green PCR
Core Reagents kit and contained 200 nM of each primer, 1.25 mM dNTPs, 1x
SYBR Green buffer, 0.025 U/μL Taq polymerase, optimized concentrations of
magnesium chloride for each primer pair, 20 nM fluorescein, and 0.10 μg of
sample cDNA. The protocol for thermal cycling was:
Cycle 1: ( 1X)
Step 1:

95.0ºC

for 05:00

Step 1:

95.0ºC

for 00:45

Step 2:

60.0ºC

for 01:00

Step 3:

72.0ºC

for 01:00

Cycle 2: ( 50X)

Data collection and real-time analysis enabled.
Cycle 3: ( 1X)
Step 1:

95.0ºC

for 02:00

95.0ºC

for 00:30

Cycle 4: (100X)
Step 1:

Decrease setpoint temperature after cycle 2 by 0.5ºC
Melt curve data collection and analysis enabled.
Cycle 5: ( 1X)
Step 1:

4.0ºC
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HOLD

The mammary gland from a lactating rat 16 days post-partum was used as the
comparator for relative quantification (to generate the standard curves). The
standard curve of each qPCR has correlation coefficients > 0.99 and PCR
efficiencies of 95-100%.
Finally, to confirm the generation of a single product of appropriate size, all
amplification products were separated by 3% agarose gel electrophoresis in 1 x
TBE running buffer for 50 min at 150 mV, visualized by staining with ethidium
bromide, and imaged on an Image Station 2000 MM (Eastman Kodak, New
Haven, CT).
Results
Expression of Abcg2 in non-lactating vs lactating mammary gland
qPCR was performed to determine if the transcripts for Abcg2 in mammary gland
was increased during lactation. Rat Abcg2 amplification curve, standard curve,
single products on the melt curve analysis and agarose gel electrophoresis are
shown in Fig. A-1. After amplification Abcg2 could be detected and the product
was confirmed by agarose gel electrophoresis. The RNA expression in mammary
gland was increased almost 8 times than non-lactating rats. However one nonlactating rat had relative high Abcg2 level which is close to lactating mammary
gland.
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200 bp
125 bp

Figure 0-1 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for
Abcg2 expression in lactating and non-lactating mammary gland.

Table 0-2 mRNA of Abcg2 expression level in lactating and non-lactating mammary
gland.
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Animal #
1
Lac
0.141
Non-lac
0.00192
Ratio(Lac/non-lac)

2
3
0.433 0.0657
5.39E-05 0.0863

4 Ave.
0.0909 0.183
0.00708 0.024
7.662

Expression of Abcg2 in intestine and liver ontogeny

165

200 bp
125 bp

rAbcg2 expression in intestine normalized
to lactating mammary gland(mean SD)

Figure 0-2 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for
Abcg2 expression in intestine at different age.

2.0

b
b

1.5
1.0

a

a

0.5
0.0
7 day

21 day

42 day

112 day

Figure 0-3 The expression level of rAbcg2 in intestine at different ages. Data were
obtained from four rats in each group and the values that do not share the same letter
are significantly (P < 0.05) different from each other.
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Figure 0-4 Rat Abcg2 amplification curve, melt curve analysis, standard curve, and
agarose gel electrophoresis generated from standards over a 4-log10 dilution series for
Abcg2 expression in liver at different age.
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rAbcg2 expression in liver normalized
to lactating mammary gland(Mean SD)

0.4

a
0.3
0.2

a
b

b
c

0.1

c

0.0
1 day 7 day 21 day 42 day 77 day 112 day

Figure 0-5 The expression level of rAbcg2 in liver at different ages. Data was obtained
from four rats in each group and the values that do not share the same letter are
significantly (P < 0.05) different from each other.
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Appendix G: Inhibition of pantoprazole isomers on cimetidine transport across
MDCKII empty and MDCKII-Abcg2 monolayer.
Material and Methods
Cells were seeded on microporous membrane filters (3.0-μm pore size, 24mm diameter; Transwell 3414; Corning Inc., Corning, NY) at a density of 1.0 ×
106 cells/well. Cells were grown for 4 days to achieve transepithelial electrical
resistance >200 Ω ∙ cm2, and medium was replaced every other day. Before the
experiment, the medium at both the apical and basolateral side of the monolayer
was replaced with 2 ml of OptiMEM medium (Invitrogen) without serum and
either 100μM each pantoprazole isomer or OptiMEM only with 5 μM cimeditine
traced with 0.1μM 3H cimetidine containing 0.2 μCi/ml [14C]sucrose. Cells were
incubated at 37°C in 5% CO2. We required that layers restricted sucrose
transport to <1% of the total radioactivity per hour. 150-μl aliquots were taken
and accounted at 0.5, 1 and 2h for cimetidine and sucrose transport.
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Results

A

Cimetidine transferred
(pmol, n=3, mean+/-SD)

200

Empty (A->B)
Empty (B->A)
Abcg2 (A->B)
Abcg2(B->A)

150
100
50
0
0.0

0.5

1.0

1.5

2.0

2.5

Time(hour)

200

Cimetidine transferred
(pmol, n=3, mean+/-SD)

B

150

Empty (B->A)
Abcg2(B->A)
Abcg2 (B->A) with (-)PAN
Abcg2(B->A) with (+)PAN

100
50
0
0.0

0.5

1.0

1.5

2.0

2.5

Time(hour)
Figure 0-6 Inhibition of pantoprazole isomers on cimetidine transport across MDCKII
empty and MDCKII-Abcg2 monolayer. A: Cimetidine transports in empty and rAbcg2MDCKII cell lines; B: Cimetidine transports in rAbcg2-MDCKII cell line in absence or
presence of PAN isomers.
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Appendix H: Rat Abcg2 expressed in Sf9 system: the structure of vector,
screening procedure, expression level and function study.
Establishment of rAbcg2 in Sf9 system
The total RNA was isolated from rat liver. Specific RNA of Abcg2 was
amplified to cDNA which was purified and identified in DNA gel. Both the cDNA
of Abcg2 and pENTR vector were digested by enzyme Not I and Asc I. Abcg2
was inserted into pENTR vector. The structure of pENTR vector and combined
pENTR-Abcg2 are shown in Figure A-7. Combined pENTR-Abcg2 was amplified
in Ecoli. DNA was extracted and purified. After digested at attRI and attRII
positions, it was inserted into pIB/V5- His-DEST vector (Figure A-8). The pIB/V5His-DEST vector-rat Abcg2 was transfected into Sf9 cells.
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M 13 forw ard priming s ite
Not I (673)

pENTR?D-TOPO-rABCG2
4554 bp

rABCG2

Eco RI (2442)

Figure 0-7 The structure of pENTR vector (Left) and combined pENTR-Abcg2 (Right).
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OpIE2 promote r
Eco RV (566)

Ampicillin re sis ta nc e ORF

Eco RI (570)
Pst I (580)
Eco RV (843)

Blsticidin res is tance ORF
EM 7 promote r

pIB/V5-His-DEST-ratABCG2
5394 bp

Pst I (3849)

Pst I (1518)

Spe I (3772)

ZraI (1533)

GP6 4 promote r

ra tABCG2

pUC origin
Eco RI (2401)

OpIE2 polyadenylation

XbaI (2676)

V5 e pitope
Figure 0-8 The structure of pIB/V5- His-DEST vector (upper) and pIB/V5- His-DEST-rat
Abcg2 (lower).
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Establishment of rAbcg2 in Sf9 system
Population screening of rAbcg2-Sf9
The rAbcg2-Sf9 population with higher Abcg2 expression level was sorted by
Flow-Cytometry. The population was selected according to the comparison of
fluoresce intension from Hoechst 33342 in vector and Abcg2-Sf9 combined with
the result absence or presence of GF120918 in rAbcg2-Sf9. In order to get better
rAbcg2-Sf9 population, they were grew and sorted after first sorting (Figure A-9).
We tried to grow single clone rAbcg2-Sf9 by growing one cell but it was failed. So
at last we chose to grow them as a population.
First sorting
A

B

C

R4

Second sorting
A

B

R4

C

R4

Figure 0-9 The rAbcg2-Sf9 population with higher Abcg2 expression level was sorted by
Flow-Cytometry. Upper: first sorting. Lower: second sorting. A: Grey: vector; blue:
rAbcg2. B: Grey: vector; blue: Vector+ GF120918. C: Grey: rAbcg2; blue: rAbcg2+
GF120918. R4: sorted rAbcg2 population.
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Expression level of rAbcg2 in Abcg2-Sf9
Crude membrane fractions were prepared from vector only or rAbcg2-Sf9
cells, rat lactating mammary gland and kidney. The western blot was performed
to test the expression level of Abcg2. The result was shown in Figure A-10.

Magic marker
MG G2 Vector
40 μg
5 μg

80
Abcg2 60

Sorting
PNGase
Loading

G2-Sf9
nd
nd
1
2
2
+

Kidney

MG

st

10μg 10 μg

+

20 μg 80μg 100μg

40μg

Abcg2

Figure 0-10 The Western result of rAbcg2 expression in Sf9 cells.
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+
60μg

Function of rAbcg2 in Sf9
The plasma vesicles were prepared by the method in Leier’s paper (Leier et
al., 1994). ATP dependent methotrexate (1000μM) accumulation in vesicles at 20
minutes was performed according to the methods in Gerk’s paper (Gerk et al.,
2007). Forty μg vesicle proteins were used for each reaction of experiment. The
results are shown in Figure A-11and time dependent experiment is shown in
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Figure A-12.

Figure 0-11 Methotrexate accumulated in presence of ATP or AMP in vesicle of vector
or rAbcg2 in Sf9 cells (left panel). ATP dependent methotrexate transport by membrane
vesicle from vector or rAbcg2 in Sf9 cells (right panel). Data are presented as mean±S.D
(n=3).
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Figure 0-12 Time dependent of methotrexate accumulation in presence of ATP or AMP
in vesicle of vector or rAbcg2 in Sf9 cells.

The problem of ABCG2/Abcg2-Sf9 vesicle experiment
In vesicle experiment the time dependent and concentration dependent
experiments were performed for the estimation of Km and Vmax of Abcg2/ABCG2.
The linear range of “uptake” of Abcg2/ABCG2 has been observed in time
dependent experiment. Thus, the best incubation time could be determined.
However, the saturation could not be clearly observed in concentration
dependent experiment. The variability is big and could not see a smooth plateau.
One of the possible reason is the Abcg2-Sf9 is a population not monoclonal cell
line. Some of cells might have low Abcg2 expression and increased passive
diffusion so that the active efflux mediated by Abcg2 can be masked.
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Appendix I: The mass transport of pantoprazole isomers in human ABCG2
expressing in MDCKII cell lines at 3-200μM concentrations. (Note: this is the
same data as shown in chapter 5. In this part, the data is shown as mass transfer
rate from both directions vs donor concentration.Figure A-13 and A-14)
Note: Mass transport of a drug mediated by an active transporter vs donor
concentration is a common method to describe the transport profile. From it, the
kinetic parameters can be estimated, such as Km and Tmax. However, Transport
data by Transwell model is different from that in vesicle transport studies. In
order to get a direct picture and see how different between Transwell data and
vesicle data, the mass transport of pantoprazole isomers in human ABCG2
expressing in MDCKII cell lines at 3-200 µM concentrations are shown as bellow.
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Figure 0-13 PAN isomers are transported in empty (upper) and ABCG2(lower) in
MDCKII cells from 3-200μM concentrations.
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Figure 0-14 PAN isomers are transported from A to B or B to A direction in empty and
ABCG2 in MDCKII cells at each concentration.
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